Document:

Exhibit 10.16

 

Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions.

 

CANCER LICENSE AGREEMENT

 

THIS CANCER LICENSE AGREEMENT (this “Agreement”) dated as of September 11, 2015 (the “Effective Date”) is entered into between TMRC Co., Ltd., a Japanese corporation having a place of business at 1-12-12, Kita Shinjuku, Shinjuku-ku, Tokyo 164-0074, Japan (“TMRC”) and Syros Pharmaceuticals, Inc., a Delaware corporation having a place of business at 620 Memorial Drive, Suite 300, Cambridge MA 02139 USA (“Syros”).

 

WHEREAS, TMRC owns or has rights in the Technology (as defined below).

 

WHEREAS, Syros desires to obtain an exclusive license under TMRC’s rights in the Technology on the terms and conditions set forth below.

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, the parties hereby agree as follows:

 

1.                                      DEFINITIONS

 

For purposes of this Agreement, the terms defined in this Section 1 shall have the respective meanings set forth below:

 

1.1.                            “Affiliate” means, with respect to any Person, any other Person which directly or indirectly controls, is controlled by, or is under common control with, such Person.  A Person shall be regarded as in control of another Person if it owns, or directly or indirectly controls, at least fifty percent (50%) of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever.

 

1.2.                            “API” means active pharmaceutical ingredient in bulk form that is manufactured from the Technology.

 

1.3.                            “Business Day” means a day that is not a Saturday, Sunday or a day on which banks in Boston, Massachusetts are authorized to remain closed.

 

1.4.                            “Clinical Trial” means a Phase I Clinical Trial, a Phase II Clinical Trial or a Phase III Clinical Trial.

 

1.5.                            “Competent Authority” means, collectively, the governmental authorities in each country responsible for (a) the regulation of any Product intended for use in the Field, including the FDA, (b) the establishment, maintenance or protection of rights related to the Patent Rights licensed hereunder, or (c) any other applicable regulatory or administrative agency in any country in the Territory that is comparable to, or a counterpart of, the foregoing.

 

1.6.                            “Confidential Information” means any proprietary or confidential Know-how of a party which is disclosed (whether in written, graphic, oral, electronic or other form) by or on behalf of such party (the “Disclosing Party”) to the other party (the “Receiving Party”) pursuant to this Agreement, including:  information regarding the Disclosing Party’s technology, products, programs, business, financial status, biological or chemical substances, formulations, techniques,

 

1

 

methodology, equipment, sources of supply, patent positioning or business plans.  In addition, the terms of this Agreement shall be deemed Confidential Information of each party, and neither party may rely on clause (ii) to exclude the terms of this Agreement from Confidential Information.  Confidential Information excludes any information that:  (i) is or becomes generally known to the public other than by fault of the Receiving Party or its Personnel or by breach of this Agreement, (ii) is demonstrated by documentation to have been in the Receiving Party’s possession at the time of disclosure, (iii) was disclosed to the Receiving Party on an unrestricted basis from a source not under a duty of confidentiality to the Disclosing Party or (iv) is independently developed by the Receiving Party without reference or reliance upon any of the Disclosing Party’s Confidential Information.

 

1.7.                            “Control” or “Controlled” means, with respect to a Person and an item of or right under Know-how or Patent Rights, the ability of such Person or its Affiliates, whether by ownership or a license (other than pursuant to a license granted under this Agreement), to assign, transfer or grant access to, or a license or sublicense under, such item or right as provided for herein without violating the terms of any agreement or other arrangement with any Third Party.

 

1.8.                            “Data Room” means the electronic data room by which TMRC shared certain materials with Syros under the Memorandum between the parties dated as of July 16, 2015.

 

1.9.                            “EMA” means the European Medicines Agency of the European Union, or the successor thereto.

 

1.10.                     “FDA” means the Food and Drug Administration of the United States, or the successor thereto.

 

1.11.                     “Field” means any and all uses for the treatment of human cancer indications, excluding supportive care.

 

1.12.                     “First Commercial Sale” shall mean, with respect to any Product, the first sale of such Product after all applicable marketing and pricing approvals (if any) have been granted by the applicable Competent Authority for the applicable country.

 

1.13.                     “IND” or “Investigational New Drug Application” means an Investigational New Drug Application filed with the FDA in the United States or any equivalent counterpart in any country other than the United States, including any supplements or amendments thereto.

 

1.14.                     “Know-how” means any information, inventions, know-how, data, results or materials, whether patentable or not, including:  (a) ideas, discoveries, improvements or trade secrets, (b) pharmaceutical, chemical or biological materials, products, compositions, formulae or processes, (c) tests, assays, techniques, methods, procedures, formulas or processes, (d) technical, medical, clinical, toxicological or other data or other information relating to any of the foregoing, and (e) drawings, plans, designs, diagrams, sketches, specifications or other documents containing or relating to such information, inventions, know-how, data, results or materials; including any intellectual property rights therein except for Patent Rights covering the foregoing.

 

2

 

1.15.                     “Law” means any laws (including common law), statutes, regulations, rules, executive orders, supervisory requirements, licensing requirements, export requirements, directives, circulars, opinions, decrees, interpretive letters, guidance or other official releases of or by any Competent Authority or other governmental authority.

 

1.16.                     “Licensed Know-how Rights” means Know-how that is within the TMRC IP Rights.

 

1.17.                     “Licensed Patent Rights” means Patent Rights that is within the TMRC IP Rights, including the Patent Rights set forth on Exhibit A.

 

1.18.                     “Make, Have Made” or “Make and Have Made” means making and/or having made finished Product from Sales API.

 

1.19.                     “NDA” means a New Drug Application, or similar application for marketing approval of a Product for use in the Field submitted to the FDA, or its foreign equivalent.

 

1.20.                     “NDA Acceptance” means acceptance for filing of an NDA by the applicable Competent Authority in the applicable jurisdiction.

 

1.21.                     “NDA Approval” means (a) in the case of the United States, approval by FDA of an NDA granting marketing approval for a Product; and (b) in the case of the European Union, approval by the EMA of an NDA granting marketing approval and pricing approval by the applicable Competent Authorities in any one (1) of the following countries: the United Kingdom, Germany, France, Italy or Spain.

 

1.22.                     “Net Sales” means, with respect to any Product, the gross sales price of such Product invoiced by Syros and its Affiliates and sublicensees to Third Party customers (who are not Affiliates) less, to the extent actually paid or accrued by Syros or its Affiliates or sublicensees (as applicable), (a) credits, allowances, discounts and rebates to, and chargebacks from the account of, such customers for nonconforming, damaged, outdated or returned Product; (b) freight and insurance costs incurred by Syros or its Affiliates or sublicensees (as applicable) in transporting such Product to such customers; (c) cash, quantity and trade discounts, rebates and other price reductions for such Product given to such customers under price reduction programs; (d) sales, use, value-added and other direct taxes incurred on the sale of such Product to such customers; (e) customs duties, tariffs, surcharges and other governmental charges incurred in exporting or importing such Product to such customers; (f) sales commissions incurred on the sale of such Product to such customers; and (g) an allowance for uncollectible or bad debts determined in accordance with generally accepted accounting principles.

 

1.23.                     “Neutropenia Agreement” means an agreement to be negotiated between the parties, which will have terms comparable to those herein, and which has the effect of expanding the Field applicable to Syros’s licenses to API and Products to include the treatment of neutropenia in humans.

 

1.24.                     “Patent Family 3” means the Patent Rights identified as “Family 3” in Exhibit A.

 

3

 

1.25.                     “Patent Rights” mean patents, patent applications, utility models, and certificates of invention and other governmental grants for the protection of inventions (including any provisional application, continuation, continuation-in-part, divisional, reissue, renewal, re-examination, extension, or supplementary protection certificate granted in relation thereto, as well as any utility model, innovation patent, petty patent, patent of addition, inventor’s certificate or equivalent in any country or jurisdiction).

 

1.26.                     “Person” means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.

 

1.27.                     “Phase I Clinical Trial” means any human clinical trial (whether including a phase 1a or a phase 1b trial) in any country, the principal purpose of which is a preliminary determination of safety in individuals or patients, that would satisfy the requirements of 21 C.F.R. §312.21(a), or an equivalent clinical study required by a Competent Authority outside of the United States.

 

1.28.                     “Phase II Clinical Trial” means any human clinical trial conducted in any country, intended to explore multiple doses, dose response and duration of effect to generate initial evidence of safety and activity in a target patient population, that would satisfy the requirements of 21 C.F.R. §312.21(b), or an equivalent clinical study required by a Competent Authority outside of the United States.

 

1.29.                     “Phase III Clinical Trial” means any human clinical trial in any country that would satisfy the requirements of 21 C.F.R. §312.21(c), or an equivalent clinical study required by a Competent Authority outside of the United States.

 

1.30.                     “Product” means any pharmaceutical product made from or comprising API for human use in the Field.

 

1.31.                     “Registration” means any and all permits, licenses, authorizations, registrations or regulatory approvals (including NDAs) required or granted by any Competent Authority as a prerequisite to the development, manufacturing, packaging, marketing or selling of any Product.

 

1.32.                     “Royalty Term” means, with respect to each Product in each country, the term, if any, during which (a) a Valid Claim remains in effect and would be infringed but for the license granted by this Agreement, by the use, offer for sale, sale or import of such Product in such country in the Field and (b) no Third Party generic product that has received marketing approval pursuant to an abbreviated regulatory process under which the applicable Third Party or Competent Authority has relied on data or other information in any Registration for the applicable Product is commercially available in such country.

 

1.33.                     “Sales API” means API supplied by TMRC to Syros pursuant to the Supply Agreement (or otherwise supplied by TMRC to Syros as mutually agreed by the parties).

 

1.34.                     “Supply Agreement” means a supply agreement to be entered into between TMRC and Syros that includes the terms set forth in Exhibit D, and other reasonable and

 

4

 

customary terms, including specifications and conditions of delivery, mutually agreed upon by the TMRC and Syros, pursuant to which TMRC shall supply Syros’s requirements for Sales API to Syros and Syros shall purchase its requirements for Sales API from TMRC.

 

1.35.                     “Technology” means the compound known as AM80 (Tamibarotene) listed on Exhibit B, in all formulations.

 

1.36.                     “Territory” means (a) North America (the United States of America, Canada, and Mexico); (b) Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland and the United Kingdom; and (c) any other country to which the EMA’s regulatory jurisdiction extends.

 

1.37.                     “Third Party” means any Person other than TMRC, Syros and their respective Affiliates.

 

1.38.                     “TMRC IP Rights” means TMRC’s own rights and rights TMRC has the right to license consisting of: (1) (i) the patents and patent applications listed in Exhibit A; (ii) the foreign equivalent and national phase patent applications of (i); (iii) the patents proceeding from (i) and (ii); (iv) all claims of continuations-in-part that are entitled to the benefit of the priority date of (i) or any applications to which they make a claim of priority; and (v) divisionals, continuations, reissues, reexaminations, and extensions of any patent or application set forth in (i)-(iv) above, so long as said patents have not been held invalid and/or unenforceable by a court of competent jurisdiction from which there is no appeal or, if appealable, from which no appeal has been taken; (2) clinical data and preclinical data for Technology controlled by, or belonging to, TMRC; (3) Letter(s) of Authorization to reference the contents of the drug master file of TMRC’s licensor for Technology and all rights associated with and contents of the manufacturing records and analytical records of Technology which TMRC has rights to license; and (4) Know-how rights and Patent Rights that are Controlled by TMRC as of the Effective Date or come into the Control of TMRC at any time after the Effective Date that related to AM80 (Tamibarotene).

 

1.39.                     “Toko” means Toko Pharmaceutical Ind. Co., Ltd., a Japanese corporation.

 

1.40.                     “Toko Agreement” means the agreement between Toko and TMRC entitled “License Agreement for the development et al. of retinoid based drug in foreign countries” dated August 15, 2008.

 

1.41.                     “Toko Information” means information which is (a) owned, controlled or disclosed by Toko; and (b) subject to the provisions of the Toko Agreement.

 

1.42.                     “Toko Letter Agreement” means a Consent and Stand-by License between Toko and Syros that is substantially in the form of Exhibit E and reasonably satisfactory to Syros.

 

1.43.                     “Valid Claim” means (a) any claim in any issued and unexpired patent within the Licensed Patent Rights that has not been disclaimed, revoked or held invalid or unenforceable by a decision of a court or other governmental authority of competent jurisdiction from which no

 

5

 

appeal can be taken, or with respect to which an appeal is not taken within the time allowed for appeal, and that has not been disclaimed or admitted to be invalid or unenforceable through reissue, disclaimer or otherwise; or (b) any claim of the Licensed Patent Rights in (a) that has not been finally abandoned or finally rejected and which has been pending for no more than [**] years from the date of filing of the earlier priority patent application.

 

2.                                      REPRESENTATIONS AND WARRANTIES

 

Each party hereby represents and warrants to the other party as follows:

 

2.1.                            Corporate Existence.  Such party is a corporation duly organized, validly existing and in good standing under the Laws of the jurisdiction in which it is incorporated.

 

2.2.                            Authorization and Enforcement of Obligations.  Such party (a) has the corporate power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder, and (b) has taken all necessary corporate action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder.  This Agreement has been duly executed and delivered on behalf of such party, and constitutes a legal, valid, binding obligation, enforceable against such party in accordance with its terms.

 

2.3.                            No Consents.  All necessary consents, approvals and authorizations of all governmental authorities and other Persons required to be obtained by such party in connection with license of this Agreement have been obtained.

 

2.4.                            No Conflict.  The execution and delivery of this Agreement and the performance of such party’s obligations hereunder (a) do not conflict with or violate any requirement of applicable Laws, and (b) do not conflict with, or constitute a default under, any contractual obligation of such party.

 

In addition, TMRC hereby represents and warrants to Syros as follows:

 

2.5.                            IP Rights.  TMRC (a) is the sole owner or exclusive licensee of, and Controls, the TMRC IP Rights, and except as set forth in Exhibit F, TMRC has not granted to any Third Party any license or other interest in the TMRC IP Rights in the Territory, (b) is not aware of any Third Party patent, patent application or other intellectual property rights that would be infringed (i) by practicing any process or method or by making, using or selling any composition which is claimed or disclosed in the Licensed Patent Rights or which constitutes Licensed Know-how Rights, or (ii) by making, using or selling Products, (c) Controls and has the right to license all TMRC IP Rights to Syros as provided herein (d) is not aware of any infringement or misappropriation by a Third Party of the TMRC IP Rights and (e)(i) all agreements relating to the Technology or any of the TMRC IP Rights between TMRC and Innovive Pharmaceuticals, Inc. (or its successors or assigns) (collectively, “CytRx”) have been terminated, except for a [**], terminating all other such agreements, (ii) [**] TMRC has unfettered rights to use all data and documents generated by CytRx or TMRC [**] relating to the Technology or any of the TMRC IP Rights, including the unfettered right to license and transfer such data and documents to Syros as provided herein, (iii) all litigation between CytRx and TMRC has been settled and dismissed with prejudice and all claims between CytRx and TMRC have been released, in each case that pertain to the Technology or any of the TMRC IP Rights, and (iv) CytRx does not retain any

 

6

 

right [**] or otherwise to terminate any right of TMRC to use or license data or documents generated by CytRx and TMRC pursuant to any agreement between CytRx and TMRC relating to the Technology or any of the TMRC IP Rights.

 

2.6.                            DISCLAIMER.  EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT NOTHING IN THIS AGREEMENT IS OR SHALL BE CONSTRUED AS (i) A WARRANTY OR REPRESENTATION BY TMRC AS TO THE VALIDITY OR SCOPE OF ANY LICENSED PATENT RIGHTS; (ii) A WARRANTY OR REPRESENTATION THAT ANYTHING MADE, USED, SOLD OR OTHERWISE DISPOSED OF UNDER ANY LICENSE GRANTED IN THIS AGREEMENT IS OR WILL BE FREE FROM INFRINGEMENT OF PATENTS OR OTHER INTELLECTUAL PROPERTY OF THIRD PARTIES; OR (iii) A REPRESENTATION OR WARRANTY BY TMRC OF THE ACCURACY, SAFETY OR USEFULNESS FOR ANY PURPOSE OF ANY TMRC KNOW-HOW AT ANY TIME MADE AVAILABLE BY TMRC.  TMRC SHALL HAVE NO LIABILITY WHATSOEVER TO SYROS OR ANY OTHER PERSON FOR OR ON ACCOUNT OF ANY INJURY, LOSS OR DAMAGE, OF ANY KIND OR NATURE, SUSTAINED BY, OR ANY DAMAGE ASSERTED OR ASSERTED AGAINST, OR ANY OTHER LIABILITY INCURRED BY OR IMPOSED ON SYROS OR ANY OTHER PERSON, ARISING OUT OF IN CONNECTION WITH OR RESULTING FROM (A) THE PRODUCTION, USE OR SALE OF ANY PRODUCT BY SYROS, OR THE PRACTICE OF THE LICENSED PATENT RIGHTS BY SYROS; OR (B) THE USE BY SYROS OF ANY TMRC KNOW-HOW, AND SYROS SHALL HOLD TMRC, OR ITS OFFICERS, EMPLOYEES OR AGENTS, HARMLESS IN THE EVENT TMRC, OR ITS OFFICERS, EMPLOYEES OR AGENTS, IS HELD LIABLE THEREFOR, EXCEPT TO THE EXTENT RESULTING FROM A BREACH BY TMRC OF ITS REPRESENTATIONS, WARRANTIES OR OBLIGATIONS HEREUNDER OR THE NEGLIGENCE OR WILLFUL MISCONDUCT OF TMRC OR ITS OFFICERS, EMPLOYEES OR AGENTS.

 

3.                                      LICENSES AND OTHER GRANTS OF RIGHTS; OTHER AGREEMENTS

 

3.1.                            TMRC IP Rights.

 

3.1.1.                  Grant.  TMRC hereby grants to Syros an exclusive license (with the right to grant sublicenses) under the TMRC IP Rights (excluding Patent Rights as to which Syros has opted out of pursuant to Section 9.2) to conduct research and to develop, Make, Have Made, use, offer for sale, sell and import Products in the Territory for use in the Field, provided that Syros shall not exercise such make and have made rights in any manner that conflicts with TMRC’s rights to supply under the Supply Agreement.  Syros shall not use TMRC IP Rights to make or have made API except as set forth in the Supply Agreement (or other agreement between the parties) or in the Toko Letter Agreement.

 

3.1.2.                  Ex-Territory Development.  TMRC hereby grants to Syros a non-exclusive license (with the right to grant sublicenses) under the TMRC IP Rights to conduct research, to develop and to use Products outside the Territory (excluding all Asian countries) solely for the purpose of developing and commercializing Products for use in the Field in the Territory.  For clarity, Syros shall not use TMRC IP Rights for the purpose of researching, developing or commercializing Products for use in the Field outside the Territory.

 

7

 

3.1.3.                  Manufacture.  TMRC hereby grants to Syros a non-exclusive license (with the right to grant sublicenses) under the TMRC IP Rights to Make and Have Made Products inside and outside the Territory solely for the purpose of manufacturing Products for use in the Field in the Territory, provided that Syros shall not exercise such Make and Have Made rights in any manner that conflicts with TMRC’s rights to supply under the Supply Agreement.

 

3.2.                            Information Transfer.  TMRC shall, within [**] days after the Effective Date, provide Syros with all information that was made available to Syros in the Data Room and any other Licensed Know-how Rights possessed by TMRC or its Affiliates or in respect of which TMRC or its Affiliates otherwise have the right to grant licenses as of the Effective Date.  Thereafter, on at least a [**] basis or more frequently as may be requested by Syros, TMRC shall provide Syros with updates to any chemistry, manufacturing and controls information relating to the Technology possessed by or otherwise available to TMRC or its Affiliates, if any, and with copies of or access to any other information within the Licensed Know-how Rights that Syros may request to satisfy requirements for Registrations or other required submissions to Competent Authorities, including source data and documents underlying any Registration and/or other regulatory documents to which Syros’s Right of Reference under Section 3.3 applies.

 

3.3.                            Registrations; Right of Reference.  TMRC acknowledges and agrees that Syros shall own all Registrations for Products for use in the Field in each country in the Territory.  TMRC hereby grants to Syros a fully paid-up, royalty-free right to reference and use and have full access to all Registrations held by TMRC or its Affiliates as of the Effective Date and all other regulatory documents held by TMRC or its Affiliates after the Effective Date that relate to chemistry, manufacturing and controls information for the manufacture of Products, and any supplements, amendments or updates to any of the foregoing (collectively, the “Right of Reference”) which TMRC or its Affiliates have the right to grant.  Syros shall have the right to license or sublicense the Right of Reference to its Affiliates or sublicensees.  TMRC shall promptly notify Syros of any written or oral notices received from, or inspections by any Competent Authority relating to any such Registrations, and shall promptly inform Syros of any responses to such written notices or inspections and the resolution of any issue raised by such Competent Authority.

 

3.4.                            Information Sharing Regarding Planned Clinical Trials.  Each party will use commercially reasonable efforts to share information regarding Clinical Trials to be conducted by such party or any of its Affiliates or (sub)licensees, which information shall be maintained as Confidential Information of the Disclosing Party and used solely for development, manufacture and commercialization of Products as permitted hereunder.

 

3.5.                            Pharmacovigilance Agreement.  The parties’ responsibilities concerning adverse drug reactions, safety information and compliance with regulatory requirements with respect thereto will be detailed in a separate pharmacovigilance agreement to be mutually agreed upon by the parties as soon as practicable after the Effective Date, and in any event no later than [**] days after the Effective Date.

 

3.6.                            Initial Clinical Supply Order.  Syros may submit to TMRC and TMRC shall accept and agree to fulfill, a firm order for clinical supply of Product in substantially the form set forth in Exhibit G.

 

8

 

3.7.                            Purchase.  Subject to the parties entering into the Supply Agreement and the terms and conditions thereof, Syros shall purchase from TMRC all of Syros’s requirements of Sales API under this Agreement, which is needed for manufacturing the Products for sales after approval and for use in clinical trials

 

3.8.                            Price. Subject to the parties entering into the Supply Agreement and the terms and conditions thereof, Syros shall pay TMRC $[**] per kilogram of Sales API for sales after approval and for use in clinical trials.

 

3.9.                            Clinical Supply Agreement.  The parties shall use commercially reasonable efforts to negotiate and enter into the Supply Agreement on the basis of the terms set forth in Exhibit D within sixty (60) days after the Effective Date; provided that neither party shall be obligated to enter into the Supply Agreement unless and until all of the terms thereof, including terms in addition to those set forth in Exhibit D, are reasonably satisfactory to such party.

 

3.10.                     Neutropenia Agreement.  During the [**] months following the Effective Date, unless Syros otherwise notifies TMRC in writing, the parties shall use commercially reasonable efforts to negotiate in good faith and enter into the Neutropenia Agreement, and TMRC agrees that neither it nor any of its Affiliates shall negotiate or otherwise discuss or provide any information regarding the Technology with respect to the treatment of neutropenia in humans in the Territory with or to any Third Party.

 

4.                                      FINANCIAL CONSIDERATION

 

4.1.                            Royalties.  Subject to Section 4.2, in consideration for the licenses granted to Syros herein, Syros shall pay to TMRC royalties on annual Net Sales of each Product by Syros, its Affiliates and its sublicensees, equal to:

 

(i)                                     [**] percent ([**]%) of calendar year Net Sales of such Product up to US$[**] in such Net Sales, and

 

(ii)                                  [**] percent ([**]%) of calendar year Net Sales of such Product over US$[**] in such Net Sales;

 

provided, however, that during any period within the Royalty Term in which the Valid Claims of Licensed Patent Rights that are pending claims are in effect, the foregoing royalty rates shall be reduced by half.

 

4.2.                            Royalty Term.  Royalties as calculated pursuant to Section 4.1 shall be payable on Net Sales during the Royalty Term for the applicable Product in the applicable country in the Field.  For purposes of determining the applicable royalty tier specified in Sections 4.1 for calendar year Net Sales, only Net Sales of the applicable Product in the Field made during the Royalty Term therefor shall be counted.  Following expiration of the Royalty Term applicable to a Product in the Field in a country, Syros’ licenses under Section 3.1 shall become fully paid up, non-royalty-bearing and perpetual.

 

4.3.                            Combination Products.  If a Product comprises both AM80 (Tamibarotene) and another active pharmaceutical ingredient, then for purposes of the royalty payments under

 

9

 

Section 4.1 for Net Sales of such Product in the Field, such Net Sales, prior to the royalty calculation set forth in Section 4.1, shall first shall be multiplied by the fraction A/(A+B), where A is the value of the AM80 (Tamibarotene) component, and B is the value of the other active pharmaceutical ingredient, each as reasonably determined by Syros, and such resulting amount shall be the “Net Sales” for purposes of the royalty calculation in Section 4.1 for such Product.

 

4.4.                            Allocation Between Fields.  If a Product is sold in both the Field (as defined in this Agreement) and the Field (as defined in the Neutropenia Agreement in the same country, then the parties shall mutually agree on a method for allocating the resulting Net Sales between such fields for purposes of determining the applicable royalty tiers pursuant to Section 4.1 of this Agreement and the Neutropenia Agreement, which method shall be based on such Third Party market data (such as IMS Health data) as the parties shall reasonably agree.

 

4.5.                            Upfront and Milestone Payments.  Syros shall pay to TMRC the following one-time and non-refundable upfront payments (#1 and #2) and one-time (per indication) and non-refundable milestone payments (#3-#9 or #5-#9, as applicable) for each cancer indications within, in the case of upfront payments, [**] days following the Effective Date, and, in the case of milestone payments, [**] days following the first achievement of the corresponding milestones:

 

	
1.   Upfront payment
    	
US$500,000
    
	
2.   Execution of Supply Agreement and Toko Letter Agreement
    	
US$[**]   and such additional amounts as are applicable in accordance with Exhibit C
    

 

The following milestone payments apply to the first indication and any subsequent indication, except for [**].

 

	
3. Dosing of a   first subject in a Phase I Clinical Trial of a Product for an indication in   the Field
    	
US$500,000
    
	
4. Dosing of a   first subject in a Phase II Clinical Trial of a Product for an indication in   the Field
    	
US$500,000
    
	
[**]
    	
[**]
    
	
[**]
    	
[**]
    
	
[**]
    	
[**]
    
	
[**]
    	
[**]
    
	
[**]
    	
[**]
    

 

10

 

The following milestone payments apply solely to a second indication where the [**] and, in the event that such milestones apply, are in lieu of the milestones set forth in the table above with respect to the second indication:

 

	
[**]
    	
[**]
    
	
[**]
    	
[**]
    
	
[**]
    	
[**]
    
	
[**]
    	
[**]
    
	
[**]
    	
[**]
    

 

For the purposes of this Section 4.5, an “indication” means a distinct tumor type (i.e., irrespective of patient subpopulations) that is tested in a separate Clinical Trial.

 

4.5.1.                  No Skipped Milestones.  If a milestone is not achieved for a Product for an indication, then the corresponding milestone payment will become payable upon the achievement of the next milestone for such Product for such indication in the applicable region (i.e., [**], as applicable).

 

4.6.                            Full Compensation.  The consideration set forth in this Section 4 is the only compensation due from Syros to TMRC, and TMRC shall be responsible for all of its costs and expenses for performance hereunder, including any payments made to any Third Party licensors.

 

5.                                      ROYALTY REPORTS AND ACCOUNTING

 

5.1.                            Royalty Reports.  Within [**] days after the end of each calendar quarter during the term of this Agreement following the First Commercial Sale of a Product, Syros shall furnish to TMRC a quarterly written report showing in reasonably specific detail, on a Product-by-Product and country-by-country basis:  (a) Net Sales during such calendar quarter; (b) the calculation of the royalties, if any, that shall have accrued based upon such Net Sales; (c) the withholding taxes, if any, required by applicable Law to be deducted with respect to such sales; and (d) the exchange rates, if any, used in determining Net Sales in United States dollars.  With respect to sales of Products invoiced in United States dollars, the gross sales, Net Sales and royalties payable shall be expressed in United States dollars.  With respect to Net Sales invoiced in a currency other than United States dollars, all such amounts shall be expressed both in the currency in which the distribution is invoiced and in the United States dollar equivalent.  The United States dollar equivalent shall be calculated using the average of the exchange rate (local currency per US$1) published in The Wall Street Journal, Western Edition, under the heading “Currency Trading” on the last business day of each month during the applicable calendar quarter.

 

11

 

5.2.                            Audits.

 

5.2.1.                  Upon the written request of TMRC and not more than [**], Syros shall permit an independent certified public accounting firm of internationally recognized standing selected by TMRC and reasonably acceptable to Syros, at TMRC’s expense, to have access during normal business hours to such of the financial records of Syros as may be reasonably necessary to verify the accuracy of the payment reports hereunder for the [**] immediately prior to the date of such request (other than records for which TMRC has already conducted an audit under this Section).

 

5.2.2.                  If such accounting firm concludes that additional amounts were owed during the audited period, Syros shall pay such additional amounts within [**] days after the date TMRC delivers to Syros such accounting firm’s written report so concluding.  The fees charged by such accounting firm shall be paid by TMRC; provided, however, that if the audit determines that the royalties payable by Syros for such period are more than [**] percent ([**]%) of the royalties actually paid for such period, then Syros shall pay the reasonable fees and expenses charged by such accounting firm.

 

5.2.3.                  TMRC shall cause its accounting firm to retain all financial information subject to review under this Section 5.2 in strict confidence; provided, however, that Syros shall have the right to require that such accounting firm, prior to conducting such audit, enter into an appropriate non-disclosure agreement with Syros regarding such financial information.  The accounting firm shall disclose to TMRC only whether the reports are correct or not and the amount of any discrepancy.  No other information shall be shared.  TMRC shall treat any such financial information as Syros’ Confidential Information

 

6.                                      PAYMENTS

 

6.1.                            Payment Terms.  Royalties shown to have accrued by each royalty report provided for under Section 5.1 above shall be due on the date such royalty report is due.  Payment of royalties in whole or in part may be made in advance of such due date.

 

6.2.                            Exchange Control.  If at any time legal restrictions prevent the prompt remittance of part or all royalties with respect to any country in the Territory where the Product is sold, Syros shall have the right, in its sole discretion, to make such payments by depositing the amount thereof in local currency to TMRC’s account in a bank or other depository institution in such country.  If the royalty rate specified in this Agreement should exceed the permissible rate established in any country, the royalty rate for sales in such country shall be adjusted to the highest legally permissible or government-approved rate.

 

6.3.                            Withholding Taxes.  Syros shall be entitled to deduct the amount of any withholding taxes, value-added taxes or other taxes, levies or charges with respect to amounts payable hereunder to TMRC by Syros, its Affiliates or sublicensees, and the amount of any taxes required to be withheld by Syros, its Affiliates or sublicensees with respect to amounts payable hereunder to TMRC, to the extent Syros, its Affiliates or sublicensees pay to the appropriate governmental authority on behalf of TMRC such taxes, levies or charges.  Syros shall use reasonable efforts to minimize any such taxes, levies or charges required to be paid on behalf of TMRC by Syros, its Affiliates or sublicensees.  Syros promptly shall deliver to TMRC proof of

 

12

 

payment of all such taxes, levies and other charges, together with copies of all communications from or with such governmental authority with respect thereto.

 

7.                                      DEVELOPMENT OBLIGATIONS

 

7.1.                            Development Efforts.  As between the parties, Syros shall solely control and fund all Product development activities as to Products in the Field for any of the Territory.  Syros, together with its Affiliates and sublicensees, shall use commercially reasonable efforts to: (a) commence development activities in the Field within one (1) year after the Effective Date; (b) to develop a Product for at least one indication in the Field; and (c) following marketing approval, market the Product.  Following the Effective Date, Syros shall promptly begin preparation for an IND filing.  Such commercially reasonable efforts shall require Syros to use the level of efforts and resources that Syros generally uses for products of comparable market potential at comparable stage of development, taking into account relevant costs and risks of development and commercialization, including relevant legal, regulatory, scientific, competitive and commercial factors.

 

7.2.                            Records.  Syros shall maintain records, in sufficient detail and in good scientific manner, which shall reflect all work done and results achieved in the performance of its development regarding the Products.

 

7.3.                            Reports.  Within [**] days following the end of each quarter during the term of this Agreement prior to the first marketing approval of a Product in each Field in the Territory, Syros shall prepare and deliver to TMRC a written summary report which shall describe (a) the progress of the development and testing of Product(s) in the Field together with a summary of the enrollment of then-active Clinical Trials, and (b) the status of obtaining regulatory approvals to market Product(s) in the Territory in each Field, and Syros shall inform TMRC of the commencement of Clinical Trials and receipt of regulatory approvals from time to time.  The parties shall hold a conference call on a quarterly basis at a mutually agreed upon time after TMRC’s receipt of the report mentioned above.

 

8.                                      CONFIDENTIALITY

 

8.1.                            Confidential Information.  During the term of this Agreement, and for a period of [**] years following the expiration or earlier termination hereof (or, for Toko Information, for such longer period as may be required by the Toko Agreement), each Receiving Party shall maintain in confidence all Confidential Information of the Disclosing Party, and shall not use, disclose or grant the use of the Confidential Information except on a need-to-know basis to those directors, officers, affiliates, employees, to the extent such disclosure is reasonably necessary in connection with performing its obligations or exercising its rights, including its rights to develop and commercialize the Product, under this Agreement.  To the extent that disclosure is authorized by this Agreement, prior to disclosure, each Receiving Party shall obtain agreement of any such Person to hold in confidence and not make use of the Confidential Information for any purpose other than those permitted by this Agreement.  Each Receiving Party shall notify the Disclosing Party promptly upon discovery of any unauthorized use or disclosure of the Disclosing Party’s Confidential Information.

 

13

 

8.2.                            Permitted Disclosures.  The confidentiality obligations contained in Sections 8.1 above and 8.3 below shall not apply to the extent that any Receiving Party is required (a) to disclose information by Law, including disclosure obligations under applicable securities Laws, or (b) to disclose information to any governmental authority for purposes of obtaining approval to test or market a product, provided that in either case that the Receiving Party shall provide written notice thereof to the Disclosing Party and sufficient opportunity to object to any such disclosure or to request confidential treatment thereof.  Notwithstanding any other provision of this Agreement, Syros may disclose Confidential Information of TMRC relating to information developed pursuant to this Agreement:  (x) to any Person who is permitted licensees, permitted assignees or agents, consultants, clinical investigators or clinical contractors, to the extent such disclosure is reasonably necessary in connection with performing its obligations or exercising its rights to develop and commercialize the Product under this Agreement as long as such Person has entered into a confidentiality agreement with Syros; (y) in connection with the normal course of development and commercialization of Products for the Territory, including for the filing of Registrations and satisfaction of reporting obligations to Competent Authorities and for the filing and prosecution of Patent Rights; and (z) TMRC may disclose Confidential Information of Syros, including the terms of this Agreement, to Toko, Dr. Shudo and Itsuu Laboratory to the extent such disclosure is reasonably necessary in connection with performing its obligations hereunder or under the Supply Agreement as long as Toko, Dr. Shudo and Itsuu Laboratory have entered into a confidentiality agreement with TMRC.

 

8.3.                            Press Releases and Other Public Announcements.

 

8.3.1.                  The parties will cooperate in the release of a mutually agreed press release following the Effective Date at a time to be determined by Syros.  The parties also recognize that each party may from time to time desire to issue additional press releases and make other public statements or disclosures regarding specific terms of this Agreement, which may be made pursuant to Section 8.3.3 below.

 

8.3.2.                  Syros may from time to time issue additional press releases and make other public statements or disclosures regarding the progress of its development or commercialization of Technology and Products hereunder without the need to obtain TMRC’s prior consent, so long as such press releases, other public statements or disclosures do not reference TMRC or disclose specific terms of this Agreement that have not previously been made public pursuant to this Section 8.3.

 

8.3.3.                  Notwithstanding the foregoing provisions of this Section 8.3, (a) a party may make any disclosure or public announcement if the contents of such disclosure or public announcement have previously been made public other than through a breach of this Agreement by the issuing party; (b) if a party reasonably determines that a public disclosure shall be required by Law, including in a public filing with the U.S. Securities and Exchange Commission or applicable stock exchange (including in connection with an initial public offering), such party may disclose specific terms of this Agreement where so required; provided that such party shall, to the extent practicable and permitted by applicable Law, notify the other party and allow the other party to comment on the proposed disclosure, which comments shall be considered by the party obligated to make such public disclosure in good faith; and (c) a party may disclose the terms of this Agreement to bona fide potential or actual advisors, consultants, investors,

 

14

 

acquirers, lenders, investment bankers or other potential financial partners in connection with such party’s proposed financing or business combination activities, and to bona fide potential or actual sublicensees, as reasonably necessary in connection with a permitted sublicense or license under the rights granted in this Agreement, in each case of (c) provided that such person is under an appropriate obligation of confidentiality.

 

9.                                      PATENTS

 

9.1.                            Patent Prosecution and Maintenance.  Except for Patent Family 3 (as to which responsibility for the preparation, filing, prosecution and maintenance shall remain with TMRC, at TMRC’s sole cost), Syros shall, subject to Section 9.2, control, at Syros’ cost, the preparation, filing, prosecution and maintenance of all patents and patent applications within the Licensed Patent Rights in the Territory.  Syros shall give TMRC an opportunity to review and comment on the text of each such patent application, and the preparation, filing and prosecution thereof, and shall supply TMRC with a copy of such patent application as filed, together with notice of its filing date and serial number.  TMRC shall cooperate with Syros, execute all lawful papers and instruments and make all rightful oaths and declarations as may be necessary for Syros’ preparation, prosecution and maintenance of patents and other filings referred to in this Section 9.1.

 

9.2.                            Abandonment; Reverted Patents.  If Syros, in its sole discretion, decides to abandon or not pursue the preparation, filing, prosecution or maintenance of any patent or patent application in the Licensed Patent Rights (other than Patent Family 3), then Syros shall notify TMRC in writing thereof and following the date of such notice TMRC may control, at TMRC’s cost, the preparation, filing, prosecution and maintenance of such patents and patent applications.  If Syros decides to abandon or not pursue the preparation, filing, prosecution or maintenance of any patent or patent application within any of the Licensed Patent Rights in any country of the Territory, Syros’s rights to prosecute, maintain and enforce such patent in such country will revert to TMRC, and such reverted patent in such country shall be excluded from the Licensed Patent Rights thereafter.  In the event that, as a result of such a reversion, Syros infringes a patent of TMRC, then TMRC shall promptly inform Syros thereof, and Syros and TMRC shall negotiate regarding TMRC granting a license with respect to such reverted patent, as long as TMRC still Controls such reverted Patent Rights. If such reverted Patent Rights are still Controlled by TMRC, Syros has the option to obtain a license from TMRC to such Patent Rights by paying TMRC [**] times TMRC’s out-of-pocket patent prosecution and maintenance expenses for such Patent Rights in the Field and in the applicable country in the Territory.

 

9.3.                            IP Representations.  Subject to Section 9.1, TMRC represents and warrants to Syros that as of the Effective Date and throughout the term of this Agreement TMRC has and shall maintain, together with its Affiliates and licensors, Licensed Patent Rights in the Territory to control the preparation, filing, prosecution and maintenance of all patents and patent applications within the Licensed Patent Rights and also to grant to Syros the right to prepare, file, prosecute and maintain the Licensed Patent Rights in accordance with Section 9.1.

 

9.4.                            Patent Family 3.  TMRC shall control, at TMRC’s cost, the preparation, filing, prosecution and maintenance of all patents and patent applications in Patent Family 3.

 

15

 

9.5.                            Notification of Infringement.  Each party shall notify the other party of any infringement in the Territory known to such party of any Licensed Patent Rights by a product that is competitive with the Products and shall provide the other party with the available evidence, if any, of such infringement.

 

9.6.                            Enforcement of Patent Rights.  Syros, at Syros’ expense, shall have the right to determine the appropriate course of action to enforce Licensed Patent Rights (except for any Patent Rights that have reverted to TMRC in accordance with Section 9.2) in the Territory or otherwise abate the infringement thereof, to take (or refrain from taking) appropriate action to enforce Licensed Patent Rights in the Territory, to defend any declaratory judgments seeking to invalidate or hold the Licensed Patent Rights unenforceable in the Territory, to control any litigation or other enforcement action and to enter into, or permit, the settlement of any such litigation, declaratory judgments or other enforcement action with respect to Licensed Patent Rights in the Territory, in each case in Syros’ own name and, if required by Law, in the name of TMRC and shall consider, in good faith, the interests of TMRC in so doing.  If Syros does not, within [**] days of receipt of notice from TMRC, abate the infringement or file suit to enforce the Licensed Patent Rights against at least one infringing party in the Territory, TMRC shall have the right to take whatever action it reasonably deems appropriate to enforce the Licensed Patent Rights; provided that TMRC shall consider, in good faith, the interests of Syros in so doing.  The party controlling any such enforcement action shall not settle the action or otherwise consent to an adverse judgment in such action that diminishes the rights or interests of the non-controlling party without the prior written consent of the other party.  All monies recovered upon the final judgment or settlement of any such suit to enforce the Licensed Patent Rights shall be shared, after reimbursement of expenses, in relation to the damages suffered by each party.

 

9.7.                            Cooperation.  In any suit to enforce or defend the License Patent Rights pursuant to this Section 9, the party not in control of such suit shall, at the request and expense (for out-of-pocket costs only) of the controlling party, cooperate in all respects and, to the extent possible, have its employees testify when requested and make available relevant records, papers, information, samples, specimens, and the like.

 

10.                               TERMINATION

 

10.1.                     Expiration.  Subject to Sections 10.2, 10.3, 10.4, 10.5, 10.6 and 10.7 below, this Agreement shall expire on the expiration of the last to expire Royalty Term or fifteen (15) years from the date of the First Commercial Sale of the Product in the Territory, whichever is later.

 

10.2.                     Termination by Syros.  At any time after the first anniversary of the Effective Date, Syros shall have the right at its sole discretion to terminate this Agreement upon ninety (90) days advanced written notice to TMRC for reasons such as data or results of development, issues of safety or efficacy, costs and risks of development, manufacturing and supply issues, competitive dynamics, market dynamics, government regulation and regulatory issues or pricing strategy and expected profitability from the commercialization of Products.

 

10.3.                     Termination for Supply Agreement and Related Matters.  In the event that each of the following events have not taken place within sixty (60) days after the Effective Date, Syros shall have the right to terminate this Agreement by providing written notice to TMRC: (a) the parties

 

16

 

have not entered into the Supply Agreement and (b) Toko and Syros have not executed and delivered to one another the Toko Letter Agreement and in such event: (x) Syros shall have no further commitment or restriction after the effectiveness of such termination; (y) TMRC shall be entitled to retain such payments as have been made by Syros prior to the effectiveness of such termination; and (z) TMRC shall not license any TMRC IP Rights in the Field in the Territory to a Third Party or Affiliate of TMRC for a period of [**] months after the effective date of such termination.

 

10.4.                     Termination by Syros for Breach.  Except as otherwise provided in Section 12, Syros may terminate this Agreement upon or after the material breach of this Agreement by TMRC if TMRC has not cured such breach in all material respects within [**] days after notice thereof by Syros; provided, however, that if any default is not capable of being cured within such [**] day period and TMRC is diligently undertaking to cure such default as soon as commercially feasible thereafter under the circumstances, Syros shall have no right to terminate this Agreement pursuant to this Section 10.4.

 

10.5.                     Termination by TMRC.  Except as otherwise provided in Section 12, TMRC may terminate this Agreement upon or after the material breach of this Agreement by Syros if Syros has not cured such breach in all material respects within [**] days after notice thereof by TMRC; provided, however, that if any default is not capable of being cured within such [**] day period and Syros is diligently undertaking to cure such default as soon as commercially feasible thereafter under the circumstances, TMRC shall have no right to terminate this Agreement pursuant to this Section 10.5.  Notwithstanding termination by TMRC under this Section 10.5, any royalties or milestone payments that have accrued prior to such termination shall survive such termination.

 

10.6.                     Insolvency or Bankruptcy.  To the extent permitted by applicable Laws, either party may, in addition to any other remedies available to it by Law or in equity, terminate this Agreement, in whole or in part, by written notice to the other party in the event the other party shall have become insolvent or bankrupt, or shall have made assignment for the benefit of its creditors, or there shall have been appointed a trustee or receiver of the other party.  The parties agree that, in the event of the commencement of a bankruptcy proceeding by or against TMRC or Syros under applicable Laws that has not been dismissed or resolved within [**] days, the other party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any intellectual property obtained in the course of development of the Product and all embodiments of such intellectual property shall be promptly delivered to it upon any such termination of this Agreement, upon expiration of such [**] day period upon its written request therefor, unless the insolvent or bankrupt party elects to continue to perform all of its obligations under this Agreement.

 

10.7.                     Effect of Expiration or Termination.

 

10.7.1.           Expiration or termination of this Agreement shall not relieve the parties of any right or obligation accruing prior to such expiration or termination, and the provisions of Sections 4.2, 8, 10.3, 10.7, 11 and 13 shall survive the expiration or termination of this Agreement.

 

17

 

10.7.2.           Upon any termination of this Agreement, at Syros’ request, TMRC shall grant a direct license to any sublicensee of Syros hereunder having the same scope as the sublicense granted to such sublicensee by Syros and on terms and conditions no less favorable to such sublicensee than the terms and conditions of this Agreement, provided that such sublicensee is not in default of any applicable obligations under this Agreement and agrees in writing to be bound by the terms and conditions of such direct license.

 

10.7.3.           Upon a termination of this Agreement under Sections 10.2 or 10.5 or a termination by TMRC under Section 10.6, (a) Syros shall, within [**] days after the effective date of such termination, provide TMRC with any data generated by Syros or its Affiliates as part of a Clinical Trial of the Technology; and (b) Syros hereby grants TMRC, effective as of the effective date of such termination, a Right of Reference to Registrations held by Syros or its affiliates as of the effective date of such termination that relate to the Technology, which TMRC may sublicense to its Affiliates or sublicensees.

 

11.                               INDEMNIFICATION

 

11.1.                     Indemnification.  Each party shall defend, indemnify and hold harmless the other party from all losses, liabilities, damages and expenses (including attorneys’ fees and costs) incurred as a result of any Third Party claim, demand, action or proceeding arising out of any breach of this Agreement by the indemnifying party, or the gross negligence or willful misconduct of the indemnifying party in the performance of its obligations under this Agreement, except in each case to the extent arising from the gross negligence or willful misconduct of the other party or the breach of this Agreement by the other party.

 

11.2.                     Procedure.  The indemnified party shall promptly notify the indemnifying party of any liability or action in respect of which the indemnified party intends to claim such indemnification and the indemnifying party shall have the right to assume the defense thereof with counsel selected by the indemnifying party.  The indemnity agreement in this Section 11 shall not apply to amounts paid in settlement of any loss, claim, damage, liability or action if such settlement is effected without the consent of the indemnifying party, which consent shall not be withheld unreasonably.  The failure to deliver notice to the indemnifying party within a reasonable time after the commencement of any such action, if prejudicial to its ability to defend such action, shall relieve the indemnifying party of any liability to the indemnified party under this Section 11, but the omission so to deliver notice to the indemnifying party will not relieve it of any liability that it may have to the indemnified party otherwise than under this Section 11.  The indemnified party under this Section 11, and its employees and agents, shall cooperate fully with the indemnifying party and its legal representatives in the investigation and defense of any action, claim or liability covered by this indemnification.

 

11.3.                     Insurance.  Syros shall maintain product liability insurance with respect to the research, development, manufacture and sales of Products by Syros in such amount as Syros customarily maintains with respect to the research, development, manufacture and sales of its similar products.  Syros shall maintain such insurance for so long as it continues to research, develop, manufacture or sell any Products, and thereafter for so long as Syros customarily maintains insurance covering the research, development, manufacture or sale of its similar products.

 

18

 

12.                               FORCE MAJEURE

 

Neither party shall be held liable or responsible to the other party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of this Agreement to the extent, and for so long as, such failure or delay is caused by or results from causes beyond the reasonable control of the affected party including fire, floods, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority or the other party.

 

13.                               MISCELLANEOUS

 

13.1.                     Notices.  Any consent, notice or report required or permitted to be given or made under this Agreement by one of the parties hereto to the other party shall be in writing, delivered by any lawful means to such other party at its address indicated below, or to such other address as the addressee shall have last furnished in writing to the addressor and (except as otherwise provided in this Agreement) shall be effective upon receipt by the addressee.

 

	
If to TMRC:
    	
TMRC Co., Ltd.
    
	
 
    	
1-12-12 Kita Shinjuku
    
	
 
    	
Shinjuku-ku, Tokyo, 164-0074, Japan
    
	
 
    	
Attention: Research & Development   Department
    
	
 
    	
 
    
	
If to Syros:
    	
Syros Pharmaceuticals, Inc.
    
	
 
    	
620 Memorial Drive, Suite 300
    
	
 
    	
Cambridge, MA 02139, U.S.A.
    
	
 
    	
Attention: Chief Business Officer
    

 

13.2.                     Governing Law.  This Agreement shall be governed by and construed in accordance with the Laws of the State of California, without regard to the conflicts of Law principles thereof

 

13.3.                     Arbitration.  Any dispute, controversy or claim initiated by either party arising out of or relating to this Agreement, its negotiations, execution or interpretation, or the performance by either party of its obligations under this Agreement (other than (a) any dispute, controversy or claim regarding the validity, enforceability, claim construction or infringement of any patent rights, or defenses to any of the foregoing, or (b) any bona fide third party action or proceeding filed or instituted in an action or proceeding by a Third Party against a party to this agreement), whether before or after termination of this Agreement, shall be finally resolved by binding arbitration.  Whenever a party shall decide to institute arbitration proceedings, it shall give prompt written notice to that effect to the other party.  Any such arbitration shall be conducted in the English language under the International Dispute Resolution Procedures and Arbitration Rules of the American Arbitration Association (the “Rules”) by a panel of three (3) arbitrators appointed in accordance with such Rules.  Any such arbitration shall be held in Los Angeles, California.  The method and manner of discovery in any such arbitration proceedings shall be governed by the Rules.  The arbitrators shall have the authority to grant specific performance and

 

19

 

to allocate between the parties the costs of arbitration (including attorneys’ fees and expenses of the parties) in such equitable manner as they determine.

 

Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be.  In no event shall a demand for arbitration be made after the date when institution of a legal or equitable proceeding based upon such claim, dispute or other matter in question would be barred by the applicable statute of limitations.  Notwithstanding the foregoing, either party shall have the right, without waiving any right or remedy available to such party under this Agreement or otherwise, to seek and obtain from any court of competent jurisdiction any interim or provisional relief that is necessary or desirable to protect the rights or property of such party, pending the selection of the arbitrators hereunder or pending the arbitrators’ determination of any dispute, controversy or claim hereunder.

 

13.4.                     Assignment.  Syros shall not assign its rights or obligations under this Agreement without the prior written consent of TMRC; provided, however, that Syros may, without such consent, assign this Agreement and its rights and obligations hereunder (a) to any Affiliate, or (b) in connection with the sale or transfer of all or substantially all of its business or assets relating to the subject matter of this Agreement, or in the event of its merger, consolidation, change in control or similar transaction.  Any permitted assignee shall assume all obligations of its assignor under this Agreement.

 

13.5.                     Waivers and Amendments.  No change, modification, extension, termination or waiver of this Agreement, or any of the provisions herein contained, shall be valid unless made in writing and signed by duly authorized representatives of the parties hereto.

 

13.6.                     Entire Agreement.  This Agreement embodies the entire agreement between the parties and supersedes any prior representations, understandings and agreements between the parties regarding the subject matter hereof except the Confidential Disclosure and Non-Use Agreement dated as of February 24, 2015 between TMRC and Syros (the “Existing Confidentiality Agreement”).  There are no representations, understandings or agreements, oral or written, between the parties regarding the subject matter hereof that are not fully expressed herein except the Existing Confidentiality Agreement.  Nothing in this Agreement removes or overrides any right of action by any party in respect of any fraudulent misrepresentation, fraudulent concealment or other fraudulent action.

 

13.7.                     No Benefit to Third Parties.  The provisions of this Agreement are for the sole benefit of the parties and their successors and permitted assigns, and shall not be construed as conferring any rights in any other Persons.

 

13.8.                     Severability.  Any of the provisions of this Agreement which are determined to be invalid or unenforceable in any jurisdiction shall be ineffective to the extent of such invalidity or unenforceability in such jurisdiction, without rendering invalid or unenforceable the remaining provisions hereof and without affecting the validity or enforceability of any of the terms of this Agreement in any other jurisdiction.

 

20

 

13.9.                     Waiver.  The waiver by either party of any right hereunder or the failure to perform or of a breach by the other party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other party whether of a similar nature or otherwise.

 

13.10.              Counterparts.  This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

 

[Signature page follows]

 

21

 

IN WITNESS WHEREOF, the parties have executed this Cancer License Agreement effective as of the Effective Date.

 

 

	
 
    	
TMRC   CO., LTD.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s   Hisao Ekimoto
    
	
 
    	
Name:
    	
Hisao   Ekimoto
    
	
 
    	
Title:
    	
President &   CEO
    
	
 
    	
Date:
    	
September 11,   2015
    
	
 
    	
 
    	
 
    
	
 
    	
SYROS   PHARMACEUTICALS, INC.
    
	
 
    	
 
    	
 
    
	
 
    	
By:
    	
/s/   Nancy Simonian
    
	
 
    	
Name:
    	
Nancy Simonian
    
	
 
    	
Title   :
    	
Chief   Executive Officer
    

 

[Signature page to Cancer License Agreement]

 

22

 

EXHIBIT A

 

Certain Licensed Patent Rights

 

	
Series
    	
 
    	
Country
    	
 
    	
Serial No.
    	
 
    	
Filing Date
    	
 
    	
Publication
    	
 
    	
Patent
    	
 
    	
Priority
    	
 
    	
Subject
   Matter/Other
   Info
    
	
[**]
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[**]
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
[**]
    	
 
    	
[**]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
[**]
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    	
 
    	
 
    	
 
    	
[**]
    

 

23

 

EXHIBIT B

 

AM80 (Tamibarotene)

 

 

EXHIBIT C

 

Certain Bonus Amounts

 

1.     Syros and TMRC will use commercially reasonable efforts to execute the Toko Letter Agreement and Supply Agreement.

2.     If Toko and the parties execute the Toko Letter Agreement and the parties execute the Supply Agreement, Syros will pay the US$[**] set forth in item #2 of Section 4.5, and shall also pay the following additional amount to the extent applicable:

a.                                 A bonus of US$[**] if the foregoing items are completed within [**] days after the Effective Date;

b.                                 A bonus of US$[**] if the foregoing items are completed within [**] days after the Effective Date; or

c.                                  A bonus of US$[**] if the foregoing items are completed within [**] days after the Effective Date.

 

 

EXHIBIT D

 

Possible Clinical Supply Agreement Terms

 

·                  Sourcing.  Syros shall purchase 100% of its Sales API requirements from TMRC and TMRC shall sell to Syros such quantities of Sales API as Syros shall require.

 

·                  Quality.  All Sales API shall be of pharmaceutical quality suitable for human use and meet the specifications therefor at the time of delivery.  TMRC shall provide all Sales API manufactured in conformity with specifications and applicable current good manufacturing practices (GMP) standards and in compliance with all applicable laws and regulations in the Territory.

 

·                  Information Update.   Information regarding drug manufacturing shall be updated as required to reflect the batches of Sales API as may be required from time to time, whether such information is part of the drug manufacturing file or not.

 

·                  Verification.  TMRC shall provide Syros with certificates of analysis for all Sales API it supplies.  Syros shall have to right to request and obtain from TMRC reports on manufacturing and quality controls and GMP audits at TMRC’s and its Third Party suppliers’ manufacturing facilities, and at its expense Syros may investigate such reports on site.

 

·                  Forecasts and Orders.  At the beginning of each [**] Syros will provide to TMRC written [**] rolling forecasts for the subsequent [**] for planning purposes.  Syros will submit firm purchase orders to TMRC specifying the quantity, price and delivery details no less than [**] days prior to the delivery date.  Syros may reject any non-conforming Sales API and notify TMRC within [**] days of the rejection.  TMRC will use commercially reasonable effort to replace any non-conforming Sales API at TMRC’s expense within [**] days of notice of rejection by Syros.

 

·                  Price.  Syros will pay TMRC $[**] per kilogram of Sales API.

 

·                  Regulatory Cooperation.  TMRC will cooperate with all requests from regulatory authorities for information or access to manufacturing facilities, and to cause any subcontractors to likewise cooperate, including pre-approval inspections.  TMRC will coordinate with Syros to permit Syros to be present for all inspections by regulatory authorities, and to cause any subcontractors to do the same.

 

26

 

·                  Reps and Warranties.  TMRC will provide customary reps and warranties.

 

·                  Risk Mitigation.  TMRC will in good faith discuss and cooperate with Syros and TMRC’s Third Party suppliers to develop a reasonable risk mitigation strategy and plan, which shall include the selection and oversight of back-up suppliers, to avoid potential interruptions in supply of Sales API by TMRC to Syros, and will use reasonable efforts to implement such strategy and plan with appropriate input (with Syros to bear any pass-through costs approved by Syros in advance) and participation by Syros.  Such strategy and plan will include TMRC establishing back-up suppliers of Sales API (API and bulk tableting).  TMRC will cooperate with Syros to establish a Syros back-up option that Syros can use if there is a failure to supply (below).

 

·                  Failure to supply.  TMRC and Syros will in good faith discuss and cooperate to implement a reasonable plan of action to minimize any supply interruption.  Failure to supply standard based on failure by TMRC to deliver conforming Sales API in satisfaction of Syros’ orders, with ( )-day cure period; failure to supply triggers requirement for TMRC to obtain and deliver conforming supply satisfying Syros’ orders from an alternative source for API within ( )  days; if TMRC does not cure within ( ) days and does not thereafter obtain conforming supply satisfying Syros’ orders from an alternative source within such ( )  days, Syros will have the right to source Product from suppliers other than TMRC, including any back-up supplier established pursuant to the risk mitigation strategy and plan.

 

·                  Termination.  This agreement will terminate immediately upon termination or expiration of the License Agreement.  Either party may terminate this agreement upon uncured material breach of the other party.

 

·                  Commercial Supply Agreement.  Upon Syros’s request, the parties shall negotiate in good faith a supply agreement in respect of supply of Sales API for commercial production, which the parties anticipate will happen prior to the first dosing of the first subject in a Phase III Clinical Trial.

 

27

 

EXHIBIT E

 

Possible Consent and Stand-by License

 

This CONSENT AND STAND-BY LICENSE (“Consent”) is given as of        , 2015, by TOKO PHARMACEUTICAL IND. CO., LTD., a Japanese corporation having its principal office at                   , Japan (“Toko”), to SYROS PHARMACEUTICALS, INC., a Delaware corporation having its principal office at 480 Arsenal Street, Suite 130, Watertown, Massachusetts 02472, USA (“Syros”).

 

WHEREAS, Toko is a party to an agreement with TMRC Co., Ltd., a Japanese corporation (“TMRC”) entitled “License Agreement for the development et al. of retinoid based drug in foreign countries for cancer” dated August 15, 2008 and License Agreement for the development et al. of retinoid based drug in foreign countries for neutropenia dated June 13, 2014 (collectively, the “Toko-TMRC License Agreement”) as well as one or more related supply agreements relating to the compound known as AM80 (Tamibarotene) in bulk active pharmaceutical ingredient form (collectively, the “Toko-TMRC Supply Agreement” and, together with the Toko-TMRC License Agreement, the “Toko-TMRC Agreement”);

 

WHEREAS, Syros and TMRC have negotiated and executed a license agreement for cancer dated September   , 2015 and may in the future negotiate a license agreement for neutropenia pursuant to which, upon execution, TMRC will grant to Syros certain rights and licenses under patent rights, know-how and data controlled by TMRC as to AM80 (Tamibarotene), including under certain rights and licenses therein granted to TMRC by Toko in the Toko-TMRC Agreement (collectively, the “TMRC-Syros License Agreement”); and

 

WHEREAS, pursuant to the TMRC-Syros License Agreement, TMRC and Syros will enter into one or more supply agreements pursuant to which TMRC will supply Syros’ requirements for AM80 (Tamibarotene) and Syros will purchase such requirements from TMRC (collectively, the “TMRC-Syros Supply Agreement”);

 

WHEREAS, prior to Syros entering into the TMRC-Syros License Agreement, Syros has requested that Toko provide the assurances and make the undertakings set forth herein;

 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Syros and Toko hereby agree as follows:

 

1.              If at any time the Toko-TMRC License Agreement or any right or license granted to TMRC thereunder terminates or otherwise ceases to be in effect for any reason (the effective time of such termination or other cessation, the “Effective Time”), Toko hereby grants, effective as of the Effective Time, directly to Syros, without any need for further action by Syros, such rights and licenses with respect to AM80 (Tamibarotene) and product(s) comprising AM80 (Tamibarotene) as are necessary for Syros to continue to make, use, offer for sale, sell and import AM80 (Tamibarotene)

 

28

 

products (the “Stand-by License”). In this case the word “make” means (a) making finished Product from Sales API and (b) manufacturing AM80 (Tamibarotene) to the extent permitted in paragraph 8 below.

 

 

2.              Toko will provide prompt written notice to Syros of any breach by TMRC of any agreement between Toko and TMRC.

 

3.              Toko acknowledges and agrees that nothing in the Toko-TMRC Agreement would prevent the development and commercialization of a companion diagnostic for products comprising AM80 (Tamibarotene), without obtaining any additional right or license from Toko, whether by Syros or any affiliate or third party, and acknowledges that TMRC has the right to grant such development and commercialization rights to Syros without violating the Toko-TMRC Agreement.

 

4.              To the extent that Syros requires any information regarding the manufacture of AM80 (Tamibarotene) that is possessed by Toko in order to satisfy requirements of regulatory authorities as to product(s) comprising AM80 (Tamibarotene), Toko shall provide Syros with such information as reasonably requested by Syros through TMRC and hereby grants Syros the right to use such information, and to permit its affiliates and licensees to use such information, to satisfy such regulatory requirements.

 

5.              Toko shall cooperate with Syros to comply with requests of regulatory authorities for access to and/or information regarding Toko’s manufacturing facilities and processes for product(s) comprising AM80 (Tamibarotene).

 

6.              If requested by either Toko or Syros, Toko and Syros shall enter into a reasonable and customary pharmacovigilance agreement for the maintenance and exchange of safety data relating to product(s) comprising AM80 (Tamibarotene).

 

7.              [**]

 

8.              [**].

 

9.              This Consent shall be governed by the laws of the State of California, USA, excluding the provisions thereof relating to conflicts of laws.

 

29

 

EXHIBIT F

 

TMRC Grants of Rights to Third Parties

 

The rights granted by TMRC to CHILDREN’S HOSPITAL LOS ANGELES in the COLLABORATION AGREEMENT as of July 18, 2014.

 

30

 

EXHIBIT G

 

Form of Initial Supply Order

 

PURCHASE ORDER

 

Purchase Order No.:                              

 

BETWEEN

 

	
TMRC   Co., Ltd. (“TMRC”)
    	
Syros   Pharmaceuticals, Inc. (“Syros”)
    
	
1-12-12,   Kita Shinjyuku 
    	
620   Memorial Drive, Suite 300 
    
	
Shinjuku-ku,   Tokyo 164-0074
    	
Cambridge,   MA 02139
    
	
Japan
    	
USA
    
	
 
    	
 
    
	
Principal   Contact:
    	
 
    	
 
    	
Principal   Contact:
    	
 
    
	
Phone:
    	
 
    	
 
    	
Phone:
    	
 
    
	
Fax:
    	
 
    	
 
    	
Fax:
    	
 
    
	
Email:
    	
 
    	
 
    	
Email:
    	
 
    

 

This Purchase Order is subject to the terms of the Cancer License Agreement between TMRC and Syros, dated [September 10, 2015].

 

1.                                      Sales API

 

	
Batch
   Name
    	
 
    	
DMF
   number
    	
 
    	
Destination
    	
 
    	
Delivery Date
    	
 
    	
Amount     of
   Sales API
    	
 
    	
Unit Price
    	
 
    	
Subtotal
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Grand       total   before tax
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Applicable tax
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Grand total
    	
 
    	
 
    

 

2.                                      Shipping Term

 

All Sales API shall be shipped CIF the destination set forth above (Incoterms 2010).

 

3.                                      Invoices

 

Original invoices shall be sent to: [Contact], Syros Pharmaceuticals, Inc., 620 Memorial Drive, Suite 300, Cambridge, MA 02139, USA.

 

 

	
TMRC   Co., Ltd.
    	
Syros   Pharmaceuticals, Inc.
    
	
 
    	
 
    
	
By:
    	
 
    	
 
    	
By:
    	
 
    
					

 

 

 

	
Name:
    	
 
    	
 
    	
Name:
    	
 
    
	
Title:
    	
 
    	
 
    	
Title:
    	
 
    
	
Date:
    	
 
    	
 
    	
Date:Exhibit 10.17

 

620 MEMORIAL DRIVE CAMBRIDGE, MASSACHUSETTS

 

LEASE SUMMARY SHEET

 

	
Execution Date:
    	
 
    	
March 13, 2015
    
	
 
    	
 
    	
 
    
	
Tenant:
    	
 
    	
Syros Pharmaceuticals, Inc., a Delaware corporation
    
	
 
    	
 
    	
 
    
	
Landlord:
    	
 
    	
620 Memorial Leasehold LLC, a Massachusetts limited   liability company
    
	
 
    	
 
    	
 
    
	
Building:
    	
 
    	
620 Memorial Drive, Cambridge, Massachusetts. The   Building consists of approximately 89,443 rentable square feet. The land on   which the Building is located (the “Land”) is   more particularly described in Exhibit 2 attached hereto and made a   part hereof (the Land, together with the Building, are hereinafter   collectively referred to as the “Property”).
    
	
 
    	
 
    	
 
    
	
Premises:
    	
 
    	
Approximately 21,488 rentable square feet of space   on the third (3rd)   floor of the Building, as more particularly shown as hatched, highlighted or   outlined on the plan attached hereto as Exhibit 1 and made a part hereof (the   “Lease Plan”).
    
	
 
    	
 
    	
 
    
	
Term Commencement Date:
    	
 
    	
The date on which the Premises are delivered to   Tenant with Landlord’s Work substantially complete and otherwise in the   condition required by Section 3.1 below. Targeted for August 31, 2015.
    
	
 
    	
 
    	
 
    
	
Rent Commencement Date:
    	
 
    	
Two (2) months after the Term Commencement Date.
    
	
 
    	
 
    	
 
    
	
Expiration Date:
    	
 
    	
The last day of the fifth (5th) Rent Year (hereinafter   defined)
    
	
 
    	
 
    	
 
    
	
Extension Term:
    	
 
    	
Subject to Section 1.2 below, one (1) extension term   of five (5) years
    
	
 
    	
 
    	
 
    
	
Landlord’s Contribution:
    	
 
    	
Subject to Section 3.5 below, One Million Six   Hundred Eleven Thousand Six Hundred Dollars ($1,611,600).
    
	
 
    	
 
    	
 
    
	
Permitted Uses:
    	
 
    	
Subject to Legal Requirements, general office,   research, development and laboratory use, and other ancillary uses related to   the foregoing (all in proportions consistent with the design of the base   Building).
    

 

1

 

	
Base   Rent:
    	
 
    	
RENT YEAR(1)
    	
 
    	
ANNUAL
   BASE RENT
    	
 
    	
MONTHLY
   RENT
    	
 
    
	
 
    	
 
    	
1
    	
 
    	
$
    	
1,160,352.00
    	
 
    	
$
    	
96,696.00
    	
 
    
	
 
    	
 
    	
2
    	
 
    	
$
    	
1,195,162.50
    	
 
    	
$
    	
99,596.88
    	
 
    
	
 
    	
 
    	
3
    	
 
    	
$
    	
1,231,017.30
    	
 
    	
$
    	
102,584.77
    	
 
    
	
 
    	
 
    	
4
    	
 
    	
$
    	
1,267,947.80
    	
 
    	
$
    	
105,662.31
    	
 
    
	
 
    	
 
    	
5
    	
 
    	
$
    	
1,305,986.20
    	
 
    	
108,832.18
    	
 
    
	
 
    	
 
    	
 
    
	
Operating Costs and Taxes:
    	
 
    	
See Sections 5.2 and 5.3
    
	
 
    	
 
    	
 
    
	
Tenant’s Share:
    	
 
    	
A fraction, the numerator of which is the number of rentable square   feet in the Premises and the denominator of which is the number of rentable   square feet in the Building.  As of the   Execution Date, Tenant’s Share is 24.02%.
    
	
 
    	
 
    	
 
    
	
Tenant’s Tax Share:
    	
 
    	
A fraction, the numerator of which is the number of rentable square   feet in the Premises and the denominator of which is the number of rentable   square feet in the Building recognized by the City of Cambridge as being used   for purposes which are not exempt from real estate taxation as of the date on   which the assessment is made for the tax year in question.  As of the Execution Date, Tenant’s Tax   Share is 24.02%.
    
	
 
    	
 
    	
 
    
	
Security Deposit/ Letter of Credit:
    	
 
    	
Subject to Section 7.1, $483,480.00
    

 

	
EXHIBIT   1
    	
LEASE   PLAN
    
	
EXHIBIT   2
    	
LEGAL   DESCRIPTION
    
	
EXHIBIT   3
    	
LANDLORD’S   WORK
    
	
EXHIBIT   4
    	
FORM   OF LETTER OF CREDIT
    
	
EXHIBIT   5
    	
ALTERATIONS   CHECKLIST
    
	
EXHIBIT   6
    	
TENANT’S   HAZARDOUS MATERIALS
    
	
EXHIBIT   7
    	
RULES   AND REGULATIONS
    
	
EXHIBIT   8
    	
LANDLORD’S   SERVICES
    

 

(1) For the purposes of this Lease, the first “Rent Year” shall be defined as the period commencing as of the Rent Commencement Date and ending on the last day of the twelfth full month after the Rent Commencement Date occurs; provided, however, if the Rent Commencement Date occurs on the first day of a calendar month, then the first Rent Year shall end on the day immediately preceding the first anniversary of the Rent Commencement Date. Thereafter, “Rent Year” shall be defined as any subsequent twelve (12) month period during the term of this Lease.

 

2

 

TABLE OF CONTENTS

 

	
1.
    	
LEASE GRANT; TERM;   APPURTENANT RIGHTS; EXCLUSIONS
    	
1
    
	
 
    	
 
    	
 
    
	
 
    	
1.1
    	
Lease Grant
    	
1
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
1.2
    	
Extension Term
    	
1
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
1.3
    	
Notice of Lease
    	
2
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
1.4
    	
Appurtenant Rights
    	
3
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
1.5
    	
Tenant’s Access
    	
4
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
1.6
    	
Exclusions
    	
4
    
	
 
    	
 
    	
 
    
	
2.
    	
RIGHTS RESERVED TO   LANDLORD
    	
4
    
	
 
    	
 
    	
 
    
	
 
    	
2.1
    	
Additions and   Alterations
    	
4
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
2.2
    	
Additions to the   Property
    	
4
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
2.3
    	
Name and Address of   Building
    	
4
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
2.4
    	
Landlord’s Access
    	
4
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
2.5
    	
Pipes, Ducts and   Conduits
    	
6
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
2.6
    	
Minimize Interference
    	
6
    
	
 
    	
 
    	
 
    
	
3.
    	
DELIVERY AND CONDITION   OF PREMISES; CONSTRUCTION
    	
6
    
	
 
    	
 
    	
 
    
	
 
    	
3.1
    	
Delivery and Condition   of Premises
    	
6
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
3.2
    	
Landlord’s Work
    	
6
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
3.3
    	
Substantial Completion;   Punchlist Items; Remedies for Late Delivery
    	
7
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
3.4
    	
Cost of Landlord’s Work
    	
7
    
	
 
    	
 
    	
 
    
	
4.
    	
USE OF PREMISES
    	
8
    
	
 
    	
 
    	
 
    
	
 
    	
4.1
    	
Permitted Uses
    	
8
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
4.2
    	
Prohibited Uses
    	
9
    
	
 
    	
 
    	
 
    
	
5.
    	
RENT; ADDITIONAL RENT
    	
10
    
	
 
    	
 
    	
 
    
	
 
    	
5.1
    	
Base Rent
    	
10
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
5.2
    	
Operating Costs
    	
10
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
5.3
    	
Taxes
    	
14
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
5.4
    	
Late Payments
    	
15
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
5.5
    	
No Offset; Independent   Covenants; Waiver
    	
15
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
5.6
    	
Survival
    	
16
    
	
 
    	
 
    	
 
    
	
6.
    	
RIGHT OF FIRST OFFER
    	
16
    
	
 
    	
 
    	
 
    
	
 
    	
6.1
    	
Right of First Offer
    	
16
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
6.2
    	
Offer and Acceptance   Procedures for Right of First Offer
    	
17
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
6.3
    	
Termination of Rights
    	
17
    

 

i

 

	
 
    	
6.4
    	
Rights Personal to   Tenant
    	
17
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
6.5
    	
Time is of the Essence
    	
17
    
	
 
    	
 
    	
 
    
	
7.
    	
LETTER OF CREDIT
    	
18
    
	
 
    	
 
    	
 
    
	
 
    	
7.1
    	
Amount
    	
18
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
7.2
    	
Application of Proceeds   of Letter of Credit
    	
18
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
7.3
    	
Transfer of Letter of   Credit
    	
19
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
7.4
    	
Credit of Issuer of   Letter of Credit
    	
19
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
7.5
    	
Security Deposit
    	
19
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
7.6
    	
Return of Security   Deposit or Letter of Credit
    	
19
    
	
 
    	
 
    	
 
    
	
8.
    	
INTENTIONALLY OMITTED
    	
19
    
	
 
    	
 
    	
 
    
	
9.
    	
UTILITIES, HVAC; WASTE
    	
19
    
	
 
    	
 
    	
 
    
	
 
    	
9.1
    	
Electricity
    	
19
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
9.2
    	
Water
    	
20
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
9.3
    	
Gas
    	
20
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
9.4
    	
HVAC
    	
20
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
9.5
    	
Other Utilities;   Utility Information
    	
20
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
9.6
    	
Interruption or   Curtailment of Utilities
    	
21
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
9.7
    	
Telecommunications   Providers
    	
21
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
9.8
    	
Landlord’s Services
    	
22
    
	
 
    	
 
    	
 
    
	
10.
    	
MAINTENANCE AND REPAIRS
    	
22
    
	
 
    	
 
    	
 
    
	
 
    	
10.1
    	
Maintenance and Repairs   by Tenant
    	
22
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
10.2
    	
Maintenance and Repairs   by Landlord
    	
22
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
10.3
    	
Accidents to Sanitary   and Other Systems
    	
22
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
10.4
    	
Floor Load—Heavy   Equipment
    	
23
    
	
 
    	
 
    	
 
    
	
11.
    	
ALTERATIONS AND   IMPROVEMENTS BY TENANT
    	
23
    
	
 
    	
 
    	
 
    
	
 
    	
11.1
    	
Landlord’s Consent   Required
    	
23
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
11.2
    	
Supervised Work
    	
24
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
11.3
    	
Harmonious Relations
    	
24
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
11.4
    	
Liens
    	
24
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
11.5
    	
General Requirements
    	
25
    
	
 
    	
 
    	
 
    
	
12.
    	
SIGNAGE
    	
25
    
	
 
    	
 
    	
 
    
	
 
    	
12.1
    	
Restrictions
    	
25
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
12.2
    	
Building Directory
    	
25
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
12.3
    	
Monument Sign
    	
25
    

 

ii

 

	
13.
    	
ASSIGNMENT, MORTGAGING   AND SUBLETTING
    	
26
    
	
 
    	
 
    	
 
    
	
 
    	
13.1
    	
Landlord’s Consent   Required
    	
26
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
13.2
    	
Landlord’s Recapture   Right
    	
26
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
13.3
    	
Standard of Consent to   Transfer
    	
27
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
13.4
    	
Listing Confers no   Rights
    	
27
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
13.5
    	
Profits In Connection   with Transfers
    	
27
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
13.6
    	
Prohibited Transfers
    	
27
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
13.7
    	
Exceptions to   Requirement for Consent
    	
28
    
	
 
    	
 
    	
 
    
	
14.
    	
INSURANCE;   INDEMNIFICATION; EXCULPATION
    	
28
    
	
 
    	
 
    	
 
    
	
 
    	
14.1
    	
Tenant’s Insurance
    	
28
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
14.2
    	
Indemnification
    	
29
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
14.3
    	
Property of Tenant
    	
30
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
14.4
    	
Limitation of   Landlord’s Liability for Damage or Injury
    	
30
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
14.5
    	
Waiver of Subrogation;   Mutual Release
    	
31
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
14.6
    	
Tenant’s Acts—Effect on   Insurance
    	
31
    
	
 
    	
 
    	
 
    
	
15.
    	
CASUALTY; TAKING
    	
31
    
	
 
    	
 
    	
 
    
	
 
    	
15.1
    	
Damage
    	
31
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
15.2
    	
Termination Rights
    	
32
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
15.3
    	
Taking for Temporary   Use
    	
33
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
15.4
    	
Disposition of Awards
    	
33
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
15.5
    	
Abatement
    	
33
    
	
 
    	
 
    	
 
    
	
16.
    	
ESTOPPEL CERTIFICATE
    	
33
    
	
 
    	
 
    	
 
    
	
17.
    	
HAZARDOUS MATERIALS
    	
34
    
	
 
    	
 
    	
 
    
	
 
    	
17.1
    	
Prohibition
    	
34
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
17.2
    	
Environmental Laws
    	
34
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
17.3
    	
Hazardous Material   Defined
    	
35
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
17.4
    	
Testing
    	
35
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
17.5
    	
Indemnity; Remediation
    	
35
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
17.6
    	
Disclosures
    	
37
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
17.7
    	
Removal
    	
37
    
	
 
    	
 
    	
 
    
	
18.
    	
RULES AND REGULATIONS
    	
37
    
	
 
    	
 
    	
 
    
	
 
    	
18.1
    	
Rules and Regulations
    	
37
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
18.2
    	
Energy Conservation
    	
37
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
18.3
    	
Recycling
    	
38
    

 

iii

 

	
19.
    	
LAWS AND PERMITS
    	
38
    
	
 
    	
 
    	
 
    
	
 
    	
19.1
    	
Legal Requirements
    	
38
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
19.2
    	
Required Permits
    	
38
    
	
 
    	
 
    	
 
    
	
20.
    	
DEFAULT
    	
38
    
	
 
    	
 
    	
 
    
	
 
    	
20.1
    	
Events of Default
    	
38
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
20.2
    	
Remedies
    	
40
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
20.3
    	
Damages - Termination
    	
40
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
20.4
    	
Landlord’s Self-Help;   Fees and Expenses
    	
42
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
20.5
    	
Waiver of Redemption,   Statutory Notice and Grace Periods
    	
42
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
20.6
    	
Landlord’s Remedies Not   Exclusive
    	
42
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
20.7
    	
No Waiver
    	
42
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
20.8
    	
Restrictions on   Tenant’s Rights
    	
42
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
20.9
    	
Landlord Default
    	
43
    
	
 
    	
 
    	
 
    
	
21.
    	
SURRENDER; ABANDONED   PROPERTY; HOLD-OVER
    	
43
    
	
 
    	
 
    	
 
    
	
 
    	
21.1
    	
Surrender
    	
43
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
21.2
    	
Abandoned Property
    	
45
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
21.3
    	
Holdover
    	
45
    
	
 
    	
 
    	
 
    
	
22.
    	
MORTGAGEE RIGHTS
    	
45
    
	
 
    	
 
    	
 
    
	
 
    	
22.1
    	
Subordination
    	
45
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
22.2
    	
Notices
    	
46
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
22.3
    	
Mortgagee Liability
    	
46
    
	
 
    	
 
    	
 
    
	
23.
    	
QUIET ENJOYMENT
    	
46
    
	
 
    	
 
    	
 
    
	
24.
    	
NOTICES
    	
46
    
	
 
    	
 
    	
 
    
	
25.
    	
MISCELLANEOUS
    	
47
    
	
 
    	
 
    	
 
    
	
 
    	
25.1
    	
Separability
    	
47
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.2
    	
Captions
    	
47
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.3
    	
Broker
    	
48
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.4
    	
Entire Agreement
    	
48
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.5
    	
Governing Law
    	
48
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.6
    	
Representation of   Authority
    	
48
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.7
    	
Expenses Incurred by   Landlord Upon Tenant Requests
    	
48
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.8
    	
Survival
    	
48
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.9
    	
Limitation of Liability
    	
48
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.10
    	
Binding Effect
    	
49
    

 

iv

 

	
 
    	
25.11
    	
Landlord Obligations   upon Transfer
    	
49
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.12
    	
No Grant of Interest
    	
49
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.13
    	
No Air Rights
    	
49
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.14
    	
Financial Information
    	
49
    
	
 
    	
 
    	
 
    	
 
    
	
 
    	
25.15
    	
Confidentiality
    	
49
    

 

v

 

THIS INDENTURE OF LEASE (this “Lease”) is hereby made and entered into on the Execution Date by and between Landlord and Tenant.

 

This Lease and all of its terms, covenants, representations, warranties, agreements and conditions are in all respects subject and subordinate to that certain Master Lease Agreement dated as of May 15, 2014 by and between MIT 620 Memorial LLC (“Fee Owner”), as landlord, and Landlord, as tenant (as it may be amended from time to time, the “Ground Lease”), a redacted copy of which has been delivered to Tenant.  Tenant acknowledges notice and full knowledge of all of the terms, covenants and conditions of the Ground Lease.

 

Each reference in this Lease to any of the terms and titles contained in any Exhibit attached to this Lease shall be deemed and construed to incorporate the data stated under that term or title in such Exhibit.  All capitalized terms not otherwise defined herein shall have the meanings ascribed to them as set forth in the Lease Summary Sheet which is attached hereto and incorporated herein by reference.

 

1.                                      LEASE GRANT; TERM; APPURTENANT RIGHTS; EXCLUSIONS.

 

1.1                               Lease Grant.  Landlord hereby leases to Tenant, and Tenant hereby leases from Landlord, the Premises upon and subject to terms and conditions of this Lease, for a term of years commencing on the Term Commencement Date and, unless earlier terminated or extended pursuant to the terms hereof, ending on the Expiration Date (the “Initial Term”; the Initial Term and any duly exercised Extension Terms are hereinafter collectively referred to as the “Term”).

 

1.2                               Extension Term.

 

(a)                                 Provided (i) Tenant, an Affiliated Entity (hereinafter defined), a Successor (hereinafter defined) or an assignee pursuant to a Permitted Transfer (hereinafter defined) is occupying(2) at least sixty-five percent (65%) of the Premises; and (ii) there is no Event of Default (1) as of the date of the Extension Notice (hereinafter defined), and (2) at the commencement of the applicable Extension Term (hereinafter defined), Tenant shall have the option to extend the Term for one (1) additional term of five (5) years (the “Extension Term”), commencing as of the expiration of the Initial Term.  Tenant must exercise such option to extend by giving Landlord written notice (the “Extension Notice”) on or before the date that is twelve (12) months prior to the expiration of the then-current term of this Lease, time being of the essence.  Notwithstanding the foregoing, Landlord may nullify Tenant’s exercise of its option to extend the Term by written notice to Tenant (the “Nullification Notice”) if (A) on the date Landlord receives the applicable Extension Notice, there is an event which, with the passage of time and/or the giving of notice, would constitute an Event of Default hereunder and (B) Tenant fails to cure such default within the applicable cure period set forth in Section 20.1 after receipt of the Nullification Notice.  Upon the timely giving of such notice, the Term shall be deemed extended upon all of the terms and conditions of this Lease, except that Base Rent during the Extension Term shall be calculated in accordance with this Section 1.2, Landlord shall have no obligation to construct or renovate the Premises and Tenant shall have no further right to extend the Term.  If Tenant fails to give timely notice, as aforesaid, Tenant shall have no further right to extend the Term.  Notwithstanding the

 

(2) For purposes of this Section 1.2, space shall be deemed “occupied” if it is not subject to any sublease, license or use or occupancy agreement

 

1

 

fact that Tenant’s proper and timely exercise of such option to extend the Term shall be self executing, the parties shall promptly execute a lease amendment reflecting such Extension Term after Tenant exercises such option.  The execution of such lease amendment shall not be deemed to waive any of the conditions to Tenant’s exercise of its rights under this Section 1.2.

 

(b)                                 The Base Rent during the Extension Term (the “Extension Term Base Rent”) shall be determined in accordance with the process described hereafter.  Extension Term Base Rent shall be the greater of (i) Base Rent for the last Rent Year of the prior term, or (ii) the fair market rental value of the Premises then demised to Tenant as of the commencement of the Extension Term as determined in accordance with the process described below, for renewals of combination laboratory and office space in the vicinity of the Building of equivalent quality, size, utility and location, with all relevant factors to be taken into account.  Within thirty (30) days after receipt of the Extension Notice, Landlord shall deliver to Tenant written notice of its determination of the Extension Term Base Rent for the Extension Term.  Tenant shall, within thirty (30) days after receipt of such notice, notify Landlord in writing whether Tenant accepts or rejects Landlord’s determination of the Extension Term Base Rent (“Tenant’s Response Notice”).  If Tenant fails timely to deliver Tenant’s Response Notice, Landlord’s determination of the Extension Term Base Rent shall be binding on Tenant.

 

(c)                                  If and only if Tenant’s Response Notice is timely delivered to Landlord and indicates both that Tenant rejects Landlord’s determination of the Extension Term Base Rent and desires to submit the matter to arbitration, then the Extension Term Base Rent shall be determined in accordance with the procedure set forth in this Section 1.2(c).  In such event, within ten (10) days after receipt by Landlord of Tenant’s Response Notice indicating Tenant’s desire to submit the determination of the Extension Term Base Rent to arbitration, Tenant and Landlord shall each notify the other, in writing, of their respective selections of an appraiser (respectively, “Landlord’s Appraiser” and “Tenant’s Appraiser”).  Landlord’s Appraiser and Tenant’s Appraiser shall then jointly select a third appraiser (the “Third Appraiser”) within ten (10) days of their appointment.  All of the appraisers selected shall be individuals with at least five (5) consecutive years’ commercial appraisal experience in the area in which the Premises are located, shall be members of the Appraisal Institute (M.A.I.), and, in the case of the Third Appraiser, shall not have acted in any capacity for either Landlord or Tenant within five (5) years of his or her selection.  The three appraisers shall determine the Extension Term Base Rent in accordance with the requirements and criteria set forth in Section 1.2(b) above, employing the method commonly known as Baseball Arbitration, whereby Landlord’s Appraiser and Tenant’s Appraiser each sets forth its determination of the Extension Term Base Rent as defined above, and the Third Appraiser must select one or the other (it being understood that the Third Appraiser shall be expressly prohibited from selecting a compromise figure).  Landlord’s Appraiser and Tenant’s Appraiser shall deliver their determinations of the Extension Term Base Rent to the Third Appraiser within five (5) days of the appointment of the Third Appraiser and the Third Appraiser shall render his or her decision within ten (10) days after receipt of both of the other two determinations of the Extension Term Base Rent.  The Third Appraiser’s decision shall be binding on both Landlord and Tenant.  Each party shall bear the cost of its own appraiser and shall share equally in the cost of the Third Appraiser.

 

1.3                               Notice of Lease.  Neither party shall record this Lease, but each of the parties hereto agrees to join in the execution, in recordable form, of a statutory notice of lease and/or

 

2

 

written declaration in which shall be stated the Term Commencement Date, the number and length of the Extension Terms and the Expiration Date, which notice of lease may be recorded by Tenant with the Middlesex South Registry of Deeds and/or filed with the Registry District of the Land Court, as appropriate (collectively, the “Registry”) at Tenant’s sole cost and expense.  If a notice of lease was previously recorded with the Registry, upon the expiration or earlier termination of this Lease, Landlord shall deliver to Tenant a notice of termination of lease and Tenant shall promptly execute and deliver the same to Landlord for Landlord’s execution and recordation with the Registry.  If Tenant fails to deliver the executed notice of termination of lease within ten (10) days of receipt thereof, time being of the essence, Tenant hereby appoints Landlord as Tenant’s attorney-in-fact to execute the same, such appointment being coupled with an interest.

 

1.4                               Appurtenant Rights.

 

(a)                                 Common Areas.  Subject to the terms of this Lease and the Rules and Regulations (hereinafter defined), Tenant shall have, as appurtenant to the Premises, rights to use in common with others entitled thereto, the areas designated from time to time for the common use of Tenant and other tenants of the Property (such areas are hereinafter referred to as the “Common Areas”).  The Common Areas include:  (i) the common lobbies, passenger and freight elevators, loading docks, hallways and stairways of the Building serving the Premises, (ii) common walkways necessary for access to the Building, (iii) if the Premises include less than the entire rentable area of any floor, the common toilets and other common facilities of such floor; and (iv) other areas designated by Landlord from time to time for the common use of Tenant and other tenants of the Building; and no other appurtenant rights or easements

 

(b)                                 Parking.  During the Term, commencing on the Term Commencement Date, Landlord shall, subject to the terms hereof, make available up to twenty-one (21) parking spaces for Tenant’s use in the parking areas serving the Building (which parking spaces are, subject to the last sentence of this Section 1.4(b), located in the surface lot in front of the Building).  The number of parking spaces in the parking areas reserved for Tenant, as modified pursuant to this Lease or as otherwise permitted by Landlord are hereinafter referred to as the “Parking Spaces.” Tenant shall have no right to hypothecate or encumber the Parking Spaces, and shall not sublet, assign, or otherwise transfer the Parking Spaces other than to employees of Tenant occupying the Premises or to a Successor (hereinafter defined), an Affiliated Entity (hereinafter defined) or a transferee pursuant to an approved Transfer under Section 13 of this Lease.  Throughout the Term, Tenant shall pay Landlord (or at Landlord’s direction, directly to the parking operator(3)) for all of the Parking Spaces at the then-current prevailing rate, as such rate may vary from time to time.  As of the Execution Date, the monthly charge for parking is Two Hundred Dollars ($200) per Parking Space per month.  If, for any reason, Tenant shall fail timely to pay the charge for any of said Parking Spaces, and if such default continues for ten (10) business days after written notice thereof, Tenant shall have no further right to the Parking Spaces for which Tenant failed to pay the charge under this Section 1.4(b) and Landlord may allocate such Parking Spaces for use by other tenants of the Property free and clear of Tenant’s rights under this Section 1.4(b).  Said Parking Spaces will be on an unassigned, non-reserved basis, and shall be subject to such reasonable rules and regulations as may be in effect for the use of the parking areas from time to time (including, without limitation, Landlord’s right, without additional charge to Tenant above

 

(3) e.g., in the event that the Landlord has leased or subleased the parking areas to a third party

 

3

 

the prevailing rate for Parking Spaces, to institute a valet or attendant-managed parking system).  Reserved and handicap parking spaces must be honored.  Notwithstanding anything to the contrary contained herein, in connection with the exercise of Landlord’s rights pursuant to Section 2.2 below, or in connection with the development or redevelopment of other property owned or controlled by Landlord, Landlord shall have the right to relocate the Parking Spaces from time to time to other property owned or controlled by Landlord or its affiliates, so long as such other property is within 1,000 feet of the Land.

 

1.5                               Tenant’s Access.  From and after the Term Commencement Date and until the end of the Term, Tenant shall have access to the Premises twenty-four (24) hours a day, seven (7) days a week, subject to Legal Requirements, the Rules and Regulations, the terms of this Lease , Landlord’s Force Majeure (hereinafter defined) and matters of record.

 

1.6                               Exclusions.  The following are expressly excluded from the Premises and reserved to Landlord:  all the perimeter walls of the Premises (except the inner surfaces thereof), the Common Areas, and any space in or adjacent to the Premises used for shafts, stacks, pipes, conduits, wires and appurtenant fixtures, fan rooms, ducts, electric or other utilities, sinks or other Building facilities, and the use of all of the foregoing, except as expressly permitted pursuant to Section 1.4(a) above.

 

2.                                      RIGHTS RESERVED TO LANDLORD.

 

2.1                               Additions and Alterations.  Landlord reserves the right, at any time and from time to time, to make such changes, alterations, additions, improvements, repairs or replacements in or to the Property (including the Premises but, with respect to the Premises, only for purposes of repairs, maintenance, replacements and other rights expressly reserved to Landlord herein) and the fixtures and equipment therein, as well as in or to the street entrances and/or the Common Areas, as it may deem necessary or desirable, provided, however, that there be no material obstruction of access to, or material interference with the use and enjoyment of, the Premises by Tenant.  Subject to the foregoing, Landlord expressly reserves the right to temporarily close all, or any portion, of the Common Areas for the purpose of making repairs or changes thereto.

 

2.2                               Additions to the Property.  Landlord may at any time or from time to time construct additional improvements in all or any part of the Property, including, without limitation, adding additional buildings or changing the location or arrangement of any improvement in or on the Property or all or any part of the Common Areas, or add or deduct any land to or from the Property; provided that there shall be no material increase in Tenant’s obligations or material interference with Tenant’s rights under this Lease in connection with the exercise of the foregoing reserved rights.

 

2.3                               Name and Address of Building.  Landlord reserves the right at any time and from time to time to change the name or address of the Building and/or the Property, provided Landlord gives Tenant at least three (3) months’ prior written notice thereof.

 

2.4                               Landlord’s Access.  Subject to the terms hereof, Tenant shall (a) upon as much advance notice as is practical under the circumstances, and in any event at least one (1) business day’s prior written notice (except that no notice shall be required in emergency situations), permit

 

4

 

Landlord and any holder of a Mortgage (hereinafter defined) (each such holder, a “Mortgagee”), and their agents, employees and contractors, to have free and unrestricted access to and to enter upon the Premises at all reasonable hours for the purposes of inspection, making repairs, replacements or improvements in or to the Premises or the Building or equipment therein (including, without limitation, sanitary, electrical, heating, air conditioning or other systems), complying with all applicable laws, ordinances, rules, regulations, statutes, by-laws, court decisions and orders and requirements of all public authorities (collectively, “Legal Requirements”), or exercising any right reserved to Landlord under this Lease (including without limitation the right to take upon or through, or to keep and store within the Premises all necessary materials, tools and equipment); (b) permit Landlord and its agents and employees, at reasonable times, upon reasonable advance notice, to show the Premises during normal business hours (i.e. Monday - Friday 8 A.M. - 6 P.M., Saturday 8 A.M. - 1 P.M., excluding holidays) to any prospective Mortgagee or purchaser of the Building and/or the Property or of the interest of Landlord therein, and, during the last nine (9) months of the Term, prospective tenants; (c) upon reasonable prior written notice from Landlord, permit Landlord and its agents, at Landlord’s sole cost and expense, to perform environmental audits, environmental site investigations and environmental site assessments (“Site Assessments”) in, on, under and at the Premises and the Land, it being understood that Landlord shall repair any damage arising as a result of the Site Assessments, and such Site Assessments may include both above and below the ground testing and such other tests as may be necessary or appropriate to conduct the Site Assessments; and (d) in case any excavation shall be made for building or improvements or for any other purpose upon the land adjacent to or near the Premises, afford without charge to Landlord, or the person or persons, firms or corporations causing or making such excavation, license to enter upon the Premises for the purpose of doing such work as Landlord or such person or persons, firms or corporation shall deem to be necessary to preserve the walls or structures of the Building from injury, and to protect the Building by proper securing of foundations.  The parties agree and acknowledge that, despite reasonable and customary precautions (which Landlord agrees it shall exercise), any property or equipment in the Premises of a delicate, fragile or vulnerable nature may nevertheless be damaged in the course of maintenance services being performed.  Accordingly, Tenant shall take reasonable protective precautions with unusually fragile, vulnerable or sensitive property and equipment.  Landlord shall provide Tenant with written notice at least seven (7) days’ prior to performing routine maintenance which would be reasonably expected to cause such damage.

 

Tenant may identify certain areas of the Premises that require limited access and strict security measures (“Security Areas”) by written notice to Landlord from time to time.  Except in the event of an emergency threatening personal injury, damage to property or a violation of any Legal Requirement (a “Secure Area Emergency”), and except as otherwise approved by Tenant, any entry in the Secure Areas must be done in the presence of a representative of Tenant so long as Tenant makes such representative available upon at least one (1) business day’s advance notice.  Notwithstanding foregoing, in the event of a Secure Area Emergency, Landlord may enter any part of the Premises without prior notice or a representative of Tenant; provided that Landlord provides Tenant with notice of such entry as soon as reasonably possible thereafter and Landlord takes reasonable precautions to protect the health and safety of its entrants.  Nothing in this paragraph will be construed as permitting Tenant to prohibit such access to any portion of the Premises.  Except in Secure Area Emergency situations, anyone who has access to a Secure Area may, at Tenant’s election, be subject to Tenant’s reasonable security measures and protocols, which may include limiting access to normal business hours and requiring the wearing of an ID badge.

 

5

 

2.5                               Pipes, Ducts and Conduits.  Tenant shall permit Landlord to erect, use, maintain and relocate pipes, ducts and conduits in and through the Premises, provided the same do not materially reduce the floor area or materially adversely affect the appearance thereof.

 

2.6                               Minimize Interference.  Subject to the provisions of this Lease, Tenant agrees to cooperate with Landlord as reasonably necessary in connection with the exercise of Landlord’s rights under this Section 2.  Tenant further agrees that dust, noise, vibration, temporary closures of Common Areas, or other inconvenience or annoyance resulting from the exercise of Landlord’s rights under Section 2.1 and 2.2 shall not be deemed to be a breach of Landlord’s obligations under the Lease, so long as Landlord shall, except in the event of an emergency, use reasonable efforts, consistent with accepted construction practice when applicable, to avoid unreasonably interfering with the conduct of Tenant’s business and Tenant’s use and occupancy of the Premises.  Notwithstanding the foregoing, in no event shall any of the space leased by Tenant at the Property under this Lease be deprived of safe and reasonable access or rendered untenantable for the Permitted Uses by reason of Landlord’s exercise of its rights under this Section 2.

 

3.                                      DELIVERY AND CONDITION OF PREMISES; CONSTRUCTION.

 

3.1                               Delivery and Condition of Premises.  On the Term Commencement Date, the Premises shall be broom-clean with the Landlord’s Work substantially complete and the Building structure and the Building systems serving the Premises and Common Areas shall be in good working order, condition and repair.  Subject to the foregoing, Tenant acknowledges and agrees that Tenant is leasing the Premises in their “AS IS,” “WHERE IS” condition and with all faults on the Execution Date, without representations or warranties, express or implied, in fact or by law, of any kind, and without recourse to Landlord.  Within thirty (30) days after the Term Commencement Date, Landlord and Tenant shall execute a document acknowledging the actual Term Commencement Date and Expiration Date.

 

3.2                               Landlord’s Work.

 

(a)                                 Subject to delays due to governmental regulation, unusual scarcity of or inability to obtain labor or materials, labor difficulties, casualty or other causes reasonably beyond Landlord’s control (collectively “Landlord’s Force Majeure”) and subject to any act or omission by Tenant and/or Tenant’s agents, servants, employees, consultants, contractors, subcontractors, licensees and/or subtenants (collectively with Tenant, the “Tenant Parties”) which causes an actual delay in the performance of Landlord’s Work (a “Tenant Delay”), Landlord, at Landlord’s sole cost and expense, shall perform the work (“Landlord’s Work”) more particularly shown in the permit set prepared by Landlord’s architect, which permit set shall be based on the schematic plans attached hereto as Exhibit 3 and made a part hereof (the “Schematics”) and which permit set shall take into account Tenant’s input at weekly design meetings (as such permit set may be amended or modified pursuant to Section 3.2(b) below, the “Permit Set”).

 

(b)                                 Tenant shall have the right, in accordance herewith, to submit for Landlord’s approval (which approval shall not be unreasonably withheld) change proposals to amend or modify the Permit Set (each, a “Change Proposal”).  Landlord agrees to respond to any such Change Proposal within five (5) business days after the submission thereof by Tenant (unless Landlord has previously advised Tenant that a longer time period for such response is reasonably

 

6

 

necessary due to the nature and scope of the Change Proposal, together with Landlord’s good faith estimate as to the amount of additional time that will be necessary, or the fact that the information provided by Tenant in the Change Proposal is insufficient for the purposes of enabling Landlord to make the determination set forth herein), and if approved by Landlord, advising Tenant of any anticipated increase in costs associated with such Change Proposal (“Anticipated Costs”), as well as an estimate of any delay which would likely result in the completion of Landlord’s Work if a Change Proposal is made pursuant thereto (“Landlord’s Change Order Response”).  Tenant shall have the right to then approve or withdraw such Change Proposal within five (5) business days after receipt of Landlord’s Change Order Response.  If Tenant fails to respond to Landlord’s Change Order Response within such five (5) business day period, such Change Proposal shall be deemed withdrawn.  If Tenant approves Landlord’s Change Order Response, then (a) such Change Proposal shall be deemed a “Change Order” hereunder, and (b) Landlord shall perform the work described in the Change Order as part of Landlord’s Work on all the terms and conditions applicable to Landlord’s Work except as expressly set forth herein with respect to Tenant’s payment obligation.  Any actual delay in the substantial completion of Landlord’s Work resulting from Change Proposals (whether approved or not) shall constitute a Tenant Delay.

 

3.3                               Substantial Completion; Punchlist Items; Remedies for Late Delivery.

 

(a)                                 Landlord’s Work shall be deemed “substantially complete” on the date that all of Landlord’s Work has been completed, except for Punchlist Items (defined below), as certified in writing by Landlord’s architect.  Promptly following delivery of the Premises to Tenant with Landlord’s Work substantially complete, Landlord shall provide Tenant with a list prepared by Landlord’s architect (the “Punchlist”) of outstanding items (the “Punchlist Items”) which (a) need to be performed to complete Landlord’s Work, (b) do not impede the issuance of a certificate of occupancy for the Premises, and (c) do not materially impair Tenant’s ability to use the Premises for the Permitted Use.  Subject to Landlord’s Force Majeure and Tenant Delays, Landlord shall, unless otherwise specified on the Punchlist, complete all Punchlist Items within sixty (60) days of the date of the Punchlist.

 

(b)                                 Subject to Landlord’s Force Majeure and Tenant Delays, if the Term Commencement Date has not occurred on or before (i) October 1, 2015, then the Rent Commencement Date shall be delayed one day for each day after such date that the Term Commencement Date does not occur(4), and (ii) November 30, 2015, then Tenant shall be entitled to terminate this Lease by thirty (30) days’ prior written notice to Landlord (provided that such termination notice shall be of no force and effect if the Term Commencement Date occurs within such 30 day period).  The remedies set forth in this Section 3.3(b) are Tenant’s sole and exclusive rights and remedies if the Term Commencement Date does not occur on or before August 31, 2015.

 

3.4                               Cost of Landlord’s Work.

 

(a)                                 Landlord’s Contribution.  As an inducement to Tenant’s entering into this Lease, Landlord shall pay for up to One Million Six Hundred Eleven Thousand Six Hundred

 

(4) For illustration purposes only, if the Term Commencement Date occurs on October 5, 2015, then the Rent Commencement Date shall be delayed 5 days and shall occur on December 10, 2015 (which is 2 months and 5 days after the Term Commencement Date)

 

7

 

Dollars ($1,611,600) (“Landlord’s Contribution”) of the costs incurred in connection with the performance of Landlord’s Work other than the following costs (collectively, “Excluded Construction Costs”), which shall be paid for by Tenant within thirty (30) days of demand from time to time:  (i) the cost of acquiring or installing any of Tenant’s Property (hereinafter defined), including without limitation telecommunications and computer equipment and all associated wiring and cabling, any de-mountable decorations, artwork and partitions, signs, and trade fixtures (provided that, notwithstanding the foregoing, Landlord’s Contribution may be applied to the cost of any items of Tenant’s Property which constitute lab equipment and which are to become a part of the Premises and be surrendered with Premises upon the expiration of the Term), (ii) the cost of any fixtures or Alterations that will be removed at the end of the Term, (iii) more than $161,160 of any so-called “soft costs.” Landlord shall not charge any supervisory or management fees with respect to Landlord’s Work, provided, however, that the costs of any third party construction/project manager(s) engaged by Landlord shall be included in the costs of Landlord’s Work.  Landlord and Tenant agree that Consigli Construction Co., Inc. shall be the general contractor for the performance of the Landlord’s Work (as such general contractor may be replaced by Landlord with a general contractor of comparable or greater experience and reputation, the “Contractor”).

 

(b)                                 Responsibility for Costs.  If the Work Costs (defined as (i) all costs incurred in connection with Landlord’s Work, including without limitation the costs of designing, permitting and performing Landlord’s Work, as affected by any Change Orders, less (ii) the Excluded Construction Costs) exceed Landlord’s Contribution (such excess, the “Excess Costs”), Tenant shall pay, within thirty (30) days after demand from time to time, Tenant’s Proportion (hereinafter defined) of the Work Costs reflected on each requisition.  “Tenant’s Proportion” shall be a fraction, the numerator of which is the estimated Excess Costs, and the denominator of which is the estimated Work Costs.  Within ninety (90) days after final completion of Landlord’s Work, Landlord shall prepare and submit to Tenant a final reconciliation in sufficient detail to reasonably determine actual Work Costs (including without limitation all Punchlist Items) (the “Final Reconciliation”).  Within thirty (30) days after delivery of the Final Reconciliation, Tenant shall pay to Landlord any remaining Excess Costs.

 

4.                                      USE OF PREMISES.

 

4.1                               Permitted Uses.  During the Term, Tenant shall use the Premises only for the Permitted Uses and for no other purposes.  Service and utility areas (whether or not a part of the Premises) shall be used only for the particular purpose for which they are designed.  All corridor doors, when not in use, shall be kept closed.  It is understood and agreed that Tenant shall not have any obligation to continuously use and/or occupy the Premises; provided, however, if Tenant shall abandon the Premises for a period in excess of twelve (12) months (i.e., whether or not the keys shall have been surrendered or the Rent shall have been paid, Tenant is not actively operating its business in the Premises, is not actively marketing the Premises for a Transfer, there is not a sublease, licenses relating to use or occupancy of space or other occupancy agreements for the Premises to a party that is actively operating its business in the Premises, and the Premises are not undergoing material modifications or affected by casualty, condemnation or other circumstances preventing the foregoing), and either (a) Tenant fails to adequately secure the Premises, (b) Tenant fails to maintain all required insurance hereunder, or (c) subject to Legal Requirements, Tenant fails to keep the Premises reasonably lit so as not to appear unoccupied or “dark”, then Landlord

 

8

 

shall have the right to terminate this Lease upon at least ninety (90) days’ written notice to Tenant; provided, however, if Tenant notifies Landlord within thirty (30) days after receipt of any such termination notice either that (i) Tenant intends to commence operating its business in the Premises prior to the proposed effective date of such termination and Tenant does in fact commence operating its business in the Premises prior to such date, or (ii) Tenant adequately secures the Premises, maintains all required insurance and, subject to Legal Requirements, causes the Premises to be reasonably lit so as not to appear unoccupied or “dark” (and provides Landlord with reasonable evidence that the Premises shall remain secured, insured and, subject to Legal Requirements, reasonably lit), then such termination notice shall be null and void and this Lease shall continue in full force and effect.  Upon the effective date of any such termination, (a) Tenant shall surrender the Premises in the condition required under Section 21 below, and (b) all rights and obligations of the parties hereunder shall terminate and be of no further force and effect except with respect to obligations accruing with respect to the period of time prior to such termination date.

 

4.2                               Prohibited Uses.

 

(a)                                 Notwithstanding any other provision of this Lease, Tenant shall not use the Premises or the Building, or any part thereof, or suffer or permit the use or occupancy of the Premises or the Building or any part thereof by any of the Tenant Parties (i) in a manner which would violate any of the covenants, agreements, terms, provisions and conditions of this Lease or otherwise applicable to or binding upon the Premises; (ii) for any unlawful purposes or in any unlawful manner; (iii) which, in the reasonable judgment of Landlord (taking into account the use of the Building as a combination laboratory, research and development and office building and the Permitted Uses) shall (a) impair the appearance or reputation of the Building; (b) impair, interfere with or otherwise diminish the quality of any of the Building services or the proper and economic heating, cleaning, ventilating, air conditioning or other servicing of the Building or Premises, or the use or occupancy of any of the Common Areas; (c) occasion discomfort, inconvenience or annoyance in any material respect (and Tenant shall not install or use any electrical or other equipment of any kind which, in the reasonable judgment of Landlord, will cause any such impairment, interference, discomfort, inconvenience, annoyance or injury), or cause any injury or damage to any occupants of the Premises or other tenants or occupants of the Building or their property; or (d) cause harmful air emissions, laboratory odors or noises or any unusual or other objectionable odors, noises or emissions to emanate from the Premises; (iv) in a manner which is inconsistent with the operation and/or maintenance of the Building as a first-class combination office, research, development and laboratory facility; or (v) in a manner which shall increase such insurance rates on the Building or on property located therein over that applicable when Tenant first took occupancy of the Premises hereunder (unless Tenant agrees in writing to pay the cost of any such increase).

 

(b)                                 With respect to the use and occupancy of the Premises and the Common Areas, Tenant will not:  (i) place or maintain any signage, trash, refuse or other articles in any vestibule or entry of the Premises, on the footwalks or corridors adjacent thereto or elsewhere on the exterior of the Premises, nor obstruct any driveway, corridor, footwalk, parking area, mall or any other Common Areas; (ii) permit undue accumulations of or burn garbage, trash, rubbish or other refuse within or without the Premises; (iii) permit the parking of vehicles so as to interfere with the use of any driveway, corridor, footwalk, parking area, or other Common Areas; (iv)

 

9

 

receive or ship articles of any kind outside of those areas reasonably designated by Landlord; (v) conduct or permit to be conducted any auction, going out of business sale, bankruptcy sale (unless directed by court order), or other similar type sale in or connected with the Premises; (vi) use the name of the Building, the Property, Landlord, or any of Landlord’s affiliates or subsidiaries or any photograph, film, drawing, or other depiction or representation of the Building and/or the Property or any part thereof, which contains signage or distinctive architectural characteristics that cause the scene photographed, filmed, drawn, depicted, or represented to be identifiable as being the Building and/or the Property, in any publicity, promotion, trailer, press release, advertising, printed, or display materials without Landlord’s prior written consent; or (vii) except in connection with Alterations (hereinafter defined) approved by Landlord, cause or permit any hole to be drilled or made in any part of the Building.

 

5.                                      RENT; ADDITIONAL RENT.

 

5.1                               Base Rent.  During the Term, Tenant shall pay to Landlord Base Rent in equal monthly installments, in advance and without demand on the first day of each month for and with respect to such month, except that, if the Rent Commencement Date is any day other than the first day of a calendar month, Base Rent due for the period between the Rent Commencement Date and the last day of the calendar month in which the Rent Commencement Date occurs shall be due on the Rent Commencement Date.  Except to the extent otherwise set forth in Section 3.1, the payment of Base Rent and additional rent and other charges reserved and covenanted to be paid under this Lease with respect to the Premises (collectively, “Rent”) shall commence on the Rent Commencement Date, and shall be prorated for any partial months.  Rent shall be payable to Landlord or, if Landlord shall so direct in writing, to Landlord’s agent or nominee, in lawful money of the United States which shall be legal tender for payment of all debts and dues, public and private, at the time of payment.

 

5.2                               Operating Costs.

 

(a)                                 “Operating Costs” shall mean all costs incurred and expenditures of whatever nature made by Landlord in the operation and management of the Building or allocated to the Building, including without limitation any costs for utilities supplied to the Common Areas, the costs of maintaining the MWRA permit(s) for the Building, and any costs for repair and replacements, cleaning and maintenance of the Common Areas, related equipment, facilities and appurtenances and HVAC equipment, a management fee paid to Landlord’s property manager, the costs of Landlord’s management office for the Property, the cost of operating any amenities in the Property available to all tenants of the Property and any subsidy provided by Landlord for or with respect to any such amenity.  For costs and expenditures made by Landlord in connection with the operation, management, repair, replacement, maintenance and insurance of the Building as a whole, Landlord shall make a reasonable allocation thereof between the retail and non-retail portions of the Building, if applicable.  To the extent that a cost included in Operating Costs is also allocable to property other than the Property, such cost shall be equitably allocated to each parcel of property which benefits from such cost.  Operating Costs shall not include Excluded Costs (hereinafter defined).  Landlord shall have the right but not the obligation, from time to time, to equitably allocate some or all of the Operating Costs among different tenants of the Building (for example, and without limiting the generality of the foregoing, based in whole or in part on shared or similar use of particular systems or equipment).

 

10

 

(b)                                 “Excluded Costs” shall be defined as (i) any mortgage charges (including interest, principal, points and fees); (ii) brokerage commissions; (iii) salaries of executives and owners not directly employed in the management/operation of the Property; (iv) the cost of work done by Landlord for a particular tenant; (v) subject to Subsection 5.2(h) below, capital expenditures; (vi) the costs of Landlord’s Work and any contributions made by Landlord to any tenant of the Property in connection with the build-out of its premises; (vii) franchise or income taxes imposed on Landlord or Taxes; (viii) costs paid directly by individual tenants to suppliers, including tenant electricity, telephone and other utility costs; (ix) increases in premiums for insurance when such increase is caused by the use of the Building by Landlord or any other tenant of the Building; (x) maintenance and repair of capital items not a part of the Building or the Property; (xi) depreciation of the Building; (xii) costs relating to maintaining Landlord’s existence as a corporation, partnership or other entity; (xiii) advertising and other fees and costs incurred in procuring tenants; (xiv) the cost of any items for which Landlord is reimbursed by insurance, condemnation awards, refund, rebate or otherwise, and any expenses for repairs or maintenance to the extent covered by warranties, guaranties and service contracts; and (xv) costs incurred in connection with any disputes between Landlord and its employees, between Landlord and Building management, or between Landlord and other tenants or occupants ; (xvi) the cost of testing, remediation or removal, transportation or storage of Hazardous Materials (hereinafter defined) in the Building or on the Property required by Environmental Laws (hereinafter defined), provided however, that with respect to the testing, remediation or removal of (i) any material or substance located in the Building on the Execution Date and which, as of the Execution Date, is not considered, as a matter of law, to be a Hazardous Material, but which is subsequently determined to be a Hazardous Material as a matter of law, and (ii) any material or substance located in the Building after the Execution Date and which, when placed in the Building, was not considered, as a matter of law, to be a Hazardous Material, but which is subsequently determined to be a Hazardous Material as a matter of law, the costs thereof may be included in Operating Costs; (xvii) capital expenditures not expressly permitted under Section 5.2(h) below; and (xviii) amounts paid by Landlord to or at the direction of Fee Owner pursuant to the Ground Lease.

 

(c)                                  “Capital Interest Rate” shall be defined as an annual rate of either one percentage point over the AA Bond rate (Standard & Poor’s corporate composite or, if unavailable, its equivalent) as reported in the financial press at the time the capital expenditure is made or, if the capital item is acquired through third party financing, then the actual (including fluctuating) rate paid by Landlord in financing the acquisition of such capital item.

 

(d)                                 “Annual Charge Off” shall be defined as the annual amount of principal and interest payments which would be required to repay a loan (“Capital Loan”) in equal monthly installments over the Useful Life (hereinafter defined), of the capital item in question on a direct reduction basis at an annual interest rate equal to the Capital Interest Rate, where the initial principal balance is the cost of the capital item in question.

 

(e)                                  “Useful Life” shall be reasonably determined by Landlord in accordance with sound accounting principles and practices consistently applied.

 

(f)                                   Payment of Operating Costs.  Tenant shall pay to Landlord, as additional rent, Tenant’s Share of Operating Costs.  Landlord may make a good faith estimate of Tenant’s Share of Operating Costs for any fiscal year or part thereof during the term, and Tenant shall pay to

 

11

 

Landlord, on the Term Commencement Date and on the first (1st) day of each calendar month thereafter, an amount equal to Tenant’s Share of Operating Costs for such fiscal year and/or part thereof divided by the number of months therein.  Landlord may estimate and re-estimate Tenant’s Share of Operating Costs and deliver a copy of the estimate or re-estimate to Tenant.  Thereafter, the monthly installments of Tenant’s Share of Operating Costs shall be appropriately adjusted in accordance with the estimations so that, by the end of the fiscal year in question, Tenant shall have paid all of Tenant’s Share of Operating Costs as estimated by Landlord.  Any amounts paid based on such an estimate shall be subject to adjustment as herein provided when actual Operating Costs are available for each fiscal year.

 

(g)                                  Annual Reconciliation.  Landlord shall, within one hundred twenty (120) days after the end of each fiscal year, deliver to Tenant a reasonably detailed statement of the actual amount of Operating Costs for such fiscal year (“Year End Statement”).  Failure of Landlord to provide the Year End Statement within the time prescribed shall not relieve Tenant from its obligations hereunder.  If the total of such monthly remittances on account of any fiscal year is greater than Tenant’s Share of Operating Costs actually incurred for such fiscal year, then, provided no Event of Default has occurred nor any event which, with the passage of time and/or the giving of notice would constitute an Event of Default, Tenant may credit the difference against the next installment of additional rent on account of Operating Costs due hereunder, except that if such difference is determined after the end of the Term, Landlord shall refund such difference to Tenant within thirty (30) days after such determination to the extent that such difference exceeds any amounts then due from Tenant to Landlord (it being understood and agreed that if Tenant cures any default prior to the expiration of the notice and/or cure periods set forth in Section 20.1 below, Tenant shall then be entitled to take such credit).  If the total of such remittances is less than Tenant’s Share of Operating Costs actually incurred for such fiscal year, Tenant shall pay the difference to Landlord, as additional rent hereunder, within ten (10) days of Tenant’s receipt of an invoice therefor.  Landlord’s estimate of Operating Costs for the next fiscal year shall be based upon the Operating Costs actually incurred for the prior fiscal year as reflected in the Year-End Statement plus a reasonable adjustment based upon estimated increases in Operating Costs.  The provisions of this Section 5.2(g) shall survive the expiration or earlier termination of this Lease.

 

(h)                                 Capital Expenditures.  If, during the Term, Landlord shall replace any capital items or make any capital expenditures (collectively, “Capital Expenditures”) the total amount of which (net of any warranty claims) is not properly includable in Operating Costs for the fiscal year in which they were made, in accordance with sound accounting principles and practices consistently applied in effect at the time of such replacement, there shall nevertheless be included in such Operating Costs (and in Operating Costs for each succeeding fiscal year) the amount, if any, by which the Annual Charge Off (determined as hereinafter provided) of such Capital Expenditure (less insurance proceeds, if any, collected by Landlord by reason of damage to, or destruction of the capital item being replaced) exceeds the Annual Charge Off of the Capital Expenditure for the item being replaced.  If a new capital item is acquired which does not replace another capital item, and such new capital item being acquired is either (i) required by any Legal Requirements enacted after the Execution Date or (ii) reasonably projected to reduce Operating Costs, then there shall be included in Operating Costs for each fiscal year in which and after such capital expenditure is made the Annual Charge Off of such capital expenditure.

 

12

 

(i)                                     Part Years.  If the Term Commencement Date or the Expiration Date occurs in the middle of a fiscal year, Tenant shall be liable for only that portion of the Operating Costs with respect to such fiscal year within the Term.

 

(j)                                    Gross-Up.  If, during any fiscal year, less than ninety-five percent (95%) of the Building is occupied by tenants or if Landlord was not supplying all tenants with the services being supplied to Tenant hereunder, actual Operating Costs incurred shall be reasonably extrapolated by Landlord on an item-by-item basis to the reasonable Operating Costs that would have been incurred if the Building was ninety-five percent (95%) occupied and such services were being supplied to all tenants, and such extrapolated Operating Costs shall, for all purposes hereof, be deemed to be the Operating Costs for such fiscal year.

 

(k)                                 Audit Right.  Provided there is no Event of Default nor any event which, with the passage of time and/or the giving of notice would constitute an Event of Default, Tenant may, upon at least sixty (60) days’ prior written notice, inspect or audit Landlord’s records relating to Operating Costs for any periods of time within the previous fiscal year before the audit or inspection.  However, no audit or inspection shall extend to periods of time before the Term Commencement Date.  If Tenant fails to object to the calculation of Tenant’s Share of Operating Costs on the Year-End Statement within sixty (60) days after such statement has been delivered to Tenant and/or fails to complete any such audit or inspection within ninety (90) days after receipt of the Year End Statement, then Tenant shall be deemed to have waived its right to object to the calculation of Tenant’s Share of Operating Costs for the year in question and the calculation thereof as set forth on such statement shall be final.  Tenant’s audit or inspection shall be conducted only at Landlord’s offices or the offices of Landlord’s property manager during business hours reasonably designated by Landlord.  Tenant shall pay the cost of such audit or inspection, provided, however, that if such audit discloses that Tenant has been overcharged by more than five percent (5%), Landlord shall reimburse Tenant for up to Five Thousand Dollars ($5,000) of Tenant’s reasonable out of pocket costs incurred in connection with such audit.  Tenant may not conduct an inspection or have an audit performed more than once during any fiscal year.  If such inspection or audit reveals that an error was made in the calculation of Tenant’s Share of Operating Costs previously charged to Tenant, then, provided no Event of Default has occurred nor an event which, with the passage of time and/or the giving of notice would constitute an Event of Default, Tenant may credit the difference against the next installment of additional rent on account of Operating Costs due hereunder, except that if such difference is determined after the end of the Term, Landlord shall refund such difference to Tenant within thirty (30) days after such determination to the extent that such difference exceeds any amounts then due from Tenant to Landlord.  If such inspection or audit reveals an underpayment by Tenant, then Tenant shall pay to Landlord, as additional rent hereunder, any underpayment of any such costs, as the case may be, within ten (10) days after receipt of an invoice therefor.  Tenant shall maintain the results of any such audit or inspection confidential and shall not be permitted to use any third party to perform such audit or inspection, other than an independent firm of certified public accountants (A) reasonably acceptable to Landlord, (B) which is not compensated on a contingency fee basis or in any other manner which is dependent upon the results of such audit or inspection, and (C) which executes Landlord’s standard confidentiality agreement whereby it shall agree to maintain the results of such audit or inspection confidential.  The provisions of this Section 5.2(k) shall survive the expiration or earlier termination of this Lease.

 

13

 

5.3                               Taxes.

 

(a)                                 “Taxes” shall mean the real estate taxes and other taxes, levies and assessments imposed upon the Building, and upon any personal property of Landlord used in the operation of the Building, or on Landlord’s interest in the Building or such personal property or reasonably allocated thereto; charges, fees and assessments for transit, housing, police, fire or other services or purported benefits to the Building (including without limitation any community preservation assessments); service or user payments in lieu of taxes; and any and all other taxes, levies, betterments, assessments and charges arising from the ownership, leasing, operation, use or occupancy of the Building or based upon rentals derived therefrom, which are or shall be imposed by federal, state, county, municipal or other governmental authorities.  Taxes shall not include any inheritance, estate, succession, gift, franchise, rental, income or profit tax, capital stock tax, capital levy or excise, or any income taxes arising out of or related to the ownership and operation of the Building, provided, however, that any of the same and any other tax, excise, fee, levy, charge or assessment, however described, that may in the future be levied or assessed as a substitute for or an addition to, in whole or in part, any tax, levy or assessment which would otherwise constitute Taxes, whether or not now customary or in the contemplation of the parties on the Execution Date of this Lease, shall constitute Taxes, but only to the extent calculated as if the Property were the only real estate owned by Landlord.  “Taxes” shall also include reasonable expenses (including without limitation legal and consultant fees) of tax abatement or other proceedings contesting assessments or levies.

 

(b)                                 “Tax Period” shall be any fiscal/tax period in respect of which Taxes are due and payable to the appropriate governmental taxing authority (i.e., as mandated by the governmental taxing authority), any portion of which period occurs during the Term of this Lease.

 

(c)                                  Payment of Taxes.  Tenant shall pay to Landlord, as additional rent, Tenant’s Tax Share of Taxes.  Landlord may make a good faith estimate of the Taxes to be due by Tenant for any Tax Period or part thereof during the Term, and Tenant shall pay to Landlord, on the Term Commencement Date and on the first (1st) day of each calendar month thereafter, an amount equal to Tenant’s Tax Share of Taxes for such Tax Period or part thereof divided by the number of months therein.  Landlord may estimate and re-estimate Tenant’s Tax Share of Taxes and deliver a copy of the estimate or re-estimate to Tenant.  Thereafter, the monthly installments of Tenant’s Tax Share of Taxes shall be appropriately adjusted in accordance with the estimations so that, by the end of the Tax Period in question, Tenant shall have paid all of Tenant’s Tax Share of Taxes as estimated by Landlord.  Any amounts paid based on such an estimate shall be subject to adjustment as herein provided when actual Taxes are available for each Tax Period.  If the total of such monthly remittances is greater than Tenant’s Tax Share of Taxes actually due for such Tax Period, then, provided no Event of Default has occurred nor any event which, with the passage of time and/or the giving of notice would constitute an Event of Default, Tenant may credit the difference against the next installment of additional rent on account of Taxes due hereunder, except that if such difference is determined after the end of the Term, Landlord shall refund such difference to Tenant within thirty (30) days after such determination to the extent that such difference exceeds any amounts then due from Tenant to Landlord (it being understood and agreed that if Tenant cures any default prior to the expiration of the notice and/or cure periods set forth in Section 20.1 below, Tenant shall then be entitled to take such credit).  If the total of such remittances is less than Tenant’s Tax Share of Taxes actually due for such Tax Period, Tenant shall

 

14

 

pay the difference to Landlord, as additional rent hereunder, within thirty (30) days of Tenant’s receipt of an invoice therefor.  Landlord’s estimate for the next Tax Period shall be based upon actual Taxes for the prior Tax Period plus a reasonable adjustment based upon estimated increases in Taxes.  In the event that Payments in Lieu of Taxes (“PILOT”), instead of or in addition to Taxes, are separately assessed to certain portions of the Building or the Property including the Premises, Tenant agrees, except as otherwise expressly provided herein to the contrary, to pay to Landlord, as additional rent, the portion of such PILOT attributable to the Premises in the same manner as provided above for the payment of Taxes.  The provisions of this Section 5.3(c) shall survive the expiration or earlier termination of this Lease.

 

(d)                                 Effect of Abatements.  Appropriate credit against Taxes or PILOT shall be given for any refund obtained by reason of a reduction in any Taxes by the assessors or the administrative, judicial or other governmental agency responsible therefor after deduction of Landlord’s expenditures for reasonable legal fees and for other reasonable expenses incurred in obtaining the Tax or PILOT refund.

 

(e)                                  Part Years.  If the Term Commencement Date or the Expiration Date occurs in the middle of a Tax Period, Tenant shall be liable for only that portion of the Taxes, as the case may be, with respect to such Tax Period within the Term.

 

5.4                               Late Payments.

 

(a)                                 Any payment of Rent due hereunder not paid when due shall bear interest for each month or fraction thereof from the due date until paid in full at the annual rate of twelve percent (12%), or at any applicable lesser maximum legally permissible rate for debts of this nature (the “Default Rate”).  Notwithstanding the foregoing, Tenant shall be entitled to a grace period of five (5) business days after written notice from Landlord with respect to the first late payment in any twelve (12) month period.  Acceptance of interest shall not constitute a waiver of Tenant’s default with respect to the overdue amount or prevent Landlord from exercising any of the other rights and remedies available to Landlord under this Lease or at law or in equity now or hereafter in effect.

 

(b)                                 For each Tenant payment check to Landlord that is returned by a bank for any reason, Tenant shall pay a returned check charge equal to the amount as shall be customarily charged by Landlord’s bank at the time.

 

(c)                                  Money paid by Tenant to Landlord shall be applied to Tenant’s account in the following order:  first, to any unpaid additional rent, including without limitation late charges, returned check charges, legal fees and/or court costs chargeable to Tenant hereunder; and then to unpaid Base Rent.

 

5.5                               No Offset; Independent Covenants; Waiver.  Rent shall be paid without notice or demand, and without setoff, counterclaim, defense, abatement, suspension, deferment, reduction or deduction, except as expressly provided herein.  TENANT WAIVES ALL RIGHTS (I) TO ANY ABATEMENT, SUSPENSION, DEFERMENT, REDUCTION OR DEDUCTION OF OR FROM RENT, AND (II) TO QUIT, TERMINATE OR SURRENDER THIS LEASE OR THE PREMISES OR ANY PART THEREOF, EXCEPT

 

15

 

AS EXPRESSLY PROVIDED HEREIN.  TENANT HEREBY ACKNOWLEDGES AND AGREES THAT THE OBLIGATIONS OF TENANT HEREUNDER SHALL BE SEPARATE AND INDEPENDENT COVENANTS AND AGREEMENTS, THAT RENT SHALL CONTINUE TO BE PAYABLE IN ALL EVENTS AND THAT THE OBLIGATIONS OF TENANT HEREUNDER SHALL CONTINUE UNAFFECTED, UNLESS THE REQUIREMENT TO PAY OR PERFORM THE SAME SHALL HAVE BEEN TERMINATED PURSUANT TO AN EXPRESS PROVISION OF THIS LEASE.  LANDLORD AND TENANT EACH ACKNOWLEDGES AND AGREES THAT THE INDEPENDENT NATURE OF THE OBLIGATIONS OF TENANT HEREUNDER REPRESENTS FAIR, REASONABLE, AND ACCEPTED COMMERCIAL PRACTICE WITH RESPECT TO THE TYPE OF PROPERTY SUBJECT TO THIS LEASE, AND THAT THIS AGREEMENT IS THE PRODUCT OF FREE AND INFORMED NEGOTIATION DURING WHICH BOTH LANDLORD AND TENANT WERE REPRESENTED BY COUNSEL SKILLED IN NEGOTIATING AND DRAFTING COMMERCIAL LEASES IN MASSACHUSETTS, AND THAT THE ACKNOWLEDGEMENTS AND AGREEMENTS CONTAINED HEREIN ARE MADE WITH FULL KNOWLEDGE OF THE HOLDING IN WESSON V. LEONE ENTERPRISES, INC., 437 MASS. 708 (2002).  SUCH ACKNOWLEDGEMENTS, AGREEMENTS AND WAIVERS BY TENANT ARE A MATERIAL INDUCEMENT TO LANDLORD ENTERING INTO THIS LEASE.

 

5.6                               Survival.  Any obligations under this Section 5 which shall not have been paid at the expiration or earlier termination of the Term shall survive such expiration or earlier termination and shall be paid when and as the amount of same shall be determined and be due.

 

6.                                      RIGHT OF FIRST OFFER.

 

6.1                               Right of First Offer.  Subject to the provisions of this Section 6, from and after the date on which all of the rentable areas of the Building have been leased, and provided that as of the date of the ROFO Notice (hereinafter defined) (i) there has been no Event of Default nor an event which, with the passage of time and/or the giving of notice would constitute an Event of Default hereunder (it being understood that if Tenant cures a default prior to the expiration of any applicable grace period, Tenant shall then be entitled to exercise its rights under this Section 6 so long as the condition in subsection (ii) hereafter is met), and (ii) Tenant is in occupancy of all of the Premises(5), Tenant shall have a one-time right of first offer to lease less than all of the rentable space on the second floor of the Building (the “ROFO Space”) if, as and when the same shall become available for lease, upon the terms and conditions specified in the ROFO Notice but only if less than all of the rentable space on the second floor of the Building is available for lease (it being acknowledged that another tenant in the Building has a superior right of first offer to lease all rentable areas on the second floor if the full floor becomes available for lease); provided that if the superior right of first offer with respect to the entirety of the second floor is extinguished during the Term, Tenant’s right of first offer shall apply to all of the rentable space on the second floor of the Building.  Tenant’s right of first offer under this Section 6 is further subject to (a) all currently-existing extension rights and/or expansion rights of tenants of the Building, and (b) any

 

(5) For purposes of this Section 6.1, the parties agree that license agreements with respect to the use of any desks or benches and/or collaboration agreements entered into by Tenant with respect to the Premises shall not, for purposes of subsection (ii) above, prevent Tenant from exercising its right of first offer pursuant to this Section 6.1.

 

16

 

space needs of Landlord or Landlord’s affiliates or related academic and/or research entities.  It is understood and agreed that base rent for the ROFO Space shall be the greater of (A) then-current Base Rent for the Premises on a per rentable square foot basis, and (B) fair market rent.

 

6.2                               Offer and Acceptance Procedures for Right of First Offer.

 

(a)                                 Promptly after Landlord determines, in its reasonable judgment, that the ROFO Space is available for lease and all of the preconditions to the right of first offer granted to Tenant in this Section 6 have been met, Landlord shall deliver to Tenant a written notice offering to lease the ROFO Space to Tenant upon the terms and conditions set forth therein (the “ROFO Notice”).  Tenant then shall have five (5) business days after receipt of the ROFO Notice to notify Landlord in writing (the “ROFO Response”) whether Tenant will exercise its right to lease the ROFO Space upon the terms and conditions described in the ROFO Notice.  If Tenant timely exercises its right to lease the ROFO Space, the ROFO Response shall indicate whether Tenant accepts Landlord’s determination of base rent for the ROFO Space, or if Tenant disputes Landlord’s determination of fair market rent for the ROFO Space.  If the ROFO Response does not indicate that Tenant disputes Landlord’s determination of fair market rent for the ROFO Space, Landlord’s determination thereof shall be binding on Tenant.  If the ROFO Response does indicate that Tenant disputes Landlord’s determination of fair market rent for the ROFO Space, fair market rent for the ROFO Space shall be determined in the same manner as provided for the determination of fair market rental value set forth in Section 1.2 of this Lease.

 

(b)                                 If Tenant fails to notify Landlord in writing within such 5-business day period that Tenant accepts the offer contained in the ROFO Notice, or if Tenant refuses in writing the offer contained in the ROFO Notice, Landlord shall have the right to lease the ROFO Space to any third party tenant on whatever terms and conditions Landlord may determine in its sole discretion.  If Tenant timely notifies Landlord of its desire to lease the ROFO Space pursuant to this Section 6, Landlord shall submit to Tenant, and Tenant shall execute and deliver to Landlord within thirty (30) days of receipt thereof, a lease amendment which incorporates all of the terms and conditions set forth in the ROFO Notice.  Landlord and Tenant shall reasonably diligently negotiate such lease amendment in good faith.

 

6.3                               Termination of Rights.  All rights of Tenant under this Section 6 shall terminate upon the expiration or earlier termination of the Term of this Lease.

 

6.4                               Rights Personal to Tenant.  Except in connection with a Transfer (hereinafter defined) pursuant to Section 13 below, Tenant may not assign, mortgage, pledge, encumber or otherwise transfer its interest or rights under this Section 6, and any such purported transfer or attempt to transfer shall be void and without effect, shall terminate Tenant’s rights under this Section 6, and shall constitute an Event of Default under this Lease.

 

6.5                               Time is of the Essence.  Time is of the essence with respect to all aspects of this Section 6.

 

17

 

7.                                      LETTER OF CREDIT.

 

7.1                               Amount.

 

(a)                                 Contemporaneously with the execution of this Lease, Tenant shall deliver to Landlord either (i) cash in an amount specified in the Lease Summary Sheet (the “Cash Security Deposit”), which shall be held by Landlord in accordance with Section 7.5 below, or (ii) an irrevocable letter of credit which shall (a) be in the amount specified in the Lease Summary Sheet and otherwise in the form attached hereto as Exhibit 4; (b) issued by a bank reasonably acceptable to Landlord upon which presentment may be made in Boston, Massachusetts (if Landlord so requires at the time of its approval thereof); and (c) be for a term of one (1) year, subject to extension in accordance with the terms hereof (the “Letter of Credit”).  The Letter of Credit shall be held by Landlord, without liability for interest, as security for the faithful performance by Tenant of all of the terms, covenants and conditions of this Lease by the Tenant to be kept and performed during the Term.  In no event shall the Letter of Credit be deemed to be a prepayment of Rent nor shall it be considered a measure of liquidated damages.  Unless the Letter of Credit is automatically renewing, at least thirty (30) days prior to the maturity date of the Letter of Credit (or any replacement Letter of Credit), Tenant shall deliver to Landlord a replacement Letter of Credit which shall have a maturity date no earlier than the next anniversary of the Term Commencement Date or one (1) year from its date of delivery to Landlord, whichever is later.

 

(b)                                 If no Event of Default has occurred and there is no event which, with the passage of time and/or the giving of notice, would constitute an Event of Default, and further provided that there is no material adverse change in Tenant’s net worth at the commencement of such Rent Year as verified by Landlord based upon a certificate from Tenant’s chief financial officer and Tenant’s audited financials, then the Cash Security Deposit or face amount of the Letter of Credit, as applicable, may be reduced by Tenant to (a) $386,784.00 at the commencement of the second Rent Year, (b) $290,088.00 at the commencement of the third Rent Year, and (c) $193,392.00 at the commencement of the fifth Rent Year; it being understood that if and when Tenant cures a default prior to the expiration of the applicable grace period, Tenant shall then be entitled to effect such reduction in accordance with this Section 7.1(b).  Landlord shall, at no cost to Landlord, cooperate with Tenant and the issuer of the Letter of Credit, if applicable, in connection with such reduction.

 

7.2                               Application of Proceeds of Letter of Credit.  Upon an Event of Default, or if any proceeding shall be instituted by or against Tenant pursuant to any of the provisions of any Act of Congress or State law relating to bankruptcy, reorganizations, arrangements, compositions or other relief from creditors (and, in the case of any proceeding instituted against it, if Tenant shall fail to have such proceedings dismissed within thirty (30) days) or if Tenant is adjudged bankrupt or insolvent as a result of any such proceeding, or upon the end of the Term if there remains any uncured default of which Tenant shall have received notice, Landlord at its sole option may draw down all or a part of the Letter of Credit.  The balance of any Letter of Credit cash proceeds shall be held in accordance with Section 7.5 below.  Should the entire Letter of Credit, or any portion thereof, be drawn down by Landlord, Tenant shall, upon the written demand of Landlord, deliver a replacement Letter of Credit in the amount drawn, and Tenant’s failure to do so within ten (10) days after receipt of such written demand shall constitute an additional Event of Default hereunder.  The application of all or any part of the cash proceeds of the Letter of Credit to any obligation or default of Tenant under this Lease shall not deprive Landlord of any other rights or remedies Landlord may have nor shall such application by Landlord constitute a waiver by Landlord.

 

18

 

7.3                               Transfer of Letter of Credit.  In the event that Landlord transfers its interest in the Premises, Tenant shall upon notice from and at no cost to Landlord, deliver to Landlord an amendment to the Letter of Credit or a replacement Letter of Credit naming Landlord’s successor as the beneficiary thereof.  If Tenant fails to deliver such amendment or replacement within twenty (20) days after written notice from Landlord, Landlord shall have the right to draw down the entire amount of the Letter of Credit and hold the proceeds thereof in accordance with Section 7.5 below.

 

7.4                               Credit of Issuer of Letter of Credit.  In event of a material adverse change in the financial position of any bank or institution which has issued the Letter of Credit or any replacement Letter of Credit hereunder, Landlord reserves the right to require that Tenant change the issuing bank or institution to another bank or institution reasonably approved by Landlord.  Tenant shall, within ten (10) days after receipt of written notice from Landlord, which notice shall include the basis for Landlord’s reasonable belief that there has been a material adverse change in the financial position of the issuer of the Letter of Credit, replace the then-outstanding letter of credit with a like Letter of Credit from another bank or institution approved by Landlord.

 

7.5                               Security Deposit.  Landlord shall hold the Cash Security Deposit and/or the balance of proceeds remaining after a draw on the Letter of Credit (each hereinafter referred to as the “Security Deposit”) as security for Tenant’s performance of all its Lease obligations.  After an Event of Default, or upon the end of the Term if there remains any uncured default of which Tenant shall have received notice, Landlord may apply the Security Deposit, or any part thereof, to Landlord’s damages without prejudice to any other Landlord remedy.  Should Landlord apply all or any portion of the Security Deposit in accordance with the terms of this Lease, Tenant shall, upon the written demand of Landlord, deliver cash in the amount applied, and Tenant’s failure to do so within twenty (20) days after receipt of such written demand shall constitute an additional Event of Default hereunder.  Tenant shall have the right to deliver a replacement Letter of Credit in the form and amount required hereunder, and upon receipt of such replacement Letter of Credit, Landlord shall return the Security Deposit to Tenant.  Landlord has no obligation to pay interest on the Security Deposit and may co-mingle the Security Deposit with Landlord’s funds.  If Landlord conveys its interest under this Lease, the Security Deposit, or any part not applied previously, may be turned over to the grantee in which case Tenant shall look solely to the grantee for the proper application and return of the Security Deposit.

 

7.6                               Return of Security Deposit or Letter of Credit.  Should Tenant comply with all of such terms, covenants and conditions and promptly pay all sums payable by Tenant to Landlord hereunder, the Security Deposit and/or Letter of Credit or the remaining proceeds therefrom, as applicable, shall be returned to Tenant within sixty (60) days after the end of the Term, less any portion thereof which may have been utilized by Landlord to cure any default or applied to any actual damage suffered by Landlord.

 

8.                                      INTENTIONALLY OMITTED.

 

9.                                      UTILITIES, HVAC; WASTE.

 

9.1                               Electricity.  Commencing on the Term Commencement Date, Tenant shall pay all charges for electricity furnished to the Premises and/or any equipment exclusively serving the same as additional rent as provided hereafter.  Such charges shall be based in part on (a) reasonable

 

19

 

estimates by Landlord based on percentage of air flow used by Tenant (measured through Landlord’s Building energy management system) as to equipment in the Building serving the Building, Tenant and other tenants, to be separately billed by Landlord, (b) metering equipment installed as part of Landlord’s Base Building Work, as to other electricity used in the Premises, which Tenant shall pay directly to the supplier, and (c) if applicable, such other metering equipment, if any, approved by Landlord in its reasonable discretion.  Landlord shall, at Tenant’s sole cost and expense, maintain and keep in good order, condition and repair any such metering equipment.  Tenant shall pay the full amount of any charges attributable to such meter on or before the due date therefor either to Landlord or directly to the supplier thereof, at Landlord’s election.

 

9.2                               Water.  Commencing on the Term Commencement Date, Tenant shall pay all water and sewer charges for water furnished to the Premises and/or any equipment exclusively serving the same as additional rent.  Such charges shall be reasonably estimated by Landlord based on the percentage of air flow used by Tenant (measured through Landlord’s Building energy management system).

 

9.3                               Gas.  Commencing on the Term Commencement Date, Tenant shall pay all charges for natural gas service furnished to the Premises and/or any equipment exclusively serving the same as additional rent as provided hereafter.  Such charges shall be based in part on (a) reasonable estimates by Landlord based on percentage of air flow used by Tenant (measured through Landlord’s Building energy management system) as to equipment in the Building serving the Building, Tenant, and other tenants, to be separately billed by Landlord, and (b) metering equipment installed as part of Landlord’s Base Building Work, as to natural gas used in the Premises, which Tenant shall pay directly to the supplier, and (c) if applicable, such other metering equipment, if any, approved by Landlord in its reasonable discretion.

 

9.4                               HVAC.  Consistent with the levels provided by Class A laboratory/office buildings in East Cambridge, Landlord shall provide to the Common Areas and the Premises on a twenty-four (24) hours per day, seven (7) days per week basis (i) heat 365 days/year and (ii) air conditioning during the normal cooling season; provided, however, that Landlord will provide air conditioning at such other times as reasonably requested by Tenant and (iii) general exhaust/ventilation.  Excluded from such services are air conditioning requirements for (A) personal computers in excess of an average of one personal computer per person in occupancy of the Premises, or (B) exceptional office machinery.  It is expressly acknowledged and agreed that Tenant shall be solely responsible for specialty exhaust, including without limitation exhaust for H2 rooms, radiation hoods and isotope hoods, vivarium, chemical storage rooms which require Class I, Division II classification, if any, and any other special Tenant equipment.  Whenever the air conditioning systems are in operation, Tenant agrees to use reasonable efforts to lower and close the blinds or drapes when necessary because of the sun’s position, and to cooperate fully with Landlord with regard to, and to abide by all the reasonable regulations and requirements which Landlord may prescribe for the proper functioning and protection of the air conditioning systems.

 

9.5                               Other Utilities; Utility Information.  Subject to Landlord’s reasonable rules and regulations governing the same, Tenant shall obtain and pay, as and when due, for all other utilities and services consumed in and/or furnished to the Premises, together with all taxes, penalties, surcharges and maintenance charges pertaining thereto.  Within ten (10) business days after

 

20

 

Landlord’s request from time to time, Tenant shall provide Landlord with reasonably detailed information regarding tenant’s utility usage in the Premises.

 

9.6                               Interruption or Curtailment of Utilities.

 

(a)                                 When necessary by reason of accident or emergency, or for repairs, alterations, replacements or improvements which in the reasonable judgment of Landlord are desirable or necessary to be made, Landlord reserves the right, upon as much prior notice to Tenant as is practicable under the circumstances and no less than twenty-four (24) hours’ notice except in the event of an emergency, to interrupt, curtail, or stop (i) the furnishing of hot and/or cold water, and (ii) the operation of the plumbing and electric systems.  Landlord shall exercise reasonable diligence to eliminate the cause of any such interruption, curtailment, stoppage or suspension, but, subject to Section 9.6(b) below, there shall be no diminution or abatement of Rent or other compensation due from Landlord to Tenant hereunder, nor shall this Lease be affected or any of Tenant’s obligations hereunder reduced, and Landlord shall have no responsibility or liability for any such interruption, curtailment, stoppage, or suspension of services or systems.

 

(b)                                 Notwithstanding anything to the contrary in this Lease contained, if the Premises shall lack any service which Landlord is required to provide hereunder, or if Tenant’s use and occupancy of the Premises or any part thereof shall be disturbed in violation of Section 23 hereof (thereby rendering the Premises or a portion thereof substantially untenantable) such that, for the duration of the Landlord Service Interruption Cure Period (hereinafter defined), the continued operation in the ordinary course of Tenant’s business in any portion of the Premises is materially and adversely affected, and if Tenant ceases to use the affected portion of the Premises (the “Affected Portion”) during the period of untenantability as the direct result of such lack of service or disturbance, then, provided that Tenant ceases to use the Affected Portion during the entirety of the Landlord Service Interruption Cure Period and that such untenantability and Landlord’s inability to cure such condition is not caused by the acts or omissions of any of the Tenant Parties, Base Rent shall thereafter be abated in proportion to such untenantability until the day such condition is completely corrected.  For purposes hereof, the “Landlord Service Interruption Cure Period” shall be defined as seven (7) consecutive business days after Landlord’s receipt of written notice from Tenant of the condition causing untenantability in the Affected Portion.  The provisions of this Section 9.6(b) shall not apply in the event of Casualty or Taking, or in the event of untenantability caused by causes beyond Landlord’s control or if Landlord is unable to cure such condition as the result of causes beyond Landlord’s control.  The remedy set forth in this Section 9.6(b) shall be Tenant’s sole and exclusive remedy on account of any interruption of services or Landlord’s default resulting in an interruption of services other than Tenant’s right to obtain affirmative injunctive relief.

 

9.7                               Telecommunications Providers.  Notwithstanding anything to the contrary herein or in this Lease contained, Landlord has no obligation to allow any particular telecommunications service provider to have access to the Building or to Premises other than Verizon and LightTower (collectively, the “Approved Providers”).  If Landlord permits such access, Landlord may condition such access upon (a) the execution of Landlord’s standard telecommunications agreement (which shall include a provision requiring the payment of fair market rent for any space in the Property dedicated, licensed and/or leased to such provider), and (b) the payment to Landlord by Tenant or the service provider of any costs incurred by Landlord in facilitating such

 

21

 

access.  Subject to the preceding sentence, Landlord’s consent to providing access to the Building to any service provider other than the Approved Providers shall not be unreasonably withheld, conditioned or delayed provided such access does not require any street opening permits or approvals (unless otherwise agreed to by the City of Cambridge) or would unreasonably interfere with the use of the Common Areas.  Notwithstanding the foregoing, Landlord hereby agrees to permit Cogent to have access to the Building to provide internet connectivity services to the Premises so long as (1) such access can be reasonably facilitated without interfering with current or planned use of space in the risers, conduits and elsewhere in the Building, (2) Cogent executes Landlord’s standard telecommunications agreement (which shall include a provision requiring the payment of fair market rent for any space in the Property dedicated, licensed and/or leased to Cogent and/or its affiliates), and (3) Tenant reimburses Landlord for any and all reasonable out-of-pocket costs incurred by Landlord in facilitating such access.

 

9.8                               Landlord’s Services.  Subject to reimbursement pursuant to Section 5.2 above, Landlord shall provide the services described in Exhibit 8 attached hereto and made a part hereof (“Landlord’s Services”).

 

10.                               MAINTENANCE AND REPAIRS.

 

10.1                        Maintenance and Repairs by Tenant.  Tenant shall keep all and singular the Premises (including, without limitation, doors and door frames and plate glass (provided that Landlord shall have the right to repair plate glass at Tenant’s cost)) neat and clean and free of insects, rodents, vermin and other pests and in such good repair, order and condition as the same are in on the Term Commencement Date or in such better condition as the Premises may be put in during the Term, reasonable wear and tear and damage by insured Casualty excepted.  Tenant shall be solely responsible, at Tenant’s sole cost and expense, for the proper maintenance of all building systems, sanitary, electrical, heating, air conditioning, plumbing, security or other systems and of all equipment and appliances installed and/or operated by Tenant and/or exclusively serving the Premises.  Tenant agrees to provide regular maintenance by contract with a reputable qualified service contractor for the heating and air conditioning equipment exclusively servicing the Premises.  Such maintenance contract and contractor shall be subject to Landlord’s reasonable approval.  Tenant, at Landlord’s request, shall at reasonable intervals provide Landlord with copies of such contracts and maintenance and repair records and/or reports.

 

10.2                        Maintenance and Repairs by Landlord.  Except as otherwise provided in Section 15, and subject to Tenant’s obligations in Section 10.1 above, Landlord shall keep and maintain the roof, Building structure, exterior window frames, structural floor slabs and columns and base building and common systems (including without limitation life-safety, sanitary, electrical, heating, air conditioning, plumbing, security or other systems) in good repair, order and condition.  In addition, Landlord shall operate and maintain the Common Areas in substantially the same manner as other first-class combination office and laboratory facilities in the vicinity of the Building.

 

10.3                        Accidents to Sanitary and Other Systems.  Tenant shall give to Landlord prompt notice of any fire or accident in the Premises or, if Tenant has knowledge thereof, elsewhere in the Building and of any damage to, or defective condition in, any part or appurtenance of the Building including, without limitation, sanitary, electrical, ventilation, heating and air conditioning or other

 

22

 

systems located in, or passing through, the Premises.  Except as otherwise provided in Section 15, and subject to Tenant’s obligations in Section 10.1 above, such damage or defective condition shall be remedied by Landlord with reasonable diligence, but, subject to Section 14.5 below, if such damage or defective condition was caused by any of the Tenant Parties, the cost to remedy the same shall be paid by Tenant.

 

10.4                        Floor Load—Heavy Equipment.  Tenant shall not place a load upon any floor of the Premises exceeding the floor load per square foot of area which such floor was designed to carry and which is allowed by Legal Requirements.  Landlord reserves the right to prescribe the weight and position of all safes, heavy machinery, heavy equipment, freight, bulky matter or fixtures (collectively, “Heavy Equipment”), which shall be placed so as to distribute the weight.  Heavy Equipment shall be placed and maintained by Tenant at Tenant’s expense in settings sufficient in Landlord’s reasonable judgment to absorb and prevent vibration, noise and annoyance.  Tenant shall not move any Heavy Equipment into or out of the Building without giving Landlord prior written notice thereof and observing all of Landlord’s Rules and Regulations with respect to the same.  If such Heavy Equipment requires special handling, Tenant agrees to employ only persons holding a Master Rigger’s License to do said work, and that all work in connection therewith shall comply with Legal Requirements.  Any such moving shall be at the sole risk and hazard of Tenant and Tenant will defend, indemnify and save Landlord and Landlord’s agents (including without limitation its property manager), contractors and employees (collectively with Landlord, the “Landlord Parties”) harmless from and against any and all claims, damages, losses, penalties, costs, expenses and fees (including without limitation reasonable legal fees) (collectively, “Claims”) resulting directly or indirectly from such moving.  Proper placement of all Heavy Equipment in the Premises shall be Tenant’s responsibility.

 

11.                               ALTERATIONS AND IMPROVEMENTS BY TENANT.

 

11.1                        Landlord’s Consent Required.  Tenant shall not make any alterations, decorations, installations, removals, additions or improvements (collectively, “Alterations”) in or to the Premises without Landlord’s prior written approval of the contractor(s), written plans and specifications, a time schedule therefor and the items listed in Exhibit 5 attached hereto and made a part hereof.  Landlord reserves the right to require that Tenant use Landlord’s preferred vendor(s) for any Alterations that involve roof penetrations, alarm tie-ins, sprinklers, fire alarm and other life safety equipment.  Tenant shall not make any amendments or additions to plans and specifications approved by Landlord without Landlord’s prior written consent.  Landlord’s approval of non-structural Alterations and Tenant’s contractor(s) shall not be unreasonably withheld, conditioned or delayed.  Notwithstanding the foregoing, Landlord may withhold its consent in its sole discretion (a) to any Alteration to or affecting the lab benches, fume hoods, roof and/or building systems, (b) with respect to matters of aesthetics relating to Alterations to or affecting the exterior of the Building, and (c) to any Alteration affecting the Building structure.  Notwithstanding the foregoing, Landlord’s consent shall not be required (but the applicable Exhibit 5 items shall be provided if reasonably required by Landlord) with respect to Alterations that are purely decorative in nature nor with respect to non-structural Alterations that do not trigger any requirement for Alterations outside the Premises and which cost less than $25,000 in any one instance (and $75,000 in the aggregate per year) so long as such Alterations do not materially adversely affect the roof, Building systems or Building exterior (each, a “Permitted Alteration”), provided Tenant shall provide Landlord with reasonably detailed prior written notice thereof.

 

23

 

Tenant shall be responsible for all elements of the design of Tenant’s plans (including, without limitation, compliance with Legal Requirements, functionality of design, the structural integrity of the design, the configuration of the Premises and the placement of Tenant’s furniture, appliances and equipment), and Landlord’s approval of Tenant’s plans shall in no event relieve Tenant of the responsibility for such design.  Landlord shall have no liability or responsibility for any claim, injury or damage alleged to have been caused by the particular materials (whether building standard or non-building standard), appliances or equipment selected by Tenant in connection with any work performed by or on behalf of Tenant.  Except as otherwise expressly set forth herein, all Alterations shall be done at Tenant’s sole cost and expense and at such times and in such manner as Landlord may from time to time reasonably designate.  If Tenant shall make any Alterations, then Landlord may elect, at the time Landlord approves such Alterations (or, for Permitted Alterations, promptly after Tenant notifies the Landlord of Tenant’s intent to make such Permitted Alterations and provides Landlord with the applicable Exhibit 5 items related thereto), to require Tenant at the expiration or sooner termination of the Term to restore the Premises to substantially the same condition as existed immediately prior to the Alterations.  If Landlord does not so elect, then any such Alteration shall become a part of the Premises upon installation, and shall be surrendered with the Premises at the end of the Term.  Tenant shall provide Landlord with reproducible record drawings (in CAD format) of all Alterations within sixty (60) days after completion thereof.

 

11.2                        Supervised Work.  Landlord and Tenant recognize that to the extent Landlord permits Tenant to perform any Alterations outside the Premises and/or affecting the Building systems, or if required by Legal Requirements, Landlord will need to make arrangements to have supervisory personnel on site.  Accordingly, Landlord and Tenant agree as follows:  Tenant shall give Landlord at least two (2) business days’ prior written notice of any time outside of normal construction hours when Tenant intends to perform portions of Alterations (the “Supervised Work”).  Tenant shall reimburse Landlord, within thirty (30) days after demand therefor, for the reasonable cost of Landlord’s supervisory personnel overseeing the Supervised Work.

 

11.3                        Harmonious Relations.  Tenant agrees that it will not, either directly or indirectly, use any contractors and/or materials if their use will create any difficulty, whether in the nature of a labor dispute or otherwise, with other contractors and/or labor engaged by Tenant or Landlord or others in the construction, maintenance and/or operation of the Building, the Property or any part thereof.  In the event of any such difficulty, upon Landlord’s request, Tenant shall cause all contractors, mechanics or laborers causing such difficulty to leave the Property immediately.

 

11.4                        Liens.  No Alterations shall be undertaken by Tenant until Tenant has made provision for written waiver of liens from all contractors for such Alteration and taken other appropriate protective measures approved and/or required by Landlord.  Tenant shall either:  (a) demonstrate to Landlord, to Landlord’s reasonable satisfaction, that Tenant is able to pay for the cost of such Alteration, or (b) provide to Landlord security, in form and amount reasonably satisfactory to Landlord (such as a letter of credit, escrowed funds, payment, performance and lien bonds or a guaranty), securing Tenant’s obligation to pay for the entire cost of such Alteration.  Any mechanic’s lien filed against the Premises or the Building for work claimed to have been done for, or materials claimed to have been furnished to, Tenant shall be discharged by Tenant within ten (10) days thereafter, at Tenant’s expense by filing the bond required by law or otherwise.

 

24

 

11.5                        General Requirements.  Unless Landlord and Tenant otherwise agree in writing, Tenant shall (a) obtain Landlord’s written approval of any and all building permit applications relating to Alterations to the Premises prior to submission thereof; (b) procure or cause others to procure on its behalf all necessary permits before undertaking any Alterations in the Premises (and provide copies thereof to Landlord); (c) perform all of such Alterations in a good and workmanlike manner, employing materials of good quality and in compliance with Landlord’s construction rules and regulations, all insurance requirements of this Lease, and Legal Requirements; and (d) defend, indemnify and hold the Landlord Parties harmless from and against any and all Claims occasioned by or growing out of such Alterations.  Tenant shall cause contractors employed by Tenant to (i) carry Worker’s Compensation Insurance in accordance with statutory requirements, (ii) carry Automobile Liability Insurance and Commercial General Liability Insurance (A) naming Landlord as an additional insured, and (B) covering such contractors on or about the Premises in the amounts stated in Section 14 hereof or in such other reasonable amounts as Landlord shall require, and (iii) submit binders evidencing such coverage to Landlord prior to the commencement of any such Alterations.  In addition, if construction during normal business hours unreasonably disturbs other tenants of the Property, in Landlord’s sole discretion, Landlord may require Tenant to stop the performance of Alterations during normal business hours and to perform the same after hours.

 

12.                               SIGNAGE.

 

12.1                        Restrictions.  Tenant shall have the right to install Building standard signage identifying Tenant’s business at the entrance to the Premises, which signage shall be subject to Landlord’s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed so long as the same complies with Landlord’s then-current signage guidelines for the Building).  Subject to the foregoing, Tenant shall not place or suffer to be placed or maintained on the exterior of the Premises, or any part of the interior visible from the exterior thereof, any sign, banner, advertising matter or any other thing of any kind (including, without limitation, any hand-lettered advertising), and shall not place or maintain any decoration, letter or advertising matter on the glass of any window or door of the Premises without first obtaining Landlord’s written approval.  No signs or blinds may be put on or in any window or elsewhere if visible from the exterior of the Building.  Landlord may provide Tenant with building standard blinds for each window within the Premises and Tenant shall install the same at Tenant’s sole cost and expense.  Tenant may not remove the building standard blinds without Landlord’s prior written consent.  Tenant may hang its own drapes, provided that they shall not in any way interfere with any building standard drapery or blinds provided by Landlord or be visible from the exterior of the Building, and that such drapes are so hung and installed that, when drawn, the building standard drapery or blinds are automatically also drawn.

 

12.2                        Building Directory.  Landlord shall list Tenant within the directory in the Building lobby at Landlord’s sole cost and expense.  Subject to reasonable limits on the number of lines on the directory Landlord can provide and all such additional signage in the lobby directory, Landlord shall add the names of any approved subtenants or licensees occupying any portion of the Premises at Tenant’s sole cost and expense.

 

12.3                        Monument Sign.  Subject to the issuance of applicable permits and approvals and subject further to Legal Requirements as of right, Landlord intends to install a monument sign on

 

25

 

the Property on which Landlord shall list Tenant’s name (as well as the names of other tenants or occupants of the Building).  Such listing shall comply with Landlord’s then-current signage guidelines for the Property.

 

13.                               ASSIGNMENT, MORTGAGING AND SUBLETTING.

 

13.1                        Landlord’s Consent Required.  Tenant shall not, without Landlord’s prior written consent, which consent may be withheld in Landlord’s sole discretion, mortgage or otherwise encumber this Lease or the Premises in whole or in part.  Except as expressly otherwise set forth herein, Tenant shall not, without Landlord’s prior written consent, which consent shall be granted or may be withheld in accordance with Section 13.3 below, assign, sublet, mortgage, license, transfer or encumber this Lease or the Premises in whole or in part whether by changes in the ownership or control of Tenant, or any direct or indirect owner of Tenant, whether at one time or at intervals, by sale or transfer of stock, partnership or beneficial interests, operation of law or otherwise, or permit the occupancy of all or any portion of the Premises by any person or entity other than Tenant’s employees (each of the foregoing, a “Transfer”).  Any purported Transfer made without Landlord’s consent, if required hereunder, shall be void and confer no rights upon any third person, provided that if there is a Transfer, Landlord may collect rent from the transferee without waiving the prohibition against Transfers, accepting the transferee, or releasing Tenant from full performance under this Lease.  In the event of any Transfer in violation of this Section 13, Landlord shall have the right to terminate this Lease upon thirty (30) days’ written notice to Tenant given within sixty (60) days after receipt of written notice from Tenant to Landlord of any Transfer, or within one (1) year after Landlord first learns of the Transfer if no notice is given.  No Transfer shall relieve Tenant of its primary obligation as party Tenant hereunder, nor shall it reduce or increase Landlord’s obligations under this Lease.  In no event shall any transfer of shares in Tenant over a nationally recognized stock exchange be deemed to be a Transfer.

 

13.2                        Landlord’s Recapture Right.

 

(a)                                 Subject to Section 13.7 below, Tenant shall, prior to offering or advertising the Premises or any portion thereof for a Transfer, give a written notice (the “Recapture Notice”) to Landlord which:  (i) states that Tenant desires to make a Transfer, (ii) identifies the affected portion of the Premises (the “Recapture Premises”), (iii) identifies the period of time (the “Recapture Period”) during which Tenant proposes to sublet the Recapture Premises, or indicates that Tenant proposes to assign its interest in this Lease, and (iv) offers to Landlord to terminate this Lease with respect to the Recapture Premises (in the case of a proposed assignment of Tenant’s interest in this Lease or a subletting for the remainder of the term of this Lease) or to suspend the Term for the Recapture Period (i.e. the Term with respect to the Recapture Premises shall be terminated during the Recapture Period and Tenant’s rental obligations shall be proportionately reduced).  Landlord shall have fifteen (15) business days within which to respond to the Recapture Notice.

 

(b)                                 If Tenant does not enter into a Transfer on the terms and conditions contained in the Recapture Notice on or before the date which is one hundred eighty (180) days after the earlier of:  (x) the expiration of the 15-business day period specified in Section 13.2(a) above, or (y) the date that Landlord notifies Tenant that Landlord will not accept Tenant’s offer contained in the Recapture Notice, time being of the essence, then prior to entering into any

 

26

 

Transfer after such 180-day period, Tenant must deliver to Landlord a new Recapture Notice in accordance with Section 13.2(a) above.

 

(c)                                  Notwithstanding anything to the contrary contained herein, if Landlord notifies Tenant that it accepts the offer contained in the Recapture Notice or any subsequent Recapture Notice, Tenant shall have the right, for a period of fifteen (15) days following receipt of such notice from Landlord, time being of the essence, to notify Landlord in writing that it wishes to withdraw such offer and this Lease shall continue in full force and effect.

 

13.3                        Standard of Consent to Transfer.  If Landlord does not timely give written notice to Tenant accepting an offer contemplated in a Recapture Notice or declines to accept the same, then Landlord agrees that, subject to the provisions of this Section 13, Landlord shall not unreasonably withhold, condition or delay its consent to a Transfer at fair market rent and otherwise on the terms contained in the Recapture Notice to an entity which will use the Premises for the Permitted Uses (provided that such consent shall be given or denied within thirty (30) days after Tenant submits a request therefor together with all other required information) and, in Landlord’s reasonable opinion:  (a) has a tangible net worth and other financial indicators sufficient to meet the Transferee’s obligations under the Transfer instrument in question; (b) has a business reputation compatible with the operation of a first-class combination laboratory, research, development and office building; and (c) the intended use of such entity does not violate any exclusive or restrictive use provisions of any leases then in effect with respect to space in the Building; provided, however, if there shall be, at the time that Landlord is otherwise required to provide its consent, an event which, with the passage of time and/or the giving of notice, would constitute an Event of Default, then it shall be reasonable for Landlord to condition its consent to the Transfer in question on Tenant’s cure of such default prior to the expiration of applicable cure periods set forth in Section 20.1 (any Transfer to which Landlord’s consent has been given pursuant this Section 13.3, a “Permitted Transfer”).

 

13.4                        Listing Confers no Rights.  The listing of any name other than that of Tenant, whether on the doors of the Premises or on the Building directory, or otherwise, shall not operate to vest in any such other person, firm or corporation any right or interest in this Lease or in the Premises or be deemed to effect or evidence any consent of Landlord, it being expressly understood that any such listing is a privilege extended by Landlord revocable at will by written notice to Tenant.

 

13.5                        Profits In Connection with Transfers.  Tenant shall, within thirty (30) days of receipt thereof, pay to Landlord fifty percent (50%) of any rent, sum or other consideration to be paid or given in connection with any Transfer, either initially or over time, after deducting reasonable actual out-of-pocket legal, and brokerage expenses incurred by Tenant, market concessions granted to the applicable Transferee and unamortized improvements paid for by Tenant in connection therewith, in excess of Rent hereunder as if such amount were originally called for by the terms of this Lease as additional rent.  This Section 13.5 shall not apply to any Transfer to a Successor.

 

13.6                        Prohibited Transfers.  Notwithstanding any contrary provision of this Lease, Tenant shall have no right to make a Transfer unless on both (i) the date on which Tenant notifies Landlord of its intention to enter into a Transfer and (ii) the date on which such Transfer is to take

 

27

 

effect, there is not an Event of Default.  Notwithstanding anything to the contrary contained herein, Tenant agrees that in no event shall Tenant make a Transfer to (a) any government agency; (b) any tenant, subtenant or occupant of other space in the Building; or (c) any entity with whom Landlord shall have negotiated for space in the Property in the six (6) months immediately preceding such proposed Transfer.

 

13.7                        Exceptions to Requirement for Consent.  Notwithstanding anything to the contrary herein contained, Tenant shall have the right, without obtaining Landlord’s consent and without giving Landlord a Recapture Notice, to make a Transfer to (a) an Affiliated Entity (hereinafter defined) so long as such entity remains in such relationship to Tenant, and (b) a Successor, provided that prior to or simultaneously with any such Transfer, such Affiliated Entity or Successor, as the case may be, and Tenant execute and deliver to Landlord an assignment and assumption agreement in form and substance reasonably acceptable to Landlord whereby such Affiliated Entity or Successor, as the case may be, shall agree to be independently bound by and upon all the covenants, agreements, terms, provisions and conditions set forth in the Lease on the part of Tenant to be performed, and whereby such Affiliated Entity or Successor, as the case may be, shall expressly agree that the provisions of this Section 13 shall, notwithstanding such Transfer, continue to be binding upon it with respect to all future Transfers.  For the purposes hereof, an “Affiliated Entity” shall be defined as any entity which is controlled by, is under common control with, or which controls Tenant.  For the purposes hereof, a “Successor” shall be defined as any entity into or with which Tenant is merged or with which Tenant is consolidated or which acquires all or substantially all of Tenant’s stock or assets, provided that the surviving entity shall have a net worth and other financial indicators sufficient to meet Tenant’s obligations hereunder.  Notwithstanding the provisions of this Section 13.7, no transaction or series of transactions which are effected solely for the purpose of qualifying as a transaction which does not require Landlord’s consent (i.e. and thereby avoiding the operation of the provisions of this Article 13) shall be permitted pursuant to this Section 13.7.

 

14.                               INSURANCE; INDEMNIFICATION; EXCULPATION.

 

14.1                        Tenant’s Insurance.

 

(a)                                 Tenant shall procure, pay for and keep in force throughout the Term (and for so long thereafter as Tenant remains in occupancy of the Premises) commercial general liability insurance insuring Tenant on an occurrence basis against all claims and demands for personal injury liability (including, without limitation, bodily injury, sickness, disease, and death) or damage to property which may be claimed to have occurred from and after the time any of the Tenant Parties shall first enter the Premises, of not less than Three Million Dollars ($3,000,000) per occurrence, Five Million Dollars ($5,000,000) aggregate, and from time to time thereafter shall be not less than such higher amounts, if procurable, as may be reasonably required by Landlord.  Tenant shall also carry umbrella liability coverage in an amount of no less than Five Million Dollars ($5,000,000).  Such policy shall also include contractual liability coverage covering Tenant’s liability assumed under this Lease, including without limitation Tenant’s indemnification obligations.  Such insurance policy(ies) shall name Landlord, Landlord’s managing agent and persons claiming by, through or under them, if any, as additional insureds.

 

28

 

(b)                                 Tenant shall take out and maintain throughout the Term a policy of fire, vandalism, malicious mischief, extended coverage and so-called “all risk” coverage insurance in an amount equal to one hundred percent (100%) of the replacement cost insuring (i) all items or components of Tenant’s Alterations (collectively, the “Tenant-Insured Improvements”), and (ii) Tenant’s furniture, equipment, fixtures and property of every kind, nature and description related or arising out of Tenant’s leasehold estate hereunder, which may be in or upon the Premises or the Building (collectively, “Tenant’s Property”).  Such insurance shall insure the interests of both Landlord and Tenant as their respective interests may appear from time to time.

 

(c)                                  Tenant shall take out and maintain a policy of business interruption insurance throughout the Term sufficient to cover at least twelve (12) months of Rent due hereunder and Tenant’s business losses during such 12-month period.

 

(d)                                 Tenant shall procure and maintain at its sole expense such additional insurance as may be necessary to comply with any Legal Requirements.

 

(e)                                  During periods when any Alterations are being performed, Builders Risk Insurance .

 

(f)                                   The insurance required pursuant to Sections 14.1(a), (b), (c), (d) and (e) (collectively, “Tenant’s Insurance Policies”) shall be effected with insurers approved by Landlord, with a rating of not less than “A-XI” in the current Best’s Insurance Reports, and authorized to do business in the Commonwealth of Massachusetts under valid and enforceable policies.  Tenant’s Insurance Policies shall each provide that it shall not be canceled or modified without at least thirty (30) days’ prior written notice to each insured named therein (or, in the case of a cancellation due to non-payment of premium, without at least ten (10) days prior written notice to each insured named therein).  Tenant’s Insurance Policies may include no greater than commercially reasonable deductible amounts.  On or before the date on which any of the Tenant Parties shall first enter the Premises and thereafter prior to the expiration date of each expiring policy, Tenant shall deliver to Landlord binders of Tenant’s Insurance Policies issued by the respective insurers setting forth in full the provisions thereof together with evidence satisfactory to Landlord of the payment of all premiums for such policies.  In the event of any claim, and upon Landlord’s request, Tenant shall deliver to Landlord complete copies of Tenant’s Insurance Policies.  Upon request of Landlord, Tenant shall deliver to any Mortgagee copies of the foregoing documents.

 

14.2                        Indemnification.

 

(a)                                 Except to the extent caused by the negligence or willful misconduct of any of the Landlord Parties, Tenant shall defend, indemnify and save the Landlord Parties harmless from and against any and all Claims asserted by or on behalf of any person, firm, corporation or public authority arising from:

 

(i)                                     Tenant’s breach of any covenant or obligation under this Lease;

 

29

 

(ii)                                  Any injury to or death of any person, or loss of or damage to property, sustained or occurring in, upon, at or about the Premises during the Term and any period thereafter, if any, during which any Tenant Party holds over;

 

(iii)                               Any injury to or death of any person, or loss of or damage to property arising out of the use or occupancy of the Premises by or the negligence or willful misconduct of any of the Tenant Parties; and

 

(iv)                              On account of or based upon any work or thing whatsoever done (other than by Landlord or any of the Landlord Parties) at the Premises during the Term and during the period of time, if any, prior to the Term Commencement Date that any of the Tenant Parties may have been given access to the Premises.

 

(b)                                 Except to the extent caused by the negligence or willful misconduct of any of the Tenant Parties, Landlord shall defend, indemnify and save Tenant harmless from and against any and all Claims asserted by or on behalf of any person, firm, corporation or public authority arising from (i) Landlord’s breach of any covenant or obligation under this Lease, or (ii) any injury to or death of any person, or loss of or damage to property arising out of the negligence or willful misconduct of any of the Landlord Parties.

 

14.3                        Property of Tenant.  Tenant covenants and agrees that, to the maximum extent permitted by Legal Requirements, all of Tenant’s Property at the Premises shall be at the sole risk and hazard of Tenant, and that if the whole or any part thereof shall be damaged, destroyed, stolen or removed from any cause or reason whatsoever, no part of said damage or loss shall be charged to, or borne by, Landlord, except, subject to Section 14.5 hereof, to the extent such damage or loss is due to the negligence or willful misconduct of any of the Landlord Parties.

 

14.4                        Limitation of Landlord’s Liability for Damage or Injury.  Landlord shall not be liable for any injury or damage to persons, animals, or property resulting from fire, explosion, falling plaster, steam, gas, air contaminants or emissions, electricity, electrical or electronic emanations or disturbance, water, rain or snow or leaks from any part of the Building or from the pipes, appliances, equipment or plumbing works or from the roof, street or sub-surface or from any other place or caused by dampness, vandalism, malicious mischief or by any other cause of whatever nature, except to the extent caused by or due to the negligence or willful misconduct of any of the Landlord Parties, and then, where notice and an opportunity to cure are appropriate (i.e., where Tenant has an opportunity to know or should have known of such condition sufficiently in advance of the occurrence of any such injury or damage resulting therefrom as would have enabled Landlord to prevent such damage or loss had Tenant notified Landlord of such condition) only after (i) notice to Landlord of the condition claimed to constitute negligence or willful misconduct, and (ii) the expiration of a reasonable time after such notice has been received by Landlord without Landlord having commenced to take all reasonable and practicable means to cure or correct such condition; and pending such cure or correction by Landlord, Tenant shall take all reasonably prudent temporary measures and safeguards to prevent any injury, loss or damage to persons or property.  Notwithstanding the foregoing, in no event shall any of the Landlord Parties be liable for any loss which is covered by insurance policies actually carried or required to be so carried by this Lease; nor shall any of the Landlord Parties be liable for any such damage caused by other tenants or persons in the Building or caused by operations in construction of any private, public, or

 

30

 

quasi-public work; nor shall any of the Landlord Parties be liable for any latent defect in the Premises or in the Building.

 

14.5                        Waiver of Subrogation; Mutual Release.  Landlord and Tenant each hereby waives on behalf of itself and its property insurers (none of which shall ever be assigned any such claim or be entitled thereto due to subrogation or otherwise) any and all rights of recovery, claim, action, or cause of action against the other and its agents, officers, servants, partners, shareholders, or employees (collectively, the “Related Parties”) for any loss or damage (excluding rights of recovery, claims, actions, and causes of action relating to damage to the roof of the Building caused by Tenant but including rights of recovery, claims, actions, and causes of action relating to damage to the roof of the Building caused by any Casualty (hereinafter defined)) that may occur to or within the Premises or the Building or any improvements thereto, or any personal property of such party therein which is insured against under any property insurance policy actually being maintained by the waiving party from time to time, even if not required hereunder, or which would be insured against under the terms of any insurance policy required to be carried or maintained by the waiving party hereunder, whether or not such insurance coverage is actually being maintained, including, in every instance, such loss or damage that may be caused by the negligence of the other party hereto and/or its Related Parties.  Landlord and Tenant each agrees to cause appropriate clauses to be included in its property insurance policies necessary to implement the foregoing provisions.

 

14.6                        Tenant’s Acts—Effect on Insurance.  Tenant shall not do or permit any Tenant Party to do any act or thing upon the Premises or elsewhere in the Building which will invalidate or be in conflict with any insurance policies or warranties covering the Building and the fixtures and property therein; and shall not do, or permit to be done, any act or thing upon the Premises which shall subject Landlord to any liability or responsibility for injury to any person or persons or to property by reason of any business or operation being carried on upon said Premises or for any other reason.  If by reason of the failure of Tenant to comply with the provisions hereof the insurance rate applicable to any policy of insurance shall at any time thereafter be higher than it otherwise would be, Tenant shall reimburse Landlord upon demand for that part of any insurance premiums which shall have been charged because of such failure by Tenant, together with interest at the Default Rate until paid in full, within ten (10) days after receipt of an invoice therefor.

 

15.                               CASUALTY; TAKING.

 

15.1                        Damage.  If the Premises are damaged in whole or part because of fire or other insured casualty (“Casualty”), or if the Premises are subject to a taking in connection with the exercise of any power of eminent domain, condemnation, or purchase under threat or in lieu thereof (any of the foregoing, a “Taking”), then unless this Lease is terminated in accordance with Section 15.2 below, Landlord shall restore the Building and/or the Premises to substantially the same condition as existed immediately following completion of Landlord’s Work, or in the event of a partial Taking which affects the Building and the Premises, restore the remainder of the Building and the Premises not so Taken to substantially the same condition as is reasonably feasible.  Within ninety (90) days following such Casualty or Taking, Landlord shall provide Tenant with a written notice (the “Restoration Notice”) indicating the expected timeframe for completion of Landlord’s repair and restoration.  If, in Landlord’s reasonable judgment, any element of the Tenant-Insured Improvements can more effectively be restored as an integral part

 

31

 

of Landlord’s restoration of the Building or the Premises, such restoration shall also be made by Landlord, but at Tenant’s sole cost and expense.  Subject to rights of Mortgagees, Tenant Delays, Legal Requirements then in existence and to delays for adjustment of insurance proceeds or Taking awards, as the case may be, and instances of Landlord’s Force Majeure, Landlord shall exercise diligent efforts to substantially complete such restoration within the time period set forth in the Restoration Notice.  Upon substantial completion of such restoration by Landlord, Tenant shall use diligent efforts to complete restoration of the Premises to substantially the same condition as existed immediately prior to such Casualty or Taking, as the case may be, as soon as reasonably possible, subject to Force Majeure and Landlord-caused delays.  Tenant agrees to cooperate with Landlord in such manner as Landlord may reasonably request to assist Landlord in collecting insurance proceeds due in connection with any Casualty which affects the Premises or the Building.  In no event shall Landlord be required to expend more than the Net (hereinafter defined) insurance proceeds Landlord receives for damage to the Premises and/or the Building or the Net Taking award attributable to the Premises and/or the Building.  “Net” means the insurance proceeds or Taking award actually paid to Landlord (and not paid over to a Mortgagee) less all costs and expenses, including adjusters and attorney’s fees, of obtaining the same.  In the Operating Year in which a Casualty occurs, there shall be included in Operating Costs Landlord’s deductible under its property insurance policy.  Except as Landlord may elect pursuant to this Section 15.1, under no circumstances shall Landlord be required to repair any damage to, or make any repairs to or replacements of, any Tenant-Insured Improvements.

 

15.2                        Termination Rights.

 

(a)                                 Landlord’s Termination Rights.  Landlord may terminate this Lease upon thirty (30) days’ prior written notice to Tenant if:

 

(i)                                     any material portion of the Building or any material means of access thereto is taken; or

 

(ii)                                  more than thirty-five percent (35%) of the Building is damaged by Casualty.

 

(b)                                 Tenant’s Termination Right.  If Landlord is so required but fails to complete restoration of the Premises within one (1) year from the date of Casualty or Taking, subject to the conditions set forth in Section 15.1 above, then Tenant may terminate this Lease upon thirty (30) days’ written notice to Landlord; provided, however, that in the case of clause (i) of this Section 15.2(b), if Landlord completes such restoration within thirty (30) days after receipt of any such termination notice, such termination notice shall be null and void and this Lease shall continue in full force and effect.  The remedies set forth in this Section 15.2(b) and in Section 15.2(c) below are Tenant’s sole and exclusive rights and remedies based upon Landlord’s failure to complete the restoration of the Premises as set forth herein.

 

(c)                                  Either Party May Terminate.  In the case of any Casualty or Taking affecting the Premises and occurring during the last six (6) months of the Term, then (i) if such Casualty or Taking results in more than ten percent (10%) of the floor area of the Premises being unsuitable for the Permitted Uses, or (ii) the damage to the Premises costs more than $100,000 to restore, then either Landlord or Tenant shall have the option to terminate this Lease upon thirty

 

32

 

(30) days’ written notice to the other.  In addition, Landlord or Tenant may terminate this Lease by written notice to the other if (A) any Mortgagee does not release sufficient insurance proceeds to cover the cost of Landlord’s restoration work and Landlord does not agree in writing to cover the difference, or (B) the estimated time to complete Landlord’s restoration exceeds one (1) year after the Casualty or Taking.

 

(d)                                 Automatic Termination.  In the case of a Taking of the entire Premises, then this Lease shall automatically terminate as of the date of possession by the Taking authority.

 

(e)                                  Notwithstanding anything to the contrary contained herein, Tenant may not terminate this Lease pursuant to this Section 15 if the Casualty in question was caused by the willful misconduct of any of the Tenant Parties.

 

15.3                        Taking for Temporary Use.  If the Premises are Taken for temporary use, this Lease and Tenant’s obligations, including without limitation the payment of Rent, shall continue.  For purposes hereof, a “Taking for temporary use” shall mean a Taking of ninety (90) days or less.

 

15.4                        Disposition of Awards.  Except for any separate award for Tenant’s movable trade fixtures, relocation expenses, and unamortized leasehold improvements paid for by Tenant (provided that the same may not reduce Landlord’s award), all Taking awards to Landlord or Tenant shall be Landlord’s property without Tenant’s participation, and Tenant hereby assigns to Landlord Tenant’s interest, if any, in such award.  Tenant may pursue its own claim against the Taking authority.

 

15.5                        Abatement.  In the event of any Casualty or Taking affecting the Premises, Base Rent and Tenant’s regular monthly payments of additional rent on account of Operating Costs and Taxes shall be equitably abated for the period from the date of such Casualty or Taking until the earlier of (a) the date that Landlord substantially completes Landlord’s restoration work (provided that if Landlord would have completed Landlord’s restoration work at an earlier date but for delays caused by the acts or wrongful or negligent omissions of any of the Tenant Parties of which Tenant has prior notice, then the Premises shall be deemed to have been repaired and restored on such earlier date), or (b) the date Tenant or other occupant reoccupies any portion of the Premises for the conduct of its business (in which case the Base Rent and Additional Rent allocable to such reoccupied portion shall be payable by Tenant from the date of such occupancy).  The reasonable determination of Landlord’s architect of the date Landlord’s restoration to the Premises shall have been substantially completed shall be controlling unless Tenant disputes same by notice to Landlord given within fifteen (15) days after receipt of written notice from Landlord setting forth such determination by Landlord, and pending resolution of such dispute, Tenant’s obligation to re-commence the payment of Rent shall commence in accordance with Landlord’s determination.  In the event of a Taking where this Lease is not terminated, a just proportion of the Rent, based on the nature and extent of the interference with Tenant’s business operations, shall, subject to Section 15.3 above, be abated for the duration of the Taking.

 

16.                               ESTOPPEL CERTIFICATE.  Tenant shall at any time and from time to time upon not less than ten (10) days’ prior notice from Landlord, execute, acknowledge and deliver to Landlord a statement in writing certifying that this Lease is unmodified and in full force and effect (or if

 

33

 

there have been modifications, that the same is in full force and effect as modified and stating the modifications), and the dates to which Rent has been paid in advance, if any, stating whether or not Landlord is in default in performance of any covenant, agreement, term, provision or condition contained in this Lease and, if so, specifying each such default, and such other facts as Landlord may reasonably request, it being intended that any such statement delivered pursuant hereto may be relied upon by Landlord, any prospective purchaser of the Building or of any interest of Landlord therein, any Mortgagee or prospective mortgagee thereof, any lessor or prospective lessor thereof, any lessee or prospective lessee thereof, or any prospective assignee of any mortgage thereof.  Time is of the essence with respect to any such requested certificate, Tenant hereby acknowledging the importance of such certificates in mortgage financing arrangements, prospective sales and the like.

 

17.                               HAZARDOUS MATERIALS.

 

17.1                        Prohibition.  Tenant shall not, without the prior written consent of Landlord, bring or permit to be brought or kept in or on the Premises or elsewhere in the Building or the Property (i) any inflammable, combustible or explosive fluid, material, chemical or substance (except for standard office supplies stored in proper containers); and (ii) any Hazardous Material (hereinafter defined), other than the types and quantities of Hazardous Materials which are listed on Exhibit 6 attached hereto (“Tenant’s Hazardous Materials”), provided that the same shall at all times be brought upon, kept or used in so-called ‘control rooms’ and in accordance with all applicable Environmental Laws (hereinafter defined) and prudent environmental practice and (with respect to medical waste and so-called “biohazard” materials) good scientific and medical practice.  Tenant shall be responsible for assuring that all laboratory uses are adequately and properly vented.  On or before each anniversary of the Rent Commencement Date, and on any earlier date during the 12-month period on which Tenant intends to add a new Hazardous Material to, or materially increase the quantity of any Hazardous Material already on, the list of Tenant’s Hazardous Materials, Tenant shall submit to Landlord an updated list of Tenant’s Hazardous Materials for Landlord’s review and approval, which approval shall not be unreasonably withheld, conditioned or delayed.  Landlord shall have the right, from time to time, to inspect the Premises for compliance with the terms of this Section 17.1 at Tenant’s sole cost and expense.  Notwithstanding the foregoing, with respect to any of Tenant’s Hazardous Materials which Tenant does not properly handle, store or dispose of in compliance with all applicable Environmental Laws (hereinafter defined), prudent environmental practice and (with respect to medical waste and so-called “biohazard” materials) good scientific and medical practice, Tenant shall, upon written notice from Landlord, no longer have the right to bring such material into the Building or the Property until Tenant has demonstrated, to Landlord’s reasonable satisfaction, that Tenant has implemented programs to thereafter properly handle, store or dispose of such material.

 

17.2                        Environmental Laws.  For purposes hereof, “Environmental Laws” shall mean all laws, statutes, ordinances, rules and regulations of any local, state or federal governmental authority having jurisdiction concerning environmental, health and safety matters, including but not limited to any discharge by any of the Tenant Parties into the air, surface water, sewers, soil or groundwater of any Hazardous Material (hereinafter defined) whether within or outside the Premises, including, without limitation (a) the Federal Water Pollution Control Act, 33 U.S.C. Section 1251 et seq., (b) the Federal Resource Conservation and Recovery Act, 42 U.S.C. Section 6901 et seq., (c) the Comprehensive Environmental Response, Compensation and Liability Act, 42

 

34

 

U.S.C. Section 9601 et seq., (d) the Toxic Substances Control Act of 1976, 15 U.S.C. Section 2601 et seq., and (e) Chapter 21E of the General Laws of Massachusetts.  Tenant, at its sole cost and expense, shall comply with (i) all Environmental Laws, and (ii) any rules, requirements and safety procedures of the Massachusetts Department of Environmental Protection, the City of Cambridge and any insurer of the Building or the Premises with respect to Tenant’s use, storage and disposal of any Hazardous Materials.

 

17.3                        Hazardous Material Defined.  As used herein, the term “Hazardous Material” means asbestos, oil or any hazardous, radioactive or toxic substance, material or waste or petroleum derivative which is or becomes regulated by any Environmental Law, including without limitation live organisms, viruses and fungi, medical waste and any so-called “biohazard” materials.”.  The term “Hazardous Material” includes, without limitation, oil and/or any material or substance which is (i) designated as a “hazardous substance,” “hazardous material,” “oil,” “hazardous waste” or toxic substance under any Environmental Law.

 

17.4                        Testing.  If any Mortgagee or governmental authority requires testing to determine whether there has been any release of Hazardous Materials and such testing is required as a result of the acts or omissions of any of the Tenant Parties, then Tenant shall reimburse Landlord upon demand, as additional rent, for the reasonable costs thereof, together with interest at the Default Rate until paid in full.  Tenant shall execute affidavits, certifications and the like, as may be reasonably requested by Landlord from time to time concerning Tenant’s best knowledge and belief concerning the presence of Hazardous Materials in or on the Premises, the Building or the Property.

 

17.5                        Indemnity; Remediation.

 

(a)                                 Tenant hereby covenants and agrees to indemnify, defend and hold the Landlord Parties harmless from and against any and all Claims against any of the Landlord Parties arising out of contamination of any part of the Property or other adjacent property, which contamination arises as a result of:  (i) the presence of Hazardous Material in the Premises, the presence of which is caused by any act or omission of any of the Tenant Parties, or (ii) from a breach by Tenant of its obligations under this Section 17.  This indemnification of the Landlord Parties by Tenant includes, without limitation, reasonable costs incurred in connection with any investigation of site conditions or any cleanup, remedial, removal or restoration work or any other response action required by any federal, state or local governmental agency or political subdivision because of Hazardous Material present in the soil, soil vapor, or ground water on or under, or any indoor air in, the Building based upon the circumstances identified in the first sentence of this Section 17.5.  The indemnification and hold harmless obligations of Tenant under this Section 17.5 shall survive the expiration or any earlier termination of this Lease.  Without limiting the foregoing, if the presence of any Hazardous Material in the Building or otherwise at the Property is caused or permitted by any of the Tenant Parties and results in any contamination of any part of the Property or any adjacent property, Tenant shall promptly take all actions at Tenant’s sole cost and expense as are necessary to return the Property and/or the Building or any adjacent property to their condition as of the date of this Lease, provided that Tenant shall first obtain Landlord’s written approval of such actions, which approval shall not be unreasonably withheld, conditioned or delayed so long as such actions, in Landlord’s reasonable discretion, would not

 

35

 

potentially have any adverse effect on the Property, and, in any event, Landlord shall not withhold its approval of any proposed actions which are required by applicable Environmental Laws.

 

(b)                                 Without limiting the obligations set forth in Section 17.5(a) above, if any Hazardous Material is in, on, under, at or about the Building or the Property as a result of the acts or omissions of any of the Tenant Parties and results in any contamination of any part of the Property or any adjacent property that is in violation of any applicable Environmental Law or that requires the performance of any response action pursuant to any Environmental Law, Tenant shall promptly take all actions at Tenant’s sole cost and expense as are necessary to reduce such Hazardous Material to amounts below any applicable Reportable Quantity, any applicable Reportable Concentration and any other applicable standard set forth in any Environmental Law such that no further response actions are required; provided that Tenant shall first obtain Landlord’s written approval of such actions, which approval shall not be unreasonably withheld, conditioned or delayed so long as such actions would not be reasonably expected to have an adverse effect on the market value or utility of the Property for the Permitted Uses, and in any event, Landlord shall not withhold its approval of any proposed actions which are required by applicable Environmental Laws (such approved actions, “Tenant’s Remediation”).  For the avoidance of doubt, the parties acknowledge that Tenant’s Remediation with respect to the Property shall not contain any requirement that Tenant remediate any contamination to levels or standards more stringent than those associated with the use of the Property for office, research and development, laboratory, and vivarium uses.

 

(c)                                  In the event that Tenant fails to complete Tenant’s Remediation prior to the end of the Term, then:

 

(i)                                     until the completion of Tenant’s Remediation (as evidenced by the certification of Tenant’s Licensed Site Professional (as such term is defined by applicable Environmental Laws), who shall be reasonably acceptable to Landlord) (the “Remediation Completion Date”), Tenant shall pay to Landlord, with respect to the portion of the Premises which reasonably cannot be occupied by a new tenant until completion of Tenant’s Remediation, (A) Additional Rent on account of Operating Costs and Taxes and (B) Base Rent in an amount equal to the greater of (1) the fair market rental value of such portion of the Premises (determined in substantial accordance with the process described in Section 1.2 above), and (2) Base Rent attributable to such portion of the Premises in effect immediately prior to the end of the Term; and

 

(ii)                                  Tenant shall maintain responsibility for Tenant’s Remediation and Tenant shall complete Tenant’s Remediation as soon as reasonably practicable in accordance with all Environmental Laws.  If Tenant does not diligently pursue completion of Tenant’s Remediation, Landlord shall have the right to either (A) assume control for overseeing Tenant’s Remediation, in which event Tenant shall pay all reasonable costs and expenses of Tenant’s Remediation (it being understood and agreed that all costs and expenses of Tenant’s Remediation incurred pursuant to contracts entered into by Tenant shall be deemed reasonable) within thirty (30) days of demand therefor (which demand shall be made no more often than monthly), and Landlord shall be substituted as the party identified on any governmental filings as the party responsible for the performance of such Tenant’s Remediation or (B) require Tenant to maintain responsibility for Tenant’s Remediation, in which event Tenant shall complete Tenant’s Remediation as soon as reasonably practicable in accordance with all Environmental Laws, it

 

36

 

being understood that Tenant’s Remediation shall not contain any requirement that Tenant remediate any contamination to levels or standards more stringent than those associated with the Property’s current office, research and development, laboratory, and vivarium uses.

 

(d)                                 The provisions of this Section 17.5 shall survive the expiration or earlier termination of this Lease.

 

17.6                        Disclosures.  Prior to bringing any Hazardous Material into any part of the Property, Tenant shall deliver to Landlord the following information with respect thereto:  (a) a description of handling, storage, use and disposal procedures; (b) all plans or disclosures and/or emergency response plans which Tenant has prepared, including without limitation Tenant’s Spill Response Plan, and all plans which Tenant is required to supply to any governmental agency or authority pursuant to any Environmental Laws; and (c) other information reasonably requested by Landlord.

 

17.7                        Removal.  Tenant shall be responsible, at its sole cost and expense, for Hazardous Material and other biohazard disposal services for the Premises.  Such services shall be performed by contractors reasonably acceptable to Landlord and on a sufficient basis to ensure that the Premises are at all times kept neat, clean and free of Hazardous Materials and biohazards except in appropriate, specially marked containers reasonably approved by Landlord.  In addition, if any Legal Requirements or the trash removal company requires that any substances be disposed of separately from ordinary trash, Tenant shall make arrangements at Tenant’s expense for such disposal directly with a qualified and licensed disposal company at a lawful disposal site.

 

18.                               RULES AND REGULATIONS.

 

18.1                        Rules and Regulations.  Tenant will faithfully observe and comply with all rules and regulations promulgated from time to time with respect to the Building, the Property and construction within the Property (collectively, the “Rules and Regulations”).  The current version of the Rules and Regulations is attached hereto as Exhibit 7.  In the case of any conflict between the provisions of this Lease and any future rules and regulations, the provisions of this Lease shall control.  Nothing contained in this Lease shall be construed to impose upon Landlord any duty or obligation to enforce the Rules and Regulations or the terms, covenants or conditions in any other lease as against any other tenant and Landlord shall not be liable to Tenant for violation of the same by any other tenant, its servants, employees, agents, contractors, visitors, invitees or licensees.

 

18.2                        Energy Conservation.  Notwithstanding anything to the contrary contained herein, Landlord may institute upon written notice to Tenant such policies, programs and measures as may be necessary, required, or expedient for the conservation and/or preservation of energy or energy services (collectively, the “Conservation Program”), provided however, that the Conservation Program does not, by reason of such policies, programs and measures, reduce the level of energy or energy services being provided to the Premises below the level of energy or energy services then being provided in comparably aged, first-class combination laboratory, research and development and office buildings in the vicinity of the Building, or as may be necessary or required to comply with Legal Requirements or standards or the other provisions of this Lease.  Upon receipt of such notice, Tenant shall comply with the Conservation Program.

 

37

 

18.3                        Recycling.  Upon written notice, Landlord may establish policies, programs and measures for the recycling of paper, products, plastic, tin and other materials (a “Recycling Program”).  Upon receipt of such notice, Tenant will comply with the Recycling Program at Tenant’s sole cost and expense.

 

19.                               LAWS AND PERMITS.

 

19.1                        Legal Requirements.  Tenant shall be responsible at its sole cost and expense for complying with (and keeping the Premises in compliance with) all Legal Requirements which are applicable to Tenant’s particular use or occupancy of, or Alterations made by or on behalf of Tenant to, the Premises.  Tenant shall furnish all data and information to governmental authorities, with a copy to Landlord, as required in accordance with Legal Requirements as they relate to Tenant’s use or occupancy of the Premises or the Building.  If Tenant receives notice of any violation of Legal Requirements applicable to the Premises or the Building, it shall give prompt notice thereof to Landlord.  Nothing contained in this Section 19.1 shall be construed to expand the uses permitted hereunder beyond the Permitted Uses.  Landlord shall comply with any Legal Requirements and with any direction of any public office or officer relating to the maintenance or operation of the Building as a combination laboratory, research and development and office building, and the costs so incurred by Landlord shall be included in Operating Costs in accordance with the provisions of Section 5.2.

 

19.2                        Required Permits.  Tenant shall, at Tenant’s sole cost and expense, use diligent good faith efforts to apply for, seek and obtain all necessary state and local licenses, permits and approvals needed for the operation of Tenant’s business, excluding the certificate of occupancy which Tenant must obtain prior to operating its business in the Premises (collectively, the “Required Permits”), on or before the Rent Commencement Date, time being of the essence.  Tenant shall thereafter maintain all Required Permits.  Tenant, at Tenant’s expense, shall at all times comply with the terms and conditions of each such Required Permit.  Landlord shall cooperate with Tenant, at Tenant’s sole cost and expense, in connection with its application for Required Permits.

 

20.                               DEFAULT.

 

20.1                        Events of Default.  The occurrence of any one or more of the following events shall constitute an “Event of Default” hereunder by Tenant:

 

(a)                                 If Tenant fails to make any payment of Rent or any other payment required hereunder, as and when due, and such failure shall continue for a period of five (5) days after notice thereof from Landlord to Tenant; provided, however, an Event of Default shall occur hereunder without any obligation of Landlord to give any notice if (i) Tenant fails to make any payment within five (5) days after the due date therefor, and (ii) Landlord has given Tenant written notice under this Section 20.1(a) on two (2) or more occasions during the twelve (12) month interval preceding such failure by Tenant;

 

(b)                                 Intentionally omitted

 

(c)                                  If Tenant shall fail to execute and deliver to Landlord an estoppel certificate pursuant to Section 16 above or a subordination and attornment agreement pursuant to Section 22

 

38

 

below, within the timeframes set forth therein and such failure continues for five (5) days after notice thereof;

 

(d)                                 If Tenant shall fail to maintain any insurance required hereunder;

 

(e)                                  If Tenant shall fail to restore the Security Deposit to its original amount or deliver a replacement Letter of Credit as required under Section 7 above;

 

(f)                                   If Tenant causes or suffers any release of Hazardous Materials in or near the Property;

 

(g)                                  If Tenant shall make a Transfer in violation of the provisions of Section 13 above, or if any event shall occur or any contingency shall arise whereby this Lease, or the term and estate thereby created, would (by operation of law or otherwise) devolve upon or pass to any person, firm or corporation other than Tenant, except as expressly permitted under Section 13 hereof and Tenant does not cure such default within ten (10) days following written notice from Landlord;

 

(h)                                 If Tenant shall fail to timely perform its obligations under Section 3 and such failure continues for fifteen (15) days after notice;

 

(i)                                     The failure by Tenant to observe or perform any of the covenants or provisions of this Lease to be observed or performed by Tenant, other than as specified above, and such failure continues for more than thirty (30) days after notice thereof from Landlord; provided, further, that if the nature of Tenant’s default is such that more than thirty (30) days are reasonably required for its cure, then Tenant shall not be deemed to be in default if Tenant shall commence such cure within said thirty (30) day period and thereafter diligently prosecute such cure to completion, which completion shall occur not later than ninety (90) days from the date of such notice from Landlord;

 

(j)                                    Tenant shall be involved in financial difficulties as evidenced by an admission in writing by Tenant of Tenant’s inability to pay its debts generally as they become due, or by the making or offering to make a composition of its debts with its creditors;

 

(k)                                 Tenant shall make an assignment or trust mortgage, or other conveyance or transfer of like nature, of all or a substantial part of its property for the benefit of its creditors,

 

(l)                                     an attachment on mesne process, on execution or otherwise, or other legal process shall issue against Tenant or its property and a sale of any of its assets shall be held thereunder;

 

(m)                             any judgment, attachment or the like in excess of $100,000 shall be entered, recorded or filed against Tenant in any court, registry, etc.  and Tenant shall fail to pay such judgment within thirty (30) days after the judgment shall have become final beyond appeal or to discharge or secure by surety bond such lien, attachment, etc.  within thirty (30) days of such entry, recording or filing, as the case may be;

 

39

 

(n)                                 the leasehold hereby created shall be taken on execution or by other process of law and shall not be revested in Tenant within thirty (30) days thereafter;

 

(o)                                 a receiver, sequesterer, trustee or similar officer shall be appointed by a court of competent jurisdiction to take charge of all or any part of Tenant’s Property and such appointment shall not be vacated within thirty (30) days; or

 

(p)                                 any proceeding shall be instituted by or against Tenant pursuant to any of the provisions of any Act of Congress or State law relating to bankruptcy, reorganizations, arrangements, compositions or other relief from creditors, and, in the case of any proceeding instituted against it, if Tenant shall fail to have such proceedings dismissed within thirty (30) days or if Tenant is adjudged bankrupt or insolvent as a result of any such proceeding.

 

Tenant shall reimburse Landlord, within thirty (30) days after demand, for up to $1,000.00 of Landlord’s reasonable out-of-pocket costs and expenses (including without limitation legal fees and costs) incurred in connection with the preparation and delivery of each notice of default delivered pursuant to this Section 20.1.

 

20.2                        Remedies.  Upon an Event of Default, Landlord may, by notice to Tenant, elect to terminate this Lease; and thereupon (and without prejudice to any remedies which might otherwise be available for arrears of Rent or preceding breach of covenant or agreement and without prejudice to Tenant’s liability for damages as hereinafter stated), upon the giving of such notice, this Lease shall terminate as of the date specified therein as though that were the Expiration Date.  Upon such termination, Landlord shall have the right to utilize the Security Deposit or draw down the entire Letter of Credit, as applicable, and apply the proceeds thereof to its damages hereunder.  Without being taken or deemed to be guilty of any manner of trespass or conversion, and without being liable to indictment, prosecution or damages therefor, Landlord may, by lawful process, enter into and upon the Premises (or any part thereof in the name of the whole); repossess the same, as of its former estate; and expel Tenant and those claiming under Tenant.  The words “re-entry” and “re-enter” as used in this Lease are not restricted to their technical legal meanings.

 

20.3                        Damages - Termination.

 

(a)                                 Upon the termination of this Lease under the provisions of this Section 20, Tenant shall pay to Landlord Rent up to the time of such termination, shall continue to be liable for any preceding breach of covenant, and in addition, shall pay to Landlord as damages, at the election of Landlord, either:

 

(i)                                     the amount (discounted to present value at the rate of five percent (5%) per annum) by which, at the time of the termination of this Lease (or at any time thereafter if Landlord shall have initially elected damages under Section 20.3(a)(ii) below), (x) the aggregate of Rent projected over the period commencing with such termination and ending on the Expiration Date, exceeds (y) the aggregate projected fair market rental value of the Premises for such period, taking into account a reasonable time period during which the Premises shall be unoccupied, plus all Reletting Costs (hereinafter defined); or (ii) amounts equal to Rent which would have been payable by Tenant had this Lease not been so terminated, payable upon the due dates therefor specified herein following such termination and until the Expiration Date, provided, however, if

 

40

 

Landlord shall re-let the Premises during such period, that Landlord shall credit Tenant with the net rents received by Landlord from such re-letting, such net rents to be determined by first deducting from the gross rents as and when received by Landlord from such re-letting the expenses incurred or paid by Landlord in terminating this Lease, as well as the expenses of re-letting, including altering and preparing the Premises for new tenants, brokers’ commissions, and all other similar and dissimilar expenses properly chargeable against the Premises and the rental therefrom (collectively, “Reletting Costs”), it being understood that any such re-letting may be for a period equal to or shorter or longer than the remaining Term; and provided, further, that (x) in no event shall Tenant be entitled to receive any excess of such net rents over the sums payable by Tenant to Landlord hereunder and (y) in no event shall Tenant be entitled in any suit for the collection of damages pursuant to this Section 20.3(a)(ii) to a credit in respect of any net rents from a re-letting except to the extent that such net rents are actually received by Landlord prior to the commencement of such suit.  If the Premises or any part thereof should be re-let in combination with other space, then proper apportionment on a square foot area basis shall be made of the rent received from such re-letting and of the expenses of re-letting.  Landlord shall use reasonable efforts to mitigate any damages hereunder following any termination of this Lease or any termination of Tenant’s possession of the Premises.  The obligation of Landlord to use reasonable efforts to mitigate damages shall not be construed to require Landlord to rent all or any portion of the Premises for a use which, or to a tenant who, would not qualify pursuant to the assignment provisions of this Lease, or to prioritize the renting of the Premises over other space which Landlord may have available in the Building or in other buildings owned by Landlord or its affiliates.

 

(b)                                 In calculating the amount due under Section 20.3(a)(i), above, there shall be included, in addition to the Base Rent, all other considerations agreed to be paid or performed by Tenant, including without limitation Tenant’s Share of Operating Costs and Tenant’s Tax Share of Taxes, on the assumption that all such amounts and considerations would have increased at the rate of five percent (5%) per annum for the balance of the full term hereby granted.

 

(c)                                  Suit or suits for the recovery of such damages, or any installments thereof, may be brought by Landlord from time to time at its election, and nothing contained herein shall be deemed to require Landlord to postpone suit until the date when the Term would have expired if it had not been terminated hereunder.

 

(d)                                 Nothing herein contained shall be construed as limiting or precluding the recovery by Landlord against Tenant of any sums or damages to which, in addition to the damages particularly provided above, Landlord may lawfully be entitled by reason of any Event of Default hereunder.

 

(e)                                  In lieu of any other damages or indemnity and in lieu of full recovery by Landlord of all sums payable under all the foregoing provisions of this Section 20.3, Landlord may, by written notice to Tenant, at any time after this Lease is terminated under any of the provisions herein contained or is otherwise terminated for breach of any obligation of Tenant and before such full recovery, elect to recover, and Tenant shall thereupon pay, as liquidated damages, an amount equal to the aggregate of (x) an amount equal to the lesser of (1) Rent accrued under this Lease in the twelve (12) months immediately prior to such termination, or (2) Rent payable during the remaining months of the Term if this Lease had not been terminated, plus (y) the amount of

 

41

 

Rent accrued and unpaid at the time of termination, less (z) the amount of any recovery by Landlord under the foregoing provisions of this Section 20.3 up to the time of payment of such liquidated damages.

 

20.4                        Landlord’s Self-Help; Fees and Expenses.  If Tenant shall default in the performance of any covenant on Tenant’s part to be performed in this Lease contained, including without limitation the obligation to maintain the Premises in the required condition pursuant to Section 10.1 above, Landlord may, upon reasonable advance notice, except that no notice shall be required in an emergency, immediately, or at any time thereafter, perform the same for the account of Tenant.  Tenant shall pay to Landlord upon demand therefor any costs incurred by Landlord in connection therewith, together with interest at the Default Rate until paid in full.  In addition, Tenant shall pay all of Landlord’s costs and expenses, including without limitation reasonable attorneys’ fees, incurred (i) in enforcing any obligation of Tenant under this Lease or (ii) as a result of Landlord or any of the Landlord Parties, without its fault, being made party to any litigation pending by or against any of the Tenant Parties.

 

20.5                        Waiver of Redemption, Statutory Notice and Grace Periods.  Tenant does hereby waive and surrender all rights and privileges which it might have under or by reason of any present or future Legal Requirements to redeem the Premises or to have a continuance of this Lease for the Term hereby demised after being dispossessed or ejected therefrom by process of law or under the terms of this Lease or after the termination of this Lease as herein provided.  Except to the extent prohibited by Legal Requirements, any statutory notice and grace periods provided to Tenant by law are hereby expressly waived by Tenant.

 

20.6                        Landlord’s Remedies Not Exclusive.  The specified remedies to which Landlord may resort hereunder are cumulative and are not intended to be exclusive of any remedies or means of redress to which Landlord may at any time be lawfully entitled, and Landlord may invoke any remedy (including the remedy of specific performance) allowed at law or in equity as if specific remedies were not herein provided for.

 

20.7                        No Waiver.  Landlord’s failure to seek redress for violation, or to insist upon the strict performance, of any covenant or condition of this Lease, or any of the Rules and Regulations promulgated hereunder, shall not prevent a subsequent act, which would have originally constituted a violation, from having all the force and effect of an original violation.  The receipt by Landlord of Rent with knowledge of the breach of any covenant of this Lease shall not be deemed a waiver of such breach.  The failure of Landlord to enforce any of such Rules and Regulations against Tenant and/or any other tenant in the Building shall not be deemed a waiver of any such Rules and Regulations.  No provisions of this Lease shall be deemed to have been waived by either party unless such waiver be in writing signed by such party.  No payment by Tenant or receipt by Landlord of a lesser amount than the Rent herein stipulated shall be deemed to be other than on account of the stipulated Rent, nor shall any endorsement or statement on any check or any letter accompanying any check or payment as Rent be deemed an accord and satisfaction, and Landlord may accept such check or payment without prejudice to Landlord’s right to recover the balance of such Rent or pursue any other remedy in this Lease provided.

 

20.8                        Restrictions on Tenant’s Rights.  During the continuation of any Event of Default, (a) Landlord shall not be obligated to provide Tenant with any notice pursuant to Sections

 

42

 

2.3 and 2.4 above; and (b) Tenant shall not have the right to make, nor to request Landlord’s consent or approval with respect to, any Alterations.

 

20.9                        Landlord Default.  Notwithstanding anything to the contrary contained in the Lease, Landlord shall in no event be in default in the performance of any of Landlord’s obligations under this Lease unless Landlord shall have failed to perform such obligations within thirty (30) days (or such additional time as is reasonably required to correct any such default, provided Landlord commences cure within 30 days) after notice by Tenant to Landlord properly specifying wherein Landlord has failed to perform any such obligation.  Except as expressly set forth in this Lease, Tenant shall not have the right to terminate or cancel this Lease or to withhold rent or to set-off or deduct any claim or damages against rent as a result of any default by Landlord or breach by Landlord of its covenants or any warranties or promises hereunder, except in the case of a wrongful eviction of Tenant from the Premises (constructive or actual) by Landlord, and then only if the same continues after notice to Landlord thereof and an opportunity for Landlord to cure the same as set forth above.  In addition, Tenant shall not assert any right to deduct the cost of repairs or any monetary claim against Landlord from rent thereafter due and payable under this Lease.

 

21.                               SURRENDER; ABANDONED PROPERTY; HOLD-OVER.

 

21.1                        Surrender

 

(a)                                 Upon the expiration or earlier termination of the Term, Tenant shall (i) peaceably quit and surrender to Landlord the Premises (including without limitation all lab benches, fume hoods, electric, plumbing, heating and sprinkling systems, fixtures and outlets, vaults, paneling, molding, shelving, radiator enclosures, cork, rubber, linoleum and composition floors, ventilating, silencing, air conditioning and cooling equipment therein) broom clean, in good order, repair and condition excepting only ordinary wear and tear and damage by fire or other insured Casualty or loss by Taking; (ii) remove all of Tenant’s Property, all autoclaves and cage washers and, to the extent specified by Landlord in accordance with Section 11 above, Alterations made by Tenant (provided Tenant shall have no obligation to remove any part of Landlord’s Work); and (iii) repair any damages to the Premises or the Building caused by the installation or removal of Tenant’s Property and/or such Alterations.  Tenant’s obligations under this Section 21.1(a) shall survive the expiration or earlier termination of this Lease.

 

(b)                                 At least thirty (30) days prior to the expiration of the Term (or, if applicable, within five (5) business days after any earlier termination of this Lease), Tenant shall deliver to Landlord a narrative description of the actions proposed (or required by any Legal Requirements) to be taken by Tenant in order to render the Premises (including, without limitation, floors, walls, ceilings, counters, piping, supply lines, waste lines and plumbing in or serving the Premises and all exhaust or other ductwork in or serving the Premises) free of Hazardous Materials other than Third Party Hazardous Materials(6) and otherwise released for unrestricted use and occupancy, including without limitation causing the Premises to be decommissioned in accordance with the regulations of the U.S. Nuclear Regulatory Commission and/or the Massachusetts Department of Public Health (the “MDPH”) for the control of radiation and cause the Premises to be releases for

 

(6)  For purposes hereof, “Third Party Hazardous Materials” means Hazardous Materials, the presence of which Tenant demonstrates to Landlord’s reasonable satisfaction results from the acts or omissions of third parties unrelated to the Tenant Parties.

 

43

 

unrestricted use by the Radiation Control Program of the MDPH (the “Surrender Plan”).  The Surrender Plan (i) shall be accompanied by a current list of (A) all local, state and federal licenses, permits and approvals held by or on behalf of any Tenant Party with respect to Hazardous Materials in, on, under, at or about the Premises, and (B) Tenant’s Hazardous Materials, and (ii) shall be subject to the review and approval of Landlord’s environmental consultant.  In connection with review and approval of the Surrender Plan, upon request of Landlord, Tenant shall deliver to Landlord or its consultant such additional non-proprietary information concerning the use of and operations within the Premises as Landlord shall reasonably request.  On or before the expiration of the Term (or within thirty (30) days after any earlier termination of this Lease during which period Tenant’s use and occupancy of the Premises shall be governed by Section 21.3 below unless such termination is due to a Casualty or Taking), Tenant shall (i) perform or cause to be performed all actions described in the approved Surrender Plan, and (ii) deliver to Landlord a certification from a certified third party industrial hygienist reasonably acceptable to Landlord certifying that the Premises do not contain any Hazardous Materials other than Third Party Hazardous Materials and evidence that the approved Surrender Plan shall have been satisfactorily completed by a contractor acceptable to Landlord (the “Surrender Report”), and Landlord shall have the right, subject to reimbursement at Tenant’s expense as set forth below, to cause Landlord’s environmental consultant to inspect the Premises and perform such additional procedures as may be deemed reasonably necessary to confirm that the Premises are, as of the expiration of the Term (or, if applicable, the date which is thirty (30) days after any earlier termination of this Lease), free of Hazardous Materials other than Third Party Hazardous Materials and otherwise available for unrestricted use and occupancy as aforesaid.  Landlord shall have the unrestricted right to deliver the Surrender Plan, the Surrender Report and any report by Landlord’s environmental consultant with respect to the surrender of the Premises to third parties.  Such third parties and the Landlord Parties shall be entitled to rely on the Surrender Report.  If Tenant shall fail to prepare a Surrender Plan or submit a Surrender Report based on the Surrender Plan approved by Landlord, or if Tenant shall fail to complete the approved Surrender Plan, or if such Surrender Plan, whether or not approved by Landlord, shall fail to adequately address the use of Hazardous Materials by any of the Tenant Parties in, on, at, under or about the Premises, (A) Landlord shall have the right to take any such actions as Landlord may deem reasonable or appropriate to assure that the Premises and the Property are surrendered in the condition required hereunder, the cost of which actions shall be reimbursed by Tenant as Additional Rent upon demand; and (B) if the Term shall have ended, unless and until Landlord elects to take such actions to assure that the Premises are surrendered in the condition required hereunder, Tenant shall be deemed to be a holdover tenant subject to the provisions of Section 21.3 below until the date on which Tenant delivers the Surrender Report (in the form required hereunder) to Landlord.  Tenant’s obligations under this Section 21.1(b) shall survive the expiration or earlier termination of the Term.

 

(c)                                  No act or thing done by Landlord during the Term shall be deemed an acceptance of a surrender of the Premises, and no agreement to accept such surrender shall be valid, unless in writing signed by Landlord.  Unless otherwise agreed by the parties in writing, no employee of Landlord or of Landlord’s agents shall have any power to accept the keys of the Premises prior to the expiration or earlier termination of this Lease.  The delivery of keys to any employee of Landlord or of Landlord’s agents shall not operate as a termination of this Lease or a surrender of the Premises.

 

44

 

(d)                                 Notwithstanding anything to the contrary contained herein, Tenant shall, at its sole cost and expense, remove from the Premises, prior to the end of the Term, any item installed by or for Tenant and which, pursuant to Legal Requirements, must be removed therefrom before the Premises may be used by a subsequent tenant.

 

(e)                                  Tenant hereby assigns to Landlord any warranties in effect on the last day of the Term with respect to any fixtures and Alterations installed in the Premises.  Tenant shall provide Landlord with copies of any such warranties prior to the expiration of the Term (or, if the Lease is earlier terminated, within 5 days thereafter).

 

21.2                        Abandoned Property.  After the expiration or earlier termination hereof, if Tenant fails to remove any property from the Building or the Premises which Tenant is obligated by the terms of this Lease to remove within five (5) business days after written notice from Landlord, such property (the “Abandoned Property”) shall be conclusively deemed to have been abandoned, and may either be retained by Landlord as its property or sold or otherwise disposed of in such manner as Landlord may see fit.  If any item of Abandoned Property shall be sold, Tenant hereby agrees that Landlord may receive and retain the proceeds of such sale and apply the same, at its option, to the expenses of the sale, the cost of moving and storage, any damages to which Landlord may be entitled under Section 20 hereof or pursuant to law, and to any arrears of Rent.

 

21.3                        Holdover.  If any of the Tenant Parties holds over after the end of the Term, Tenant shall be deemed a tenant-at-sufferance subject to the provisions of this Lease; provided that whether or not Landlord has previously accepted payments of Rent from Tenant, (i) Tenant shall pay Base Rent at 150% of the highest rate of Base Rent payable during the Term, (ii) Tenant shall continue to pay to Landlord all additional rent, and (iii) if such holdover continues for more than thirty (30) days, Tenant shall be liable for all damages, including without limitation lost business and consequential damages, incurred by Landlord as a result of such holding over, Tenant hereby acknowledging that Landlord may need the Premises after the end of the Term for other tenants and that the damages which Landlord may suffer as the result of Tenant’s holding over cannot be determined as of the Execution Date.  Nothing contained herein shall grant Tenant the right to holdover after the expiration or earlier termination of the Term.

 

22.                               MORTGAGEE RIGHTS.

 

22.1                        Subordination.  Tenant’s rights and interests under this Lease shall be (i) subject and subordinate to any ground lease (including without limitation the Ground Lease), and to any mortgages, deeds of trust, overleases, or similar instruments covering the Premises, the Building and/or the Land and to all advances, modifications, renewals, replacements, and extensions thereof (each of the foregoing, a “Mortgage”), or (ii) if any Mortgagee elects, prior to the lien of any present or future Mortgage.  Tenant further shall attorn to and recognize any successor landlord, whether through foreclosure or otherwise, as if the successor landlord were the originally named landlord.  The provisions of this Section 22.1 shall be self-operative and no further instrument shall be required to effect such subordination or attornment; however, Tenant agrees to execute, acknowledge and deliver such instruments, confirming such subordination and attornment in such form as shall be requested by any such holder within fifteen (15) days of request therefor.  Landlord shall use commercially reasonable efforts to cause any future Mortgagee to execute a

 

45

 

commercially reasonable so-called subordination, non-disturbance and attornment agreement with respect to this Lease.

 

22.2                        Notices.  Tenant shall give each Mortgagee the same notices given to Landlord concurrently with the notice to Landlord, and each Mortgagee shall have a reasonable opportunity thereafter to cure a Landlord default, and Mortgagee’s curing of any of Landlord’s default shall be treated as performance by Landlord.

 

22.3                        Mortgagee Liability.  Tenant acknowledges and agrees that if any Mortgage shall be foreclosed, (a) the liability of the Mortgagee and its successors and assigns shall exist only so long as such Mortgagee or purchaser is the owner of the Premises, and such liability shall not continue or survive after further transfer of ownership; and (b) such Mortgagee and its successors or assigns shall not be (i) liable for any act or omission of any prior lessor under this Lease, provided, however, that the foregoing shall not release such Mortgagee and/or its successors or assigns from liability for any default of its obligations under the Lease occurring after the date on which such Mortgagee succeeds to Landlord’s interest hereunder, including, without limitation, any maintenance obligations; (ii) liable for the performance of Landlord’s covenants pursuant to the provisions of this Lease which arise and accrue prior to such entity succeeding to the interest of Landlord under this Lease or acquiring such right to possession; (iii) subject to any offsets or defense which Tenant may have at any time against Landlord; (iv) bound by any base rent or other sum which Tenant may have paid previously for more than one (1) month; or (v) liable for the performance of any covenant of Landlord under this Lease which is capable of performance only by the original Landlord.

 

23.                               QUIET ENJOYMENT.  Landlord covenants that so long as there is no Event of Default hereunder, Tenant shall peaceably and quietly hold, occupy and enjoy the Premises during the Term from and against the claims of all persons lawfully claiming by, through or under Landlord subject, nevertheless, to the covenants, agreements, terms, provisions and conditions of this Lease, any matters of record or of which Tenant has knowledge and to any Mortgage to which this Lease is subject and subordinate, as hereinabove set forth.

 

24.                               NOTICES.  Any notice, consent, request, bill, demand or statement hereunder (each, a “Notice”) by either party to the other party shall be in writing and shall be deemed to have been duly given when either delivered by hand or by nationally recognized overnight courier (in either case with evidence of delivery or refusal thereof) addressed as follows:

 

	
 
    	
If to Landlord:
    	
620 Memorial Leasehold LLC
    
	
 
    	
 
    	
c/o MIT Investment Management Company
    
	
 
    	
 
    	
238 Main Street, Suite 200
    
	
 
    	
 
    	
Cambridge, MA 02142
    
	
 
    	
 
    	
Attention: Steven C. Marsh
    
	
 
    	
 
    	
 
    
	
 
    	
With copies to:
    	
Goulston & Storrs
    
	
 
    	
 
    	
400 Atlantic Avenue
    
	
 
    	
 
    	
Boston, MA 02110
    
	
 
    	
 
    	
Attention: Colleen P. Hussey, Esquire
    
	
 
    	
 
    	
 
    
	
 
    	
and
    	
 
    

 

46

 

	
 
    	
 
    	
Colliers International
    
	
 
    	
 
    	
336 Main Street
    
	
 
    	
 
    	
Cambridge, MA 02142
    
	
 
    	
 
    	
Attention: Kristina Descoteaux
    
	
 
    	
 
    	
 
    
	
 
    	
if to Tenant:
    	
Prior to the Term Commencement Date:
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Syros Pharmaceuticals, Inc.
    
	
 
    	
 
    	
480 Arsenal Street, Suite 130
    
	
 
    	
 
    	
Watertown, MA 02472
    
	
 
    	
 
    	
Attention: Lisa Roberts
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
From and after the Term Commencement Date:
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
Syros Pharmaceuticals, Inc.
    
	
 
    	
 
    	
620 Memorial Drive
    
	
 
    	
 
    	
Cambridge, MA 02139
    
	
 
    	
 
    	
Attention: Lisa Roberts
    
	
 
    	
 
    	
 
    
	
 
    	
With copies to:
    	
 
    
	
 
    	
 
    	
 
    
	
 
    	
 
    	
WilmerHale LLP
    
	
 
    	
 
    	
60 State Street
    
	
 
    	
 
    	
Boston, MA 02109
    
	
 
    	
 
    	
Attention: Paul Jakubowski, Esquire
    

 

Notwithstanding the foregoing, any notice from Landlord to Tenant regarding ordinary business operations (e.g., exercise of a right of access to the Premises, maintenance activities, invoices, etc.) may also be given by written notice delivered by facsimile to any person at the Premises whom Landlord reasonably believes is authorized to receive such notice on behalf of Tenant without copies as specified above, provided that no such notice shall be relied upon for purposes of determining the running of any periods with respect to any Event of Default hereunder.  Either party may at any time change the address or specify an additional address for such Notices by delivering or mailing, as aforesaid, to the other party a notice stating the change and setting forth the changed or additional address, provided such changed or additional address is within the United States.  Notices shall be effective upon the date of receipt or refusal thereof.

 

25.                               MISCELLANEOUS.

 

25.1                        Separability.  If any provision of this Lease or portion of such provision or the application thereof to any person or circumstance is for any reason held invalid or unenforceable, the remainder of this Lease (or the remainder of such provision) and the application thereof to other persons or circumstances shall not be affected thereby.

 

25.2                        Captions.  The captions are inserted only as a matter of convenience and for reference, and in no way define, limit or describe the scope of this Lease nor the intent of any provisions thereof.

 

47

 

25.3                        Broker.  Tenant and Landlord each warrants and represents that it has dealt with no broker in connection with the consummation of this Lease other than Cushman & Wakefield (“Broker”).  Tenant and Landlord each agrees to defend, indemnify and save the other harmless from and against any Claims arising in breach of the representation and warranty set forth in the immediately preceding sentence.  Landlord shall be solely responsible for the payment of any brokerage commissions to Broker.

 

25.4                        Entire Agreement.  This Lease, Lease Summary Sheet and Exhibits 1-8 attached hereto and incorporated herein contain the entire and only agreement between the parties and any and all statements and representations, written and oral, including previous correspondence and agreements between the parties hereto, are merged herein.  Tenant acknowledges that all representations and statements upon which it relied in executing this Lease are contained herein and that Tenant in no way relied upon any other statements or representations, written or oral.  This Lease may not be modified orally or in any manner other than by written agreement signed by the parties hereto.

 

25.5                        Governing Law.  This Lease is made pursuant to, and shall be governed by, and construed in accordance with, the laws of the Commonwealth of Massachusetts and any applicable local municipal rules, regulations, by-laws, ordinances and the like.

 

25.6                        Representation of Authority.  By his or her execution hereof, each of the signatories on behalf of the respective parties hereby warrants and represents to the other that he or she is duly authorized to execute this Lease on behalf of such party.  Upon Landlord’s request, Tenant shall provide Landlord with evidence that any requisite resolution, corporate authority and any other necessary consents have been duly adopted and obtained.

 

25.7                        Expenses Incurred by Landlord Upon Tenant Requests.  Tenant shall, upon demand, reimburse Landlord for all reasonable expenses, including, without limitation, legal fees, incurred by Landlord in connection with all requests by Tenant for consents, approvals or execution of collateral documentation related to this Lease, including, without limitation, costs incurred by Landlord in the review and approval of Tenant’s plans and specifications in connection with proposed Alterations to be made by Tenant to the Premises or in connection with requests by Tenant for Landlord’s consent to make a Transfer.  Such costs shall be deemed to be additional rent under this Lease.

 

25.8                        Survival.  Without limiting any other obligation of Tenant which may survive the expiration or prior termination of the Term, all obligations on the part of Tenant to indemnify, defend, or hold Landlord harmless, as set forth in this Lease shall survive the expiration or prior termination of the Term.

 

25.9                        Limitation of Liability.  Tenant shall neither assert nor seek to enforce any claim against Landlord or any of the Landlord Parties, or the assets of any of the Landlord Parties, for breach of this Lease or otherwise, other than against Landlord’s interest in the Building and in the uncollected rents, issues and profits thereof, and Tenant agrees to look solely to such interest for the satisfaction of any liability of Landlord under this Lease.  This Section 25.9 shall not limit any right that Tenant might otherwise have to obtain injunctive relief against Landlord.  Landlord and Tenant specifically agree that in no event shall any officer, director, trustee, employee or

 

48

 

representative of Landlord or any of the other Landlord Parties ever be personally liable for any obligation under this Lease, nor shall Landlord or any of the other Landlord Parties be liable for consequential or incidental damages or for lost profits whatsoever in connection with this Lease, nor shall Tenant or any other Tenant Party or any officer, director, shareholder, trustee, employee, agent or representative of any of them be liable for consequential or incidental damages or for lost profits whatsoever in connection with this Lease except with respect to the potential liability of Tenant under Sections 17 or 21.3 hereof.

 

25.10                 Binding Effect.  The covenants, agreements, terms, provisions and conditions of this Lease shall bind and benefit the successors and assigns of the parties hereto with the same effect as if mentioned in each instance where a party hereto is named or referred to, except that no violation of the provisions of Section 13 hereof shall operate to vest any rights in any successor or assignee of Tenant.

 

25.11                 Landlord Obligations upon Transfer.  Upon any sale, transfer or other disposition of the Building, Landlord shall be entirely freed and relieved from the performance and observance thereafter of all covenants and obligations hereunder on the part of Landlord to be performed and observed, it being understood and agreed in such event (and it shall be deemed and construed as a covenant running with the land) that the person succeeding to Landlord’s ownership of said reversionary interest shall thereupon and thereafter assume, and perform and observe, any and all of such covenants and obligations of Landlord, except as otherwise agreed in writing.

 

25.12                 No Grant of Interest.  Tenant shall not grant any security interest whatsoever in (a) any fixtures within the Premises or (b) any item paid in whole or in part by Landlord without the consent of Landlord.

 

25.13                 No Air Rights.  No rights to any view or to light or air over any property, whether belonging to Landlord or any other person, are granted to Tenant by this Lease.  If at any time any windows of the Premises are temporarily darkened or the light therefrom is obstructed by reason of any repairs, improvements, maintenance or cleaning in or about the Property, the same shall be without liability to Landlord and without any reduction or diminution of Tenant’s obligations under this Lease.

 

25.14                 Financial Information.  Tenant shall deliver to Landlord, within thirty (30) days after Landlord’s reasonable request, Tenant’s most recently completed balance sheet and related statements of income, shareholder’s equity and cash flows statements (audited if available) certified by an officer of Tenant as being true and correct in all material respects.  Any such financial information may be relied upon by Landlord and any actual or potential lessor, purchaser, or mortgagee of the Property or any portion thereof.

 

25.15                 Confidentiality.

 

(a)                                 Each party hereby covenants and agrees (1) to keep the contents of the Lease confidential; and (2) not to disclose or reveal the contents of the Lease to any person other than its Engaged Persons (hereinafter defined).  In the event that either party is requested pursuant to, or required by, applicable law or regulation or by legal process to disclose all or any portion of

 

49

 

the Lease, such party agrees that it will provide the other party with reasonable notice of such request or requirement in order to enable the other party to seek an appropriate protective order or other remedy, to resist or narrow the scope of such request or legal process, or to waive compliance, in whole or in part, with the terms of this Confidentiality Agreement.  The other party shall respond in such a time and manner that does not put the disclosing party or any of its Engaged Persons at risk of violation of such law or regulation or legal process.

 

(b)                                 In connection with the Lease, Landlord has delivered and/or will deliver to Tenant from time to time certain information about the Property, which may include, without limitation, master leases, environmental reports and other title, zoning, geotechnical, permitting, environmental and operational materials relating to the Property (such information whether furnished before or after the date hereof, whether oral or written, and regardless of the manner in which it is furnished, is collectively hereinafter referred to as the “Landlord’s Proprietary Information”).  Landlord’s Proprietary Information does not include, however, information which (1) is or becomes generally available to the public other than as a result of a disclosure in violation of this Section 25.15 by Tenant or Tenant’s Engaged Persons, as defined below; (2) was available to Tenant on a non-confidential basis prior to its disclosure by Landlord; or (3) becomes available to Tenant on a non-confidential basis from a person other than Landlord who is not to the knowledge of Tenant or Tenant’s Engaged Persons otherwise bound by a confidentiality agreement with Landlord, or is otherwise not under an obligation to Landlord not to transmit the information to Tenant.

 

(i)                                     Tenant hereby covenants and agrees (A) to keep all Landlord’s Proprietary Information confidential; (B) not to disclose or reveal any Landlord’s Proprietary Information to any person other than those persons, including without limitation its and its affiliates’ employees, agents and representatives, whose duties and responsibilities reasonably require that Landlord’s Proprietary Information be disclosed to them in connection with the Lease (such persons are hereinafter referred to as “Tenant’s Engaged Persons”); (C) to cause Tenant’s Engaged Persons to observe the terms of this Section 25.15; and (D) not to use any Landlord’s Proprietary Information for any purpose other than in connection with the Lease.

 

(ii)                                  In the event that Tenant is requested pursuant to, or required by, applicable law or regulation or by legal process to disclose any Landlord’s Proprietary Information or any other information concerning the Property, Tenant agrees that it will provide Landlord with reasonable notice of such request or requirement in order to enable Landlord to seek an appropriate protective order or other remedy, to resist or narrow the scope of such request or legal process, or to waive compliance, in whole or in part, with the terms of this Section 25.15.  In any such event Landlord shall respond in such a time and manner that does not put Tenant or any of its Engaged Persons at risk of violation of such law or regulation or legal process.

 

(iii)                               Without prejudice to the rights and remedies otherwise available at law or in equity, Tenant agrees that Landlord shall be entitled to seek equitable relief by way of injunction or otherwise if Tenant or any of Tenant’s Engaged Persons breach or threaten to breach any of the provisions of this Section 25.15.

 

(c)                                  In connection with the Lease, from time to time Tenant has delivered and/or will deliver to Landlord certain information about Tenant and/or its affiliates, including but not

 

50

 

limited to financial information and other information related to the business and properties of Tenant and/or its affiliates (such information whether furnished before or after the Effective Date hereof, whether oral or written, and regardless of the manner in which it is furnished, is collectively hereinafter referred to as “Tenant’s Proprietary Information”).  Tenant’s Proprietary Information does not include, however, information which (1) is or becomes generally available to the public other than as a result of a disclosure in violation of this Section 25.15 by Landlord or Landlord’s Engaged Persons, as defined below; (2) was available to Landlord on a non-confidential basis prior to its disclosure by Tenant; or (3) becomes available to Landlord on a non-confidential basis from a person other than Tenant who is not to the knowledge of Landlord or Landlord’s Engaged Persons otherwise bound by a confidentiality agreement with Tenant, or is otherwise not under an obligation to Tenant not to transmit the information to Landlord.

 

(i)                                     Landlord hereby covenants and agrees (A) to keep all Tenant’s Proprietary Information confidential; (B) not to disclose or reveal any Tenant’s Proprietary Information to any person other than those persons, including without limitation its and its affiliates’ employees, agents and representatives, whose duties and responsibilities reasonably require that Tenant’s Proprietary Information be disclosed to them in connection with the Lease and/or Landlord’s interest in the Property (such persons are hereinafter referred to as “Landlord’s Engaged Persons”); (C) to cause Landlord’s Engaged Persons to observe the terms of this Section 25.15; and (D) not to use any Tenant’s Proprietary Information for any purpose other than in connection with the Lease and/or Landlord’s interest in the Property.

 

(ii)                                  In the event that Landlord is requested pursuant to, or required by, applicable law or regulation or by legal process to disclose any Tenant’s Proprietary Information, Landlord agrees that it will provide Tenant with reasonable notice of such request or requirement in order to enable Tenant to seek an appropriate protective order or other remedy, to resist or narrow the scope of such request or legal process, or to waive compliance, in whole or in part, with the terms of this Section 25.15.  In any such event Tenant shall respond in such a time and manner that does not put Landlord or any of its Engaged Persons at risk of violation of such law or regulation or legal process.

 

(iii)                               Without prejudice to the rights and remedies otherwise available at law or in equity, Landlord agrees that Tenant shall be entitled to seek equitable relief by way of injunction or otherwise if Landlord or any of Landlord’s Engaged Persons breach or threaten to breach any of the provisions of this Section 25.15.

 

(d)                                 Tenant will be responsible for any breach of the terms of this Section 25.15 by it and/or Tenant’s Engaged Persons.  Landlord will be responsible for any breach of the terms of this Section 25.15 by it and/or Landlord’s Engaged Persons.

 

(e)                                  The provisions of this Section 25.15 shall survive the expiration or earlier termination of the Lease for two (2) years.

 

[SIGNATURES ON FOLLOWING PAGE]

 

51

 

IN WITNESS WHEREOF the parties hereto have executed this Lease as a sealed instrument as of the Execution Date.

 

 

	
LANDLORD
    	
 
    
	
 
    	
 
    
	
620   MEMORIAL LEASEHOLD LLC
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/   Seth Alexander
    	
 
    
	
Name:   Seth Alexander
    	
 
    
	
Title:   President
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
TENANT
    	
 
    
	
 
    	
 
    
	
SYROS   PHARMACEUTICALS, INC.
    	
 
    
	
 
    	
 
    
	
 
    	
 
    
	
By:
    	
/s/   Nancy Simonian
    	
 
    
	
Name:   Nancy
    	
 
    
	
Title:   CEO
    	
 
    

 

52

 

EXHIBIT 1

 

LEASE PLAN

 

1

 

 

2

 

EXHIBIT 2

 

LEGAL DESCRIPTION

 

Parcel 1:

 

The land with the buildings thereon in Cambridge, Middlesex County, Massachusetts situated on the northerly side of Memorial Drive and the westerly side of Vassar Street, now known as and numbered 620 Memorial Drive, and shown as the parcel marked “AREA = 44,677 +1- SF” on a plan entitled “Plan of Land in Cambridge, MA Middlesex County”, prepared by Beals and Thomas, Inc., dated January 28, 1994 recorded with the Middlesex South Deeds on February 17, 1994 as Plan No.  134 of 1994 and bounded and described according to said plan as follows:

 

	
SOUTHERLY
    	
 
    	
by Memorial Drive by two curved lines, measuring   respectively, 4.62 feet and 196.73 feet;
    
	
 
    	
 
    	
 
    
	
WESTERLY
    	
 
    	
by land now or formerly of Massachusetts Institute   of Technology LC No.  2495C, 143.97 feet;
    
	
 
    	
 
    	
 
    
	
NORTHWESTERLY and NORTHERLY
    	
 
    	
by the southeasterly and southerly lines of a strip   of land marked “Railroad Way” on said plan, four lines, the third of which is   a curved line, measuring respectively 30.28 feet, 66.70 feet, 105.51 feet and   70.51 feet;
    
	
 
    	
 
    	
 
    
	
SOUTHEASTERLY and EASTERLY
    	
 
    	
by Vassar Street and by two lines, the first of   which is a curved line, measuring respectively, 84.20 feet and 148.20 feet;   and
    
	
 
    	
 
    	
 
    
	
SOUTHEASTERLY
    	
 
    	
by the intersection of Vassar Street and Memorial   Drive by a curved line, 23.50 feet.
    

 

 

Together with the benefit of and subject to the terms of, a Grant of Easement from the City of Cambridge to Charles River Building Limited Partnership dated January 9, 1997, and recorded on January 17, 1997, as Instrument No.  268 in Book 26997, Page 351.

 

Parcel 2:

 

A parcel of land on Memorial Drive, formerly Charles River Parkway, in Cambridge, Middlesex County, Massachusetts, shown as Lot 3 on a plan entitled “Subdivision Plan of Land in Cambridge” by W.T. Fairclough, dated June 23, 1953, filed for registration with the Middlesex County South Registry District of the Land Court as Plan No., 2495C with Certificate of Title No.  78992, bounded and described as follows:

 

	
NORTHWESTERLY
    	
 
    	
by Lot 2 on said plan, 183,78 feet;
    
	
 
    	
 
    	
 
    
	
EASTERLY:
    	
 
    	
by land formerly of Benjamin F. Brown et al, 143.97   feet; and
    
	
 
    	
 
    	
 
    
	
SOUTHERLY:
    	
 
    	
by Memorial Drive (Charles River Road as shown on   said plan) 139.13 feet.
    

 

1

 

EXHIBIT 3

 

LANDLORD’S WORK

 

1

 

 

2

 

EXHIBIT 4

 

FORM OF LETTER OF CREDIT

 

	
BENEFICIARY:
    	
 
    	
ISSUANCE DATE:
    
	
 
    	
 
    	
 
    
	
[LANDLORD]
    	
 
    	
IRREVOCABLE STANDBY LETTER OF CREDIT NO.
    
	
 
    	
 
    	
 
    
	
ACCOUNTEE/APPLICANT:
    	
 
    	
MAXIMUM/AGGREGATE CREDIT AMOUNT:
   USD: $       .   
    
	
 
    	
 
    	
 
    
	
<
   [TENANT]
    	
 
    	
 
    

 

LADIES AND GENTLEMEN:

 

We hereby establish our irrevocable letter of credit in your favor for account of the applicant up to an aggregate amount not to exceed                and    /100 US Dollars ($      .   ) available by your draft(s) drawn on ourselves at sight (i) bearing the clause “Drawn under Irrevocable Standby Letter of Credit Number           ,” and (ii) including a Beneficiary’s dated statement purportedly signed by an authorized signatory or agent reading:  “This draw in the amount of                     U.S. Dollars ($           ) under your Irrevocable Standby Letter of Credit No.                         represents funds due and owing to us pursuant to the terms of that certain lease by and between               , a               , as landlord, and             , as tenant (the “Lease”), and/or any amendment to the Lease or any other agreement between such parties related to the Lease,” and (iii) indicating whether payment should be made by wire transfer (including wiring instructions) or by certified check (including mailing address), accompanied by the original of this Letter of Credit and all amendments, if any.  The original Letter of Credit and all amendments, if any, shall be returned to you unless fully utilized.

 

Unless otherwise stated, all correspondence, documents and sight drafts are to be sent via facsimile to (   )   -     with originals to follow by hand delivery with receipted delivery, nationally recognized overnight courier with receipted delivery or certified mail, return receipt requested to our counters at                <address>.  The date of presentment of any draw shall be the date copies of the Letter of Credit and sight draft are faxed by Beneficiary to     <bank>.

 

You shall have the right to make partial draws against this Letter of Credit, from time to time.

 

1

 

You shall be entitled to assign your interest in this Irrevocable Standby Letter of Credit from time to time to your lender(s) and/or your successors in interest without our approval and without charge.  In the event of an assignment, we reserve the right to require reasonable evidence of such assignment as a condition to any draw hereunder.

 

Except as otherwise expressly stated herein, this Letter of Credit is subject to the “International Standby Practices 1998” promulgated jointly by the Institute for International Banking Law and Practice and the International Chamber of Commerce, effective January 1, 1999.

 

This Letter of Credit shall expire at our office on                 , 20   (the “Stated Expiration Date”).  It is a condition of this Letter of Credit that the Stated Expiration Date shall be deemed automatically extended without amendment for successive one (1) year periods from such Stated Expiration Date, unless at least sixty (60) days prior to such Stated Expiration Date (or any anniversary thereof) we shall send a written notice to you, with a copy to Goulston & Storrs, 400 Atlantic Avenue, Boston, MA 02110, Attention:  Colleen P.  Hussey and to the Accountee/Applicant, by hand delivery, nationally recognized overnight courier with receipted delivery or by certified mail (return receipt requested) that we elect not to consider this Letter of Credit extended for any such additional one (1) year period.  In the event that this Letter of Credit is not extended for an additional period as provided above, you may draw the entire amount available hereunder.

 

If at any time prior to presentation of documents for payment hereunder, we receive a notarized certificate signed by one who purports to be a duly authorized representative on your behalf to execute and deliver such certificate, stating that this Letter of Credit has been lost, stolen, damaged or destroyed, we will mail you a “Certified True Copy” of this Letter of Credit, which shall be treated by us as an original.

 

In order to cancel this Letter of Credit prior to expiration, you must return this original Letter of Credit and any amendments hereto to our counters with a statement signed by you stating that the Letter of Credit is no longer required and is being returned to the issuing bank for cancellation.  In addition, this Letter of Credit may be canceled prior to expiration upon our receipt of a dated statement purportedly signed by (i) an authorized signatory or agent of the Accountee/Applicant and (ii) an authorized signatory or agent of the beneficiary.

 

We hereby agree with the drawers, endorsers and bonafide holders that the drafts drawn under and in accordance with the terms and condition of this Letter of Credit shall be duly honored within two (2) business days after the date of presentment.

 

2

 

EXHIBIT 5

 

ALTERATIONS CHECKLIST

 

Scope letter describing project, design/construction team, and appropriate vendors.  Insurance certificate(s) for Contractors.
 Construction Documents (CDs) - Plans and Specifications - stamped by licensed AIA.  Code Review by licensed code engineer incorporated in CDs and/or by stamped letter.

 

Code specific - accessibility.
 Code specific - egress paths/exits (numbers, locations, distance).
 Code specific - fire protection, sprinkler distribution, horns/strobes/signage locations.

 

Landlord Approved architect, MEPFP engineer, code engineer, structural engineer.
 Building permit application.

 

Signatures by Architect, Licensed Construction Supervisor.

 

Cost Affidavit with backup estimate from contractor.
 Architect Affidavit.
 MEP Affidavit.
 FP Affidavit.
  Structural Affidavit.
 Construction Cost Affidavit.
 Structural Affidavit.
 Structural Affidavit.

 

Low Voltage Wiring Within Premises:
  Insurance certificate(s) for Contractor, if applicable
 If installer is employee, copy of valid government issued electrical license
 Code Review by licensed code engineer
 permit application as requested by Inspectional Services Department.

Signature by Licensed Professional (electrician)

 

Ethernet wiring within Premises:

Insurance certificate(s) for Contractor, if applicable

If installer is employee, copy of valid government issued electrical license (to the extent legally required)

Code Review by licensed code engineer
 permit application as requested by Inspectional Services Department.
 Signature by Licensed Professional (electrician) to the extent legally required

 

1

 

EXHIBIT 6

 

TENANT’S HAZARDOUS MATERIALS

 

1

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
A
    	
 
    	
4-
    	
 
    	
Amino-2,2,6,6-tetramethylpiperidine
    	
 
    	
Sigma Aldrich
    	
 
    	
36768-62-4
    	
 
    	
Combustible, corrosive
    	
 
    	
167
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
1
    	
 
    	
 
    	
 
    	
10058-F4
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
skin sensitiser, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
mg
    
	
1
    	
 
    	
 
    	
 
    	
10074-g5
    	
 
    	
Sigma Aldrich
    	
 
    	
413611-93-5
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
mg
    
	
A
    	
 
    	
bis-
    	
 
    	
AAF-R110 substrate
    	
 
    	
Promega
    	
 
    	
—
    	
 
    	
Combustible, irritant
    	
 
    	
131
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
ul
    
	
A
    	
 
    	
 
    	
 
    	
AccuTaq LA DNA Polymerase
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Combustible
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
units
    
	
A
    	
 
    	
 
    	
 
    	
Acetazolamide
    	
 
    	
Sigma Aldrich
    	
 
    	
59-66-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Acetic Acid
    	
 
    	
Sigma Aldrich
    	
 
    	
64-19-7
    	
 
    	
 
    	
 
    	
104
    	
 
    	
II
    	
 
    	
 
    	
 
    	
2.5
    	
 
    	
L
    
	
A
    	
 
    	
 
    	
 
    	
Acetone
    	
 
    	
Sigma Aldrich
    	
 
    	
67-64-1
    	
 
    	
 
    	
 
    	
1.4
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
A
    	
 
    	
 
    	
 
    	
Acetonitrile
    	
 
    	
Sigma Aldrich
    	
 
    	
75-05-8
    	
 
    	
 
    	
 
    	
35.6
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
A
    	
 
    	
 
    	
 
    	
Acetophenone
    	
 
    	
Sigma Aldrich
    	
 
    	
98-86-2
    	
 
    	
Combustible, irritant
    	
 
    	
169
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
ml
    
	
A
    	
 
    	
4-
    	
 
    	
Acetylphenylboronic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
149104-90-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Acriflavine
    	
 
    	
Sigma Aldrich
    	
 
    	
8048-52-0
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Acryloyl Chloride, 97.0%,
    	
 
    	
Sigma Aldrich
    	
 
    	
814-68-6
    	
 
    	
 
    	
 
    	
57
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Actinomycin D
    	
 
    	
Sigma Aldrich
    	
 
    	
50-76-0
    	
 
    	
Toxic by ingestion
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
mg
    
	
A
    	
 
    	
 
    	
 
    	
Adenosine 5’-triphosphate disoium salt hydrate
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
Toxic, carcinogen
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Albumin Standard
    	
 
    	
Thermo Fisher
    	
 
    	
—
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2
    	
 
    	
ml
    
	
A
    	
 
    	
 
    	
 
    	
Allyl acetate
    	
 
    	
Sigma Aldrich
    	
 
    	
591-87-7
    	
 
    	
Flammable, toxic, irritant
    	
 
    	
52
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
A
    	
 
    	
 
    	
 
    	
Aluminum Chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
7446-70-0
    	
 
    	
Teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
A
    	
 
    	
a-
    	
 
    	
Amantin
    	
 
    	
Sigma Aldrich
    	
 
    	
23109-05-9
    	
 
    	
Highly toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
mg
    
	
A
    	
 
    	
7-
    	
 
    	
Amino-3,4-dihydro-1H-isoquinoline-2-carboxylic acid   tert-butyl ester
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
Toxic
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
mg
    
	
A
    	
 
    	
4-
    	
 
    	
Amino-1-Boc-piperidine
    	
 
    	
Sigma Aldrich
    	
 
    	
87120-72-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
A
    	
 
    	
5-
    	
 
    	
Amino-2- Methoxybenzoic acid, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
3403-47-2
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
A
    	
 
    	
5-
    	
 
    	
Amino-2- Methylbenzoic acid, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
2840-04-2
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
A
    	
 
    	
6-
    	
 
    	
Amino2-azaspiro[3.3]heptane-2-carboxylic acid tert-   butyl ester
    	
 
    	
Synthonix
    	
 
    	
1211586-09-2
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
A
    	
 
    	
2-
    	
 
    	
Amino-3,5,6-Trimethyl-4 3H)-pyrimidinone
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
Harmful
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
A
    	
 
    	
2-
    	
 
    	
Amino-4-bromobenzoic acid
    	
 
    	
Sigma
    	
 
    	
20776-50-5
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    

 

2

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A
    	
 
    	
2-
    	
 
    	
Amino-7-azaspiro[3.5]nonane-7-carboxylic acid   tert-butyl ester
    	
 
    	
Synthonix
    	
 
    	
1239319-82-4
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
A
    	
 
    	
4-
    	
 
    	
Aminobenzaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
556-18-3
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
mg
    
	
A
    	
 
    	
3-
    	
 
    	
Aminobenzoic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
99-05-8
    	
 
    	
 
    	
 
    	
302
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
A
    	
 
    	
4-
    	
 
    	
Aminobenzoic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
150-13-0
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
A
    	
 
    	
4-
    	
 
    	
aminocyclohexanone
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
A
    	
 
    	
4-(2-
    	
 
    	
Aminoethyl)benzoic acid hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
60531-36-4
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
A
    	
 
    	
1 - (2-
    	
 
    	
Aminoethyl)-Pyrolidine
    	
 
    	
Sigma Aldrich
    	
 
    	
7154-73-6
    	
 
    	
Combustible
    	
 
    	
117
    	
 
    	
II
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
A
    	
 
    	
5-
    	
 
    	
Aminoisatoic Anhydride
    	
 
    	
Sigma Aldrich
    	
 
    	
169037-24-5
    	
 
    	
Sensitizer
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
A
    	
 
    	
Trans-4-
    	
 
    	
Aminomethyl) Cyclohexanecarboxylic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
1197-18-8
    	
 
    	
Irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
A
    	
 
    	
2-
    	
 
    	
Aminomethyl)benzoic acid hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
10017-39-7
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
possible sensitizer
    	
 
    	
250
    	
 
    	
mg
    
	
A
    	
 
    	
4-
    	
 
    	
Aminomethyl)Benzoic Acid, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
56-91-7
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
A
    	
 
    	
4-
    	
 
    	
Aminopyridine
    	
 
    	
Sigma Aldrich
    	
 
    	
504-24-5
    	
 
    	
Toxic, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
A
    	
 
    	
3-
    	
 
    	
Aminorhodanine
    	
 
    	
Sigma Aldrich
    	
 
    	
1438-16-0
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
A
    	
 
    	
N-(-
    	
 
    	
Aminospiro[3.3]hept-6-yl)carbamic acid butyl-ester
    	
 
    	
Synthonix
    	
 
    	
1239589-52-6
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A
    	
 
    	
 
    	
 
    	
Ammonia solution
    	
 
    	
Sigma Aldrich
    	
 
    	
7664-41-7
    	
 
    	
Flammable, toxic, corrosive
    	
 
    	
43
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
A
    	
 
    	
 
    	
 
    	
Ammonium bicarbonate
    	
 
    	
Sigma Aldrich
    	
 
    	
1066-33-7
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Ammonium carbonate
    	
 
    	
Sigma Aldrich
    	
 
    	
506-87-6
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Ammonium chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
12125-02-9
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
kg
    
	
A
    	
 
    	
 
    	
 
    	
Ammonium chloride
    	
 
    	
Fisher
    	
 
    	
12125-02-9
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Ammonium hydroxide
    	
 
    	
Fisher
    	
 
    	
7664-41-7
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2.5
    	
 
    	
ml
    
	
A
    	
 
    	
 
    	
 
    	
Ammonium molybdate
    	
 
    	
Sigma Aldrich
    	
 
    	
13106-76-8
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Ammonium phosphomolybdate hydrate
    	
 
    	
 
    	
 
    	
54723-94-3
    	
 
    	
GHS - Skin irritation, eye irritation, specific   target organ toxicity
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A
    	
 
    	
 
    	
 
    	
Ampicillin sodium salt
    	
 
    	
Sigma Aldrich
    	
 
    	
69-52-3
    	
 
    	
Skin and respiratory sensitizer
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Aniline
    	
 
    	
Sigma Aldrich
    	
 
    	
62-53-3
    	
 
    	
Combustible, toxic, skin sensitizer, carcinogen,   mutagen
    	
 
    	
158
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
5
    	
 
    	
Ml
    
	
A
    	
 
    	
 
    	
 
    	
Anthranilamide
    	
 
    	
Sigma Aldrich
    	
 
    	
88-68-6
    	
 
    	
Skin sensitizer, irritant
    	
 
    	
388
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
A
    	
 
    	
 
    	
 
    	
Anthranilic acid
    	
 
    	
Sigma
    	
 
    	
118-92-3
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    

 

3

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A
    	
 
    	
 
    	
 
    	
Anti-AXL, antibody produced in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
56-81-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
A
    	
 
    	
 
    	
 
    	
Antibodies in Phosphate
    	
 
    	
Thermo Fisher
    	
 
    	
—
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
A
    	
 
    	
 
    	
 
    	
Anti-CREB3L2, antibody produced in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
56-81-5
    	
 
    	
Irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A
    	
 
    	
 
    	
 
    	
Anti-EXT1, antibody produced in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Skin irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
A
    	
 
    	
 
    	
 
    	
Anti-HGF (ab2) antibody produced in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
Skin irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A
    	
 
    	
 
    	
 
    	
Anti-MAX, antibody produced in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
A
    	
 
    	
 
    	
 
    	
Anti-NTN4, anitbody produce in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
56-81-5
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
A
    	
 
    	
 
    	
 
    	
Anti-PRKAG2, antibody produced in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
56-81-5
    	
 
    	
Irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A
    	
 
    	
 
    	
 
    	
Anti-PTAFR antibody produced in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
56-81-5
    	
 
    	
Irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A
    	
 
    	
 
    	
 
    	
Anti-SDC1, antibody produced in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
56-81-5
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
A
    	
 
    	
 
    	
 
    	
Anti-TMEM27, antibody produced in rabbit
    	
 
    	
Sigma Aldrich
    	
 
    	
56-81-5
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
A
    	
 
    	
 
    	
 
    	
ApoTox-Glow Triplex Assay, 10ml
    	
 
    	
Promega
    	
 
    	
Kit
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
ml
    
	
A
    	
 
    	
L(+)-
    	
 
    	
Arabinose
    	
 
    	
Acros Organics
    	
 
    	
87-72-9
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
A
    	
 
    	
 
    	
 
    	
ATX Ponceau S red staining solution
    	
 
    	
Sigma Aldrich
    	
 
    	
5965-83-3
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
L
    
	
A
    	
 
    	
5-
    	
 
    	
Aza - 2’ -deoxycyt idine
    	
 
    	
Sigma Aldrich
    	
 
    	
2353-33-5
    	
 
    	
Irritant, teratogen, mutagen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
mg
    
	
B
    	
 
    	
 
    	
 
    	
BCA Protein Assay Kit
    	
 
    	
Thermo Fisher
    	
 
    	
Kit
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
KU
    
	
B
    	
 
    	
 
    	
 
    	
Benzonase Nuclease
    	
 
    	
Sigma Aldrich
    	
 
    	
9025-65-4
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
KU
    
	
B
    	
 
    	
 
    	
 
    	
Benzyl bromide, reagent grade 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
100-39-0
    	
 
    	
Combustible
    	
 
    	
187
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
B
    	
 
    	
 
    	
 
    	
Benzyl Isocyanide, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
10340-91-7
    	
 
    	
Combustible
    	
 
    	
174
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
B
    	
 
    	
 
    	
 
    	
Benzylamine
    	
 
    	
Sigma Aldrich
    	
 
    	
100-46-9
    	
 
    	
Combustible, harmful, corrosive
    	
 
    	
149
    	
 
    	
II
    	
 
    	
lachrymator
    	
 
    	
100
    	
 
    	
g
    
	
B
    	
 
    	
 
    	
 
    	
Benzylhydrazine dihydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
20570-96-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
B
    	
 
    	
N-
    	
 
    	
Biotinyl-3,6,9- Trioxaundecane-1,11-diamine   trifluoroacetate salt solution
    	
 
    	
Sigma Aldrich
    	
 
    	
945462-84-0
    	
 
    	
Combustible
    	
 
    	
189
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
B
    	
 
    	
 
    	
 
    	
BIS (((Trifluoromethyl)Sulfinyl)Oxy) Zinc
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
B
    	
 
    	
[1,1’-
    	
 
    	
Bis(diphenylphosphino)ferrocene)dichloro palladium   (II)
    	
 
    	
Sigma Aldrich
    	
 
    	
95464-05-4
    	
 
    	
Carcinogen
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
B
    	
 
    	
 
    	
 
    	
Blotting grade blocker
    	
 
    	
Bio-Rad
    	
 
    	
9000-71-9
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
B
    	
 
    	
1-
    	
 
    	
boc-3-(amino)azetidine
    	
 
    	
Sigma
    	
 
    	
—
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    

 

4

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
B
    	
 
    	
1-
    	
 
    	
Boc-3-(aminomethyl)piperdine
    	
 
    	
Sigma Aldrich
    	
 
    	
162167-97-7
    	
 
    	
harmful, irritant
    	
 
    	
>230
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
B
    	
 
    	
 
    	
 
    	
Boc-5-Ava-OH
    	
 
    	
Sigma Aldrich
    	
 
    	
27219-07-4
    	
 
    	
Irritant
    	
 
    	
235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
B
    	
 
    	
4-(
    	
 
    	
Boc-amino)benzylamine
    	
 
    	
Sigma Aldrich
    	
 
    	
220298-96-4
    	
 
    	
Harmful, skin sensitizer
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
mg
    
	
B
    	
 
    	
3-(
    	
 
    	
Boc-amino)propyl bromide
    	
 
    	
Sigma Aldrich
    	
 
    	
83948-53-2
    	
 
    	
Irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
mg
    
	
B
    	
 
    	
N-
    	
 
    	
Boc-m-phenylenediamine
    	
 
    	
Sigma Aldrich
    	
 
    	
68621-88-5
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
B
    	
 
    	
N-
    	
 
    	
Boc-M-Phenyleneduanbem >98.0%
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
B
    	
 
    	
1-
    	
 
    	
Boc-piperidine-4-carboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
137076-22-3
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
B
    	
 
    	
1-
    	
 
    	
Boc-piperzine
    	
 
    	
Sigma Aldrich
    	
 
    	
57260-71-6
    	
 
    	
 
    	
 
    	
235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
B
    	
 
    	
N-
    	
 
    	
Boc-Pyrrolidine-3-Carboxylic Acid
    	
 
    	
Sigma Aldrich
    	
 
    	
59378-75-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
B
    	
 
    	
 
    	
 
    	
Boric Acid
    	
 
    	
Sigma Aldrich
    	
 
    	
10043-35-3
    	
 
    	
Teratogen (testes)
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
B
    	
 
    	
 
    	
 
    	
Boron Tribromide, 1.0M Solution In
    	
 
    	
Sigma Aldrich
    	
 
    	
10294-33-4
    	
 
    	
Carcinogen, corrosive, fatal if inhaled
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
B
    	
 
    	
 
    	
 
    	
Boron Trifluoride Diethly Etherate
    	
 
    	
Sigma Aldrich
    	
 
    	
109-63-7
    	
 
    	
Combustible, corrsive
    	
 
    	
118
    	
 
    	
II
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
B
    	
 
    	
 
    	
 
    	
Bovine Serum Albumin, 2mg/ml
    	
 
    	
Bio-Rad
    	
 
    	
mixture
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
B
    	
 
    	
2-
    	
 
    	
Bromo-1,3-Dimethylbenzene, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
576-22-7
    	
 
    	
Combustible
    	
 
    	
165
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
B
    	
 
    	
4-
    	
 
    	
Bromo-2 Chloropyridine, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
73583-37-6
    	
 
    	
 
    	
 
    	
225
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
B
    	
 
    	
5-
    	
 
    	
Bromo-2’-Deoxyuridine
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
B
    	
 
    	
5-
    	
 
    	
Bromo-2-hydrazinopyridine
    	
 
    	
Sigma Aldrich
    	
 
    	
77992-44-0
    	
 
    	
Toxic, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
B
    	
 
    	
6-
    	
 
    	
Bromo-2-Naphthol, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
239-279-0
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
B
    	
 
    	
1-
    	
 
    	
Bromo-3-chloropropane
    	
 
    	
Sigma Aldrich
    	
 
    	
109-70-6
    	
 
    	
Combustible Liquid, Harmful by ingestion.
    	
 
    	
113
    	
 
    	
II
    	
 
    	
 
    	
 
    	
200
    	
 
    	
ml
    
	
B
    	
 
    	
 
    	
 
    	
Bromoacetic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
79-08-3
    	
 
    	
Toxic, respiratory sensitizer, corrosive
    	
 
    	
235
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
B
    	
 
    	
 
    	
 
    	
Bromoacetyl chloride
    	
 
    	
 
    	
 
    	
22118-09-8
    	
 
    	
GHS- corrosive, eye damage, specific target organ   toxicity
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
B
    	
 
    	
2-
    	
 
    	
Bromobenzoic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
88-65-3
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
B
    	
 
    	
3-
    	
 
    	
Bromobenzoic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
585-76-2
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
G
    
	
B
    	
 
    	
5
    	
 
    	
Bromodeoxyuridine
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
B
    	
 
    	
2
    	
 
    	
Bromoethylamine hydrobromide
    	
 
    	
Sigma Aldrich
    	
 
    	
2576-47-8
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    

 

5

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
B
    	
 
    	
 
    	
 
    	
Bromomethyl acetate
    	
 
    	
Sigma Aldrich
    	
 
    	
590-97-6
    	
 
    	
Combustible
    	
 
    	
135
    	
 
    	
II
    	
 
    	
 
    	
 
    	
—
    	
 
    	
g
    
	
B
    	
 
    	
2-
    	
 
    	
Bromomethyl) Acrylic Acid, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
72707-66-5
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
B
    	
 
    	
4-
    	
 
    	
Bromomethyl)benzoic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
6232-88-8
    	
 
    	
Irritant, lachrymator
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
B
    	
 
    	
3-
    	
 
    	
Bromomethyl)benzonitrile
    	
 
    	
Sigma Aldrich
    	
 
    	
28188-41-2
    	
 
    	
corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
g
    
	
B
    	
 
    	
4-
    	
 
    	
Bromomethyl)benzonitrile
    	
 
    	
Sigma Aldrich
    	
 
    	
17201-43-3
    	
 
    	
respiratory sensitizer, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
B
    	
 
    	
4-
    	
 
    	
Bromomethyl)phenylboronic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
68162-47-0
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
B
    	
 
    	
3
    	
 
    	
Bromopropionic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
590-92-1
    	
 
    	
Corrosive
    	
 
    	
151
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
B
    	
 
    	
N
    	
 
    	
Bromosuccinimide reagent plus 99%
    	
 
    	
Sigma Aldrich
    	
 
    	
128-08-5
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Bromotripyrrolidinophosphonium
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
B
    	
 
    	
 
    	
 
    	
hexafluorophosphate
    	
 
    	
Sigma Aldrich
    	
 
    	
132705-51-2
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
B
    	
 
    	
 
    	
 
    	
Buffer Solution, pH 4, pH 7, pH 10
    	
 
    	
Fisher
    	
 
    	
mixture
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
g
    
	
B
    	
 
    	
1
    	
 
    	
Butanol
    	
 
    	
Sigma Aldrich
    	
 
    	
71-36-3
    	
 
    	
Flammable
    	
 
    	
95
    	
 
    	
1C
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
B
    	
 
    	
Tert
    	
 
    	
Butanol, 99+%
    	
 
    	
Sigma Aldrich
    	
 
    	
75-65-0
    	
 
    	
Flammable
    	
 
    	
52
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
B
    	
 
    	
Tert
    	
 
    	
Butyl 1-Piperazinecarboxydate, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
B
    	
 
    	
Tert
    	
 
    	
Butyl Chloroacetate, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
107-59-5
    	
 
    	
Combustible, Corrosive
    	
 
    	
117
    	
 
    	
II
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Combustible, organic peroxide, corrosive,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
B
    	
 
    	
Tert
    	
 
    	
Butyl Hydroperoxide, 5.0-6.0M
    	
 
    	
Sigma Aldrich
    	
 
    	
75-91-2
    	
 
    	
mutagen
    	
 
    	
109
    	
 
    	
II
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Flammable, pyrophoric, corrosive,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
B
    	
 
    	
n-
    	
 
    	
Butyllithium Solution, 1.6 M in Hexane
    	
 
    	
Sigma Aldrich
    	
 
    	
109-72-8
    	
 
    	
reporductive hazard
    	
 
    	
-15
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
B
    	
 
    	
3
    	
 
    	
Butyn-1-ol
    	
 
    	
Sigma Aldrich
    	
 
    	
927-74-2
    	
 
    	
Flammable, irritant
    	
 
    	
97
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Cacodylic acid, sodium salt trihydrate
    	
 
    	
Acros Organics
    	
 
    	
6131-99-3
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
C
    	
 
    	
 
    	
 
    	
Caffeic Acid
    	
 
    	
Sigma Aldrich
    	
 
    	
331-39-5
    	
 
    	
Carcinogen, teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Caffeine
    	
 
    	
 
    	
 
    	
58-08-2
    	
 
    	
GHS- Acute toxicity
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Calcium Chloride Anhydrous
    	
 
    	
Sigma Aldrich
    	
 
    	
10043-52-4
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
mg
    
	
C
    	
 
    	
1,1’
    	
 
    	
Carbonyldimidazole, Reagent Grade
    	
 
    	
Sigma Aldrich
    	
 
    	
530-62-1
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
C
    	
 
    	
 
    	
 
    	
Caspase-Glo 3/7 Substrate
    	
 
    	
Promega
    	
 
    	
125572-95-4
    	
 
    	
Irritant
    	
 
    	
212
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
C
    	
 
    	
 
    	
 
    	
Cefixime Trihydrage
    	
 
    	
Sigma Aldrich
    	
 
    	
125110-14-7
    	
 
    	
sensitizer
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
C
    	
 
    	
 
    	
 
    	
Celastrol
    	
 
    	
Sigma
    	
 
    	
34157-83-0
    	
 
    	
Toxic by ingestion
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
mg
    

 

6

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
C
    	
 
    	
 
    	
 
    	
Celite 545, Filter aid
    	
 
    	
Sigma Aldrich
    	
 
    	
mixture
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
kg
    
	
C
    	
 
    	
 
    	
 
    	
Cerium(IV) sulfate
    	
 
    	
Sigma Aldrich
    	
 
    	
13590-82-4
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Cesium Carbonate
    	
 
    	
Sigma Aldrich
    	
 
    	
534-17-8
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Chloramphenicol
    	
 
    	
Sigma Aldrich
    	
 
    	
56-75-7
    	
 
    	
Carcinogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
C
    	
 
    	
2
    	
 
    	
Chloro -4-Nitrobenzoic Acid 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
99-60-5
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
C
    	
 
    	
4
    	
 
    	
Chloro-3-nitrobenzoic acid, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
96-99-1
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
3
    	
 
    	
Chloro-6-hydrazinopyridazine
    	
 
    	
Sigma Aldrich
    	
 
    	
17284-97-8
    	
 
    	
Harmful, skin sensitizer, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Chloroacetyl Chloride, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
79-04-9
    	
 
    	
Corrosive
    	
 
    	
212
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Chloroform
    	
 
    	
Sigma Aldrich
    	
 
    	
67-66-3
    	
 
    	
Carcinogen, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
C
    	
 
    	
5
    	
 
    	
Chloroindole-3-Carboxaldehyde, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
827-01-0
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Chloromethyl pivalate
    	
 
    	
Sigma Aldrich
    	
 
    	
18997-19-8
    	
 
    	
Combustible
    	
 
    	
104
    	
 
    	
II
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Chlorosulfonyl isocyanate
    	
 
    	
Acros Organics
    	
 
    	
1189-71-5
    	
 
    	
water reactive
    	
 
    	
230
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
5
    	
 
    	
ml
    
	
C
    	
 
    	
 
    	
 
    	
Chlorotrimethylsilane
    	
 
    	
Sigma Aldrich
    	
 
    	
75-77-4
    	
 
    	
Flammable, Corrosive
    	
 
    	
-0.4
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
C
    	
 
    	
 
    	
 
    	
Chlorox Germicidal Bleach
    	
 
    	
Clorox
    	
 
    	
7681-52-9
    	
 
    	
Corrosive
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
C
    	
 
    	
 
    	
 
    	
Cholera toxin from Vibrio Cholerae
    	
 
    	
sigma Aldrich
    	
 
    	
9012-63-9
    	
 
    	
Fatal in contact with skin
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2
    	
 
    	
mg
    
	
C
    	
 
    	
 
    	
 
    	
Chromium(0) hexacarbonyl
    	
 
    	
Sigma Aldrich
    	
 
    	
13007-92-6
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
CiDehol 70 Wipes
    	
 
    	
Decon Labs
    	
 
    	
—
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
C
    	
 
    	
 
    	
 
    	
Cinnamoyl chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
102-92-1
    	
 
    	
Corrosive
    	
 
    	
235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Citraconic anhydride
    	
 
    	
Sigma Aldrich
    	
 
    	
616-02-4
    	
 
    	
Toxic by skin absorbtion, irritant
    	
 
    	
214
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Clean-Blot IP Detection Kit
    	
 
    	
Thermo Fisher
    	
 
    	
Kit
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
C
    	
 
    	
 
    	
 
    	
CleanSolutions-Waterbath
    	
 
    	
Akron Biotech
    	
 
    	
52-51-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
C
    	
 
    	
 
    	
 
    	
Copper ( I) iodide
    	
 
    	
Sigma Aldrich
    	
 
    	
7681-65-4
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Copper ( II) Acetate 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
142-71-2
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Copper(II) iodide
    	
 
    	
Sigma Aldrich
    	
 
    	
7681-65-4
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
C
    	
 
    	
 
    	
 
    	
Copper(II) sulfate pentahydrate
    	
 
    	
Sigma Aldrich
    	
 
    	
7758-99-8
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Copper, Bare copper wire
    	
 
    	
Arcor
    	
 
    	
7440-50-8
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    

 

7

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
electronics
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
C
    	
 
    	
 
    	
 
    	
Crontonyl chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
625-35-4
    	
 
    	
Flammable, corrosive, carcinogen
    	
 
    	
95
    	
 
    	
1C
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Crotonic acid 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
107-93-7
    	
 
    	
Corrosive
    	
 
    	
190
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Curcumin
    	
 
    	
Sigma Aldrich
    	
 
    	
458-37-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Cyanoacetamide
    	
 
    	
Sigma Aldrich
    	
 
    	
107-91-5
    	
 
    	
Irritant
    	
 
    	
419
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
100
    	
 
    	
G
    
	
C
    	
 
    	
 
    	
 
    	
Cyanoacetic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
372-09-8
    	
 
    	
Corrosive
    	
 
    	
225
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Cyanogen Bromide, Reagent Grade 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
506-68-3
    	
 
    	
Toxic, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
C
    	
 
    	
4-
    	
 
    	
Cyanophenylacetic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
5462-71-5
    	
 
    	
Harmful, irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Cyanuric chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
108-77-0
    	
 
    	
Toxic, skin sensitizer, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Cyclohexyl Isocyanide, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
931-53-3
    	
 
    	
Combustible, toxic
    	
 
    	
171
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Cyclosporin A
    	
 
    	
Sigma Aldrich
    	
 
    	
59865-13-3
    	
 
    	
Carcinogen, Teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
mg
    
	
C
    	
 
    	
 
    	
 
    	
Cysteamine
    	
 
    	
Sigma Aldrich
    	
 
    	
60-23-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
C
    	
 
    	
L-
    	
 
    	
Cysteine hydrochloride monohydrate
    	
 
    	
Sigma Aldrich
    	
 
    	
7048-04-6
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
C
    	
 
    	
 
    	
 
    	
Cytosine B-D-arabinofuranoside
    	
 
    	
Sigma Aldrich
    	
 
    	
147-94-4
    	
 
    	
Skin sesitizer
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
 
    	
 
    	
Danazol
    	
 
    	
Sigma Aldrich
    	
 
    	
17230-88-5
    	
 
    	
Toxic, TOE Pituitary, Teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
D
    	
 
    	
 
    	
 
    	
Diacylglycerol Kinase Inhibitor II
    	
 
    	
Sigma Aldrich
    	
 
    	
120166-69-0
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
mg
    
	
D
    	
 
    	
1,11-
    	
 
    	
Diamino-3,6,9-Trioxaundecane, > +9&
    	
 
    	
Sigma Aldrich
    	
 
    	
929-75-9
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
D
    	
 
    	
2,3-
    	
 
    	
Diaminobenzoic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
603-81-6
    	
 
    	
Irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
D
    	
 
    	
3,4-
    	
 
    	
Diaminobenzoic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
619-05-6
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
 
    	
 
    	
(1R,2R)-(-)-
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
1,2-
    	
 
    	
Diaminocyclohexane
    	
 
    	
Sigma Aldrich
    	
 
    	
20439-47-8
    	
 
    	
Corrosive
    	
 
    	
158
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
 
    	
 
    	
(1S,2S)-(+)-
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
1,2-
    	
 
    	
Diaminocyclohexane
    	
 
    	
Sigma Aldrich
    	
 
    	
21436-03-3
    	
 
    	
Corrosive
    	
 
    	
158
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
D
    	
 
    	
cis-1,2-
    	
 
    	
Diaminocyclohexane
    	
 
    	
Sigma Aldrich
    	
 
    	
1436-59-5
    	
 
    	
Combustible, corrosive
    	
 
    	
158
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
D
    	
 
    	
trans-1,4-
    	
 
    	
Diaminocyclohexane
    	
 
    	
Sigma Aldrich
    	
 
    	
2615-25-0
    	
 
    	
harmful, corrosive
    	
 
    	
160
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
D
    	
 
    	
2,4-
    	
 
    	
Diaminotoluene
    	
 
    	
Sigma Aldrich
    	
 
    	
95-80-7
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
D
    	
 
    	
cis-
    	
 
    	
Diammineplatinum(II) dichloride
    	
 
    	
Sigma
    	
 
    	
15663-27-1
    	
 
    	
Toxic, carcinogen, eye damage
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    

 

8

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
2,4-
    	
 
    	
Dichloro-5-(trifluoromethyl)pyrimidine
    	
 
    	
sigma Aldrich
    	
 
    	
3932-97-6
    	
 
    	
Toxic by ingestion, irritant
    	
 
    	
200
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
D
    	
 
    	
2,4-
    	
 
    	
Dichloro-5-fluoropyrimidine
    	
 
    	
Sigma Aldrich
    	
 
    	
2927-71-1
    	
 
    	
Harmful, corrosive
    	
 
    	
223
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
D
    	
 
    	
2,4-
    	
 
    	
Dichloro-5-methoxypyrimidine
    	
 
    	
Sigma Aldrich
    	
 
    	
1780-31-0
    	
 
    	
Corrosive
    	
 
    	
235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
D
    	
 
    	
2,4-
    	
 
    	
Dichloro-5-methylpyrimidine
    	
 
    	
Sigma Aldrich
    	
 
    	
19646-07-2
    	
 
    	
Harmful by ingestion, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
D
    	
 
    	
1,2-
    	
 
    	
Dichloroethane, Anhydrous, 99.8%
    	
 
    	
Sigma Aldrich
    	
 
    	
107-06-2
    	
 
    	
Flammable, carcinogen
    	
 
    	
55
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
D
    	
 
    	
2,3-
    	
 
    	
Dichloromaleic anhydride
    	
 
    	
Sigma Aldrich
    	
 
    	
1122-17-4
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
D
    	
 
    	
 
    	
 
    	
Dichloromethane
    	
 
    	
Sigma Aldrich
    	
 
    	
75-09-2
    	
 
    	
Carcinogen, toxic, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
D
    	
 
    	
2,6-
    	
 
    	
Dichloropyridine, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
2402-78-0
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
D
    	
 
    	
2,4-
    	
 
    	
Dichloropyrimidine, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
3934-20-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
D
    	
 
    	
N,N’-
    	
 
    	
Dicyclohexylcarbodiimide
    	
 
    	
Sigma Aldrich
    	
 
    	
538-75-0
    	
 
    	
Toxic, corrosive
    	
 
    	
235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
 
    	
 
    	
Diethyl 1,3-acetonedicarboxylate
    	
 
    	
Sigma Aldrich
    	
 
    	
105-50-2
    	
 
    	
Combustible
    	
 
    	
160
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
D
    	
 
    	
 
    	
 
    	
Diethyl azodicarboxylate solution
    	
 
    	
Sigma Aldrich
    	
 
    	
1972-28-7
    	
 
    	
Combustible, teratogen
    	
 
    	
106
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
D
    	
 
    	
 
    	
 
    	
Diethyl ether
    	
 
    	
Sigma Aldrich
    	
 
    	
60-29-7
    	
 
    	
Flammable, harmful, irritant
    	
 
    	
-40
    	
 
    	
1A
    	
 
    	
BP 93 deg F
    	
 
    	
1
    	
 
    	
L
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Flammable, skin sensitizer, respiratory
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
 
    	
 
    	
Diethylamine
    	
 
    	
Sigma Aldrich
    	
 
    	
109-89-7
    	
 
    	
sensitizer
    	
 
    	
-9
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
L
    
	
 
    	
 
    	
 
    	
 
    	
Diethylamino)-2-Butenoic Acid
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
4-(
    	
 
    	
Hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
98548-81-3
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
3,4-
    	
 
    	
Dihydroxybenzaldehyde, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
205-377-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
D
    	
 
    	
3,4-
    	
 
    	
Dihydroxybenzoic Acid
    	
 
    	
Sigma Aldrich
    	
 
    	
99-50-3
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Flammable, water reactive, corrosive,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
 
    	
 
    	
Diisobutylaluminum hydride solution
    	
 
    	
Sigma Aldrich
    	
 
    	
1191-15-7
    	
 
    	
carcinogen
    	
 
    	
1
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
D
    	
 
    	
N,N’-
    	
 
    	
Diisopropylcarbodiimide
    	
 
    	
Sigma Aldrich
    	
 
    	
693-13-0
    	
 
    	
Flammable, sensitizer
    	
 
    	
88
    	
 
    	
1C
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
D
    	
 
    	
N,N-
    	
 
    	
Diisopropylethylamine
    	
 
    	
Sigma Aldrich
    	
 
    	
7087-68-5
    	
 
    	
Flammable, toxic, corrosive
    	
 
    	
51
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
D
    	
 
    	
N,O-
    	
 
    	
Dimehtylhydroxylamine hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
6638-79-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
D
    	
 
    	
2,4-
    	
 
    	
Dimethoxy-3-Hydroxybenzaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
mg
    
	
D
    	
 
    	
1,2-
    	
 
    	
Dimethoxyethane, Anhydrous, 99.5%
    	
 
    	
Sigma
    	
 
    	
110-71-4
    	
 
    	
Flammable, teratogen
    	
 
    	
41
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    

 

9

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
 
    	
 
    	
Dimethyl sulfoxide
    	
 
    	
Sigma Aldrich
    	
 
    	
67-68-5
    	
 
    	
Combustible
    	
 
    	
189
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
500
    	
 
    	
ml
    
	
D
    	
 
    	
N,N-
    	
 
    	
Dimethylacetamide, Anhydrous, 99.8%
    	
 
    	
Sigma Aldrich
    	
 
    	
127-19-5
    	
 
    	
Combustible, Irritant, toxic, teratogen
    	
 
    	
158
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
D
    	
 
    	
3,3-
    	
 
    	
Dimethylacryloyl chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
3350-78-5
    	
 
    	
Combustible, corrosive
    	
 
    	
124
    	
 
    	
II
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
D
    	
 
    	
 
    	
 
    	
Dimethylamine, 2.0M solution in Tetra-
    	
 
    	
Sigma Aldrich
    	
 
    	
124-40-3
    	
 
    	
Flammable, irritant, carcinogen
    	
 
    	
33
    	
 
    	
1B
    	
 
    	
Compressed gas
    	
 
    	
100
    	
 
    	
ml
    
	
D
    	
 
    	
4-(
    	
 
    	
Dimethylamino)pyridine
    	
 
    	
Sigma Aldrich
    	
 
    	
1122-58-3
    	
 
    	
Toxic, irritant
    	
 
    	
230
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Dimethylaminopropyl)-N-
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
N-(3-
    	
 
    	
ethylcarbodiimide hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
25952-53-8
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
2,6-
    	
 
    	
Dimethylbenzoic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
632-46-2
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
D
    	
 
    	
N,N-
    	
 
    	
Dimethylbenzylamine
    	
 
    	
Sigma Aldrich
    	
 
    	
103-83-3
    	
 
    	
Combustible, corrosive
    	
 
    	
127
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
D
    	
 
    	
N,N-
    	
 
    	
Dimethylformamide
    	
 
    	
Sigma Aldrich
    	
 
    	
68-12-2
    	
 
    	
Combustible, harmful, irritant, teratogen
    	
 
    	
136
    	
 
    	
II
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
D
    	
 
    	
2,4-
    	
 
    	
Dimethylglutaric acid
    	
 
    	
Acros Organics
    	
 
    	
2121-67-7
    	
 
    	
Irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
2,4-
    	
 
    	
Dimethylpyrrole
    	
 
    	
Sigma Aldrich
    	
 
    	
625-82-1
    	
 
    	
Irritant
    	
 
    	
>235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
1
    	
 
    	
G
    
	
D
    	
 
    	
1,4-
    	
 
    	
Dioxane
    	
 
    	
Sigma Aldrich
    	
 
    	
123-91-1
    	
 
    	
Flammable, Carcinogen, may form explosives
    	
 
    	
54
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
D
    	
 
    	
 
    	
 
    	
Diphenyl phosphoryl azide
    	
 
    	
Sigma Aldrich
    	
 
    	
26386-88-9
    	
 
    	
Toxic
    	
 
    	
234
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
D
    	
 
    	
 
    	
 
    	
Di-tert-butyl dicarbonate
    	
 
    	
Sigma Aldrich
    	
 
    	
24424-99-5
    	
 
    	
Flammable, toxic, irritant, skin sensitizer
    	
 
    	
99
    	
 
    	
1C
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
D
    	
 
    	
5,5’-
    	
 
    	
Dithiobis(2-nitrobenzoic acid)
    	
 
    	
Sigma Aldrich
    	
 
    	
69-78-3
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
D
    	
 
    	
2,2’-
    	
 
    	
Dithiodipyridine
    	
 
    	
Sigma Aldrich
    	
 
    	
2127-03-9
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
1,4-
    	
 
    	
Dithio-DL-Threitol
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
 
    	
 
    	
DL-Dithiothreitol
    	
 
    	
Sigma Aldrich
    	
 
    	
3483-12-3
    	
 
    	
Toxic, irritant
    	
 
    	
235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
 
    	
 
    	
DNA Plasmid Vectors
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
 
    	
 
    	
Dowex 50WX8 hydrogen form
    	
 
    	
Sigma Aldrich
    	
 
    	
69011-20-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
D
    	
 
    	
 
    	
 
    	
Doxorubicin hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
25316-40-9
    	
 
    	
Harmful, irritant, carcinogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
mg
    
	
D
    	
 
    	
 
    	
 
    	
Dri-Contrad
    	
 
    	
Decon Labs
    	
 
    	
—
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
 
    	
 
    	
Drierite
    	
 
    	
Arcor
    	
 
    	
—
    	
 
    	
—
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
 
    	
 
    	
D-Tube Dialyzer Mini, MWCO 6-8 kDa
    	
 
    	
EMD Biosciences
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
 
    	
 
    	
Dulbecco’s Modified Eagle’s Medium
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
D
    	
 
    	
 
    	
 
    	
Durac Liquid fill for thermometers
    	
 
    	
H-B
    	
 
    	
67-64-1
    	
 
    	
Flammable
    	
 
    	
-4
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    

 

10

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Instrument
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
D
    	
 
    	
 
    	
 
    	
DURAC Plus Liquid
    	
 
    	
H-B Instrument
    	
 
    	
67-64-1
    	
 
    	
Flammable
    	
 
    	
-4
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
E
    	
 
    	
 
    	
 
    	
EfferSan Multipurpose disinfecting tablets
    	
 
    	
Activon
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
E
    	
 
    	
 
    	
 
    	
Ethanol
    	
 
    	
Sigma Aldrich
    	
 
    	
64-17-5
    	
 
    	
Flammable, irritant, carcinogen
    	
 
    	
57
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
E
    	
 
    	
 
    	
 
    	
Ethanol 200 Proof
    	
 
    	
Fisher
    	
 
    	
64-17-5
    	
 
    	
Flammable, irritant, carcinogen
    	
 
    	
54
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
E
    	
 
    	
 
    	
 
    	
Ethanol SDA1, Anydrous
    	
 
    	
Fisher
    	
 
    	
64-17-5
    	
 
    	
Flammable
    	
 
    	
57
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
E
    	
 
    	
 
    	
 
    	
Ethanolamine
    	
 
    	
Sigma Aldrich
    	
 
    	
141-43-5
    	
 
    	
Combustible, corrosive
    	
 
    	
187
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
E
    	
 
    	
2-
    	
 
    	
Ethoxyethanol 99%
    	
 
    	
Sigma Aldrich
    	
 
    	
110-80-5
    	
 
    	
Combustible, teratogen
    	
 
    	
108
    	
 
    	
II
    	
 
    	
 
    	
 
    	
1
    	
 
    	
L
    
	
E
    	
 
    	
 
    	
 
    	
Ethyl 2-methylacetoacetate
    	
 
    	
Sigma Aldrich
    	
 
    	
609-14-3
    	
 
    	
Combustible
    	
 
    	
145
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
E
    	
 
    	
 
    	
 
    	
Ethyl acetate
    	
 
    	
Sigma Aldrich
    	
 
    	
141-78-6
    	
 
    	
Flammable, irritant
    	
 
    	
27
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
E
    	
 
    	
 
    	
 
    	
Ethyl chloroformate
    	
 
    	
Sigma Aldrich
    	
 
    	
541-41-3
    	
 
    	
Flammable, toxic, corrosive
    	
 
    	
50
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
E
    	
 
    	
 
    	
 
    	
Ethyl isocyanate
    	
 
    	
 
    	
 
    	
109-90-0
    	
 
    	
GHS- Flammable liquids, acute toxicity, skin   irritation, eye irritation, respiratory sensitisation, specific target organ   toxicity
    	
 
    	
14 F
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
E
    	
 
    	
 
    	
 
    	
Ethylene Glycol, ReagentPlus, >=99%
    	
 
    	
Sigma Aldrich
    	
 
    	
107-21-1
    	
 
    	
teratogen
    	
 
    	
232
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
E
    	
 
    	
 
    	
 
    	
Ethylenediaminetetraacetic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
60-00-4
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
E
    	
 
    	
N-
    	
 
    	
Ethylmaleimide
    	
 
    	
Sigma Aldrich
    	
 
    	
128-53-0
    	
 
    	
Toxic, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
 
    	
 
    	
5-{(4-
    	
 
    	
Ethylphenyl)methylene] -2-thioxo-4-thiazolidinone
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
1-
    	
 
    	
Ethynylcylohexene
    	
 
    	
Sigma Aldrich
    	
 
    	
931-4-7
    	
 
    	
Flammable
    	
 
    	
84
    	
 
    	
1B
    	
 
    	
lachrymator
    	
 
    	
—
    	
 
    	
—
    
	
 
    	
 
    	
 
    	
 
    	
Europium(III) nitrate pentahydrate
    	
 
    	
Sigma Aldrich
    	
 
    	
63026-01-7
    	
 
    	
Oxidizer, irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
EZ-Link TFPA-PEG Biotin
    	
 
    	
Thermo Fisher
    	
 
    	
—
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
 
    	
 
    	
 
    	
 
    	
FLAG M Purification Kit
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
 
    	
 
    	
 
    	
 
    	
Flavopiridol Hydrochloride Hydrate
    	
 
    	
Sigma Aldrich
    	
 
    	
131740-09-5
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Fluorescein
    	
 
    	
Sigma Aldrich
    	
 
    	
2321-07-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
 
    	
 
    	
4-
    	
 
    	
Fluoro-3-nitrobenzoic acid, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
453-71-4
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
6-
    	
 
    	
Fluoroindole-3-carboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
2795-41-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
 
    	
 
    	
1,(2-
    	
 
    	
Fluoropheyl)piperazine
    	
 
    	
Sigma Aldrich
    	
 
    	
1011-15-0
    	
 
    	
Irritant
    	
 
    	
235
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
ml
    
	
 
    	
 
    	
 
    	
 
    	
Formic Acid
    	
 
    	
Sigma Aldrich
    	
 
    	
64-18-6
    	
 
    	
Combustible, harmful, corrosive
    	
 
    	
118
    	
 
    	
II
    	
 
    	
 
    	
 
    	
500
    	
 
    	
ml
    

 

11

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
3-
    	
 
    	
Formyl-1H-Indole-5-Carbonitrile, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
17380-18-6
    	
 
    	
Harmful, skin sensitiser, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
 
    	
 
    	
3-
    	
 
    	
Formylphenylboronic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
87199-16-4
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
4-
    	
 
    	
Formylphenylboronic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
87199-17-5
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
FuGENE HD Transfection Reagent
    	
 
    	
Promega
    	
 
    	
64-17-5
    	
 
    	
Flammable, carcinogen
    	
 
    	
70
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
G
    	
 
    	
 
    	
 
    	
G 418 disulfate salt
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Sensitizer
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
G
    	
 
    	
 
    	
 
    	
Gemcitabine hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
122111-03-9
    	
 
    	
Reproductive hazard
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
mg
    
	
G
    	
 
    	
 
    	
 
    	
GenElute Plasmid Minipret Kit
    	
 
    	
Sigma Aldrich
    	
 
    	
Kit
    	
 
    	
Toxic, Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
G
    	
 
    	
 
    	
 
    	
GF-AFC substarte
    	
 
    	
Promega
    	
 
    	
—
    	
 
    	
Combistble
    	
 
    	
131
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
G
    	
 
    	
 
    	
 
    	
Glycerol
    	
 
    	
Sigma Aldrich
    	
 
    	
56-81-5
    	
 
    	
 
    	
 
    	
320
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
1
    	
 
    	
—
    
	
G
    	
 
    	
 
    	
 
    	
Glyoxilic acid monohydrate
    	
 
    	
Sigma Aldrich
    	
 
    	
563-96-2
    	
 
    	
skin sensitiser, irritant
    	
 
    	
230
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
G
    	
 
    	
 
    	
 
    	
GSK2801
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
G
    	
 
    	
 
    	
 
    	
GSK343
    	
 
    	
Sigma Aldrich
    	
 
    	
1346704-33-3
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
mg
    
	
G
    	
 
    	
 
    	
 
    	
Guanidine hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
50-01-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
G
    
	
H
    	
 
    	
 
    	
 
    	
Halt Protease Phosphatase Inhibitor Cocktail
    	
 
    	
Thermo Fisher
    	
 
    	
 
    	
 
    	
Toxic
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
H
    	
 
    	
 
    	
 
    	
Hematoxylin
    	
 
    	
 
    	
 
    	
517-28-2
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
H
    	
 
    	
 
    	
 
    	
Heptamethyleneimine
    	
 
    	
Sigma Aldrich
    	
 
    	
1121-92-2
    	
 
    	
Flammable
    	
 
    	
84
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
H
    	
 
    	
 
    	
 
    	
Hexamethylenediamine
    	
 
    	
Sigma Aldrich
    	
 
    	
124-09-4
    	
 
    	
Corrosive
    	
 
    	
176
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
H
    	
 
    	
 
    	
 
    	
Hexane
    	
 
    	
Sigma Aldrich
    	
 
    	
110-54-3
    	
 
    	
Flammable, irritant, reproductive hazard
    	
 
    	
-15
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
H
    	
 
    	
 
    	
 
    	
hexane, Mixture of Isomers, Chromasolv
    	
 
    	
Sigma Aldrich
    	
 
    	
110-54-3
    	
 
    	
Flammable, teratogen
    	
 
    	
-9
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
H
    	
 
    	
2.5-
    	
 
    	
Hexanedione
    	
 
    	
Sigma Aldrich
    	
 
    	
110-13-4
    	
 
    	
Combustible, irritant
    	
 
    	
174
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
H
    	
 
    	
 
    	
 
    	
HisPur Cobalt Resin
    	
 
    	
Thermo Fisher
    	
 
    	
7791-13-1
    	
 
    	
Flammable
    	
 
    	
90
    	
 
    	
1C
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
H
    	
 
    	
 
    	
 
    	
HIS-Select Nickel Affinity Gel
    	
 
    	
Sigma Aldrich
    	
 
    	
64-17-5
    	
 
    	
Flammable
    	
 
    	
90
    	
 
    	
1C
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
H
    	
 
    	
 
    	
 
    	
Histoprep 70% Dehydrant
    	
 
    	
 
    	
 
    	
64-17-5
   7732-18-5 67-56-1
   67-63-0
    	
 
    	
Flammable, irritant, reproductive hazard
    	
 
    	
69.8 F
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
gallon
    
	
H
    	
 
    	
 
    	
 
    	
hydralzine hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
304-20-1
    	
 
    	
Toxic, irritant, Teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
H
    	
 
    	
 
    	
 
    	
Hydrazine
    	
 
    	
Sigma Aldrich
    	
 
    	
302-01-2
    	
 
    	
Combustible, carcinogen, toxic, corrosive
    	
 
    	
126
    	
 
    	
II
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
H
    	
 
    	
2-
    	
 
    	
Hydrazinopyrazine
    	
 
    	
Sigma
    	
 
    	
54608-52-5
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    

 

12

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
H
    	
 
    	
2-
    	
 
    	
Hydrazinopyridine
    	
 
    	
Sigma Aldrich
    	
 
    	
4930-98-7
    	
 
    	
Irritant
    	
 
    	
230
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
H
    	
 
    	
4-
    	
 
    	
Hydrazinopyridine hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
52834-40-9
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
mg
    
	
H
    	
 
    	
2-
    	
 
    	
Hydrazinyl-5-trifluoromethylpyridine
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Toxic, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
H
    	
 
    	
 
    	
 
    	
Hydrochloric Acid, 37%
    	
 
    	
Sigma Aldrich
    	
 
    	
7647-01-0
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
ml
    
	
H
    	
 
    	
 
    	
 
    	
Hydrocortisone
    	
 
    	
Sigma Aldrich
    	
 
    	
50-23-7
    	
 
    	
Teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
H
    	
 
    	
 
    	
 
    	
Hydrogen chloride, 4N solution in 1,4-dioxane
    	
 
    	
Acros Organics
    	
 
    	
7647-01-0
    	
 
    	
Flammable, peroxide former
    	
 
    	
62.6
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
H
    	
 
    	
 
    	
 
    	
Hydrogen peroxide solution
    	
 
    	
Sigma Aldrich
    	
 
    	
7722-84-1
    	
 
    	
Oxidizer, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
ml
    
	
H
    	
 
    	
3-
    	
 
    	
hydroxy-2,4-dimethyoxybenzaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
32246-34-7
    	
 
    	
Harmful, skin sensitiser, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
H
    	
 
    	
4-
    	
 
    	
Hydroxybenzaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
123-08-0
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
H
    	
 
    	
4-(2-
    	
 
    	
hydroxyethoxy)benzaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Skin sensitizer, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
mg
    
	
H
    	
 
    	
4-(2-
    	
 
    	
Hydroxyethyl)morpholine, ReagentPlus
    	
 
    	
Sigma Aldrich
    	
 
    	
62240-2
    	
 
    	
Irritant
    	
 
    	
208
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
H
    	
 
    	
 
    	
 
    	
Hydroxylamine solution
    	
 
    	
Sigma Aldrich
    	
 
    	
7803-49-8
    	
 
    	
Harmful, skin sensitizer, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
ml
    
	
H
    	
 
    	
(Z)-4-
    	
 
    	
Hydroxytamoxifen
    	
 
    	
Sigma Aldrich
    	
 
    	
68047-06-3
    	
 
    	
Toxic, Teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Igepal CA-630
    	
 
    	
Sigma Aldrich
    	
 
    	
9036-19-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
 
    	
 
    	
1-[2-(1H-
    	
 
    	
imidazol-1-yl)pheyl]methyanamine
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
 
    	
 
    	
 
    	
 
    	
Imidazole
    	
 
    	
Sigma Aldrich
    	
 
    	
288-32-4
    	
 
    	
Harmful, corrosive, teratogen
    	
 
    	
>275
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
 
    	
 
    	
2-
    	
 
    	
Imidazolecarboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
10111-08-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
 
    	
 
    	
4-
    	
 
    	
Imidazolecarboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
3034-50-2
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
 
    	
 
    	
5-
    	
 
    	
Iodoisatin
    	
 
    	
Sigma Aldrich
    	
 
    	
20780-76-1
    	
 
    	
Harmful, skin sensitizer, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Iodotrimethylsilane
    	
 
    	
Sigma Aldrich
    	
 
    	
16029-98-4
    	
 
    	
Corrosive, reacts violently with water
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Iron(III) acetylacetonate
    	
 
    	
Sigma Aldrich
    	
 
    	
14024-18-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Iron(III) chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
7702-08-2
    	
 
    	
Corrosive to metals, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Isatin
    	
 
    	
Sigma Aldrich
    	
 
    	
91-56-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Isoniazid
    	
 
    	
Sigma Aldrich
    	
 
    	
54-85-3
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Isonicotinic Acid, 99%
    	
 
    	
Sigma
    	
 
    	
55-22-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    

 

13

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
Isophthalic Acid
    	
 
    	
Sigma Aldrich
    	
 
    	
121-91-5
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Isopropyl B-D-1-thiogalactopyranoside
    	
 
    	
Sigma Aldrich
    	
 
    	
123-91-1
    	
 
    	
carcinogen, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
Isopropylamine > = 99.5%
    	
 
    	
Sigma Aldrich
    	
 
    	
75-31-0
    	
 
    	
Flammable, harmful, corrosive
    	
 
    	
0
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
 
    	
 
    	
 
    	
 
    	
Isopropylmagnesium bromide solution
    	
 
    	
Sigma Aldrich
    	
 
    	
920-39-8
    	
 
    	
Flammable, Corrosive, Carcinogen
    	
 
    	
-22
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
 
    	
 
    	
 
    	
 
    	
Itaconic Anhydride, Powder, 95%
    	
 
    	
Sigma Aldrich
    	
 
    	
2170-03-8
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
J
    	
 
    	
 
    	
 
    	
JumpStart REDAccuTaq LA DNA Polymerate
    	
 
    	
Sigma Aldrich
    	
 
    	
9012-90-2
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
K
    	
 
    	
 
    	
 
    	
Kanamycin solution, from Steptomyces kanamyceticus
    	
 
    	
Sigma Aldrich
    	
 
    	
25389-94-0
    	
 
    	
Reproductive hazard
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
K
    	
 
    	
 
    	
 
    	
Kanamycin solution, from Steptomyces kanamyceticus
    	
 
    	
Sigma Aldrich
    	
 
    	
25389-94-0
    	
 
    	
Reproductive hazard
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
L
    	
 
    	
N-
    	
 
    	
Lauroylsarcosine sodium salt
    	
 
    	
Sigma Aldrich
    	
 
    	
137-16-6
    	
 
    	
Highly Toxic, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
L
    	
 
    	
 
    	
 
    	
LB Agar Kanamycin-50, Plates
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
L
    	
 
    	
 
    	
 
    	
Leflunomide
    	
 
    	
Sigma Aldrich
    	
 
    	
75706-12-6
    	
 
    	
Toxic, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
Mg
    
	
L
    	
 
    	
 
    	
 
    	
Lithium Aluminum hydride solution
    	
 
    	
Sigma Aldrich
    	
 
    	
16853-85-3
    	
 
    	
Flammable, water reactive, corrosive, carcinogen,   may form explosive peroxides
    	
 
    	
1
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
L
    	
 
    	
 
    	
 
    	
Lithium bromide
    	
 
    	
Sigma Aldrich
    	
 
    	
7550-35-8
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
L
    	
 
    	
 
    	
 
    	
Lithium Chloride Solution
    	
 
    	
Sigma Aldrich
    	
 
    	
7447-41-8
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
ml
    
	
L
    	
 
    	
 
    	
 
    	
Lithium Hydroxide, Reagent Grade, >98%
    	
 
    	
Sigma Aldrich
    	
 
    	
1310-65-2
    	
 
    	
Toxic, Corrosive
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
L
    	
 
    	
 
    	
 
    	
Luperox ® A70S, Benzoyl peroxide 70%
    	
 
    	
Sigma Aldrich
    	
 
    	
94-36-0
    	
 
    	
Organic peroxide, skin senstiser, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Magnesium
    	
 
    	
Sigma Aldrich
    	
 
    	
7439-95-4
    	
 
    	
Flammable solid
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
M
    	
 
    	
 
    	
 
    	
Magnesium acetate solution
    	
 
    	
Sigma Aldrich
    	
 
    	
142-72-3
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
M
    	
 
    	
 
    	
 
    	
Magnesium sulfate
    	
 
    	
Sigma Aldrich
    	
 
    	
7487-88-9
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Magnesium sulfate, anyhydrous
    	
 
    	
Fisher
    	
 
    	
7487-88-9
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
M
    	
 
    	
 
    	
 
    	
Maleic Anhydride, Powder, 95%
    	
 
    	
Sigma Aldrich
    	
 
    	
108-31-6
    	
 
    	
Toxic, skin and respirator sensitiser, corrosive,   irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
M
    	
 
    	
3-
    	
 
    	
Maleimidopropionic Acid, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
mg
    
	
M
    	
 
    	
N-
    	
 
    	
Maleoyl-|3-alanine
    	
 
    	
Sigma Aldrich
    	
 
    	
7423-55-4
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
M
    	
 
    	
 
    	
 
    	
Malonic acid, reagent plus, 99%
    	
 
    	
Sigma Aldrich
    	
 
    	
141-82-2
    	
 
    	
Toxic, harmful, irritant
    	
 
    	
342
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Manganese II) sulfate monohydrate
    	
 
    	
Sigma
    	
 
    	
10034-96-5
    	
 
    	
Damage to lungs, nerves with repeated
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    

 

14

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
exposure
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
M
    	
 
    	
2-
    	
 
    	
Mercaptoethanol
    	
 
    	
Sigma Aldrich
    	
 
    	
60-24-2
    	
 
    	
Combustible, toxic, mutagen, stench
    	
 
    	
154
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
M
    	
 
    	
 
    	
 
    	
Methanesulfonamide, >97.0% CHN
    	
 
    	
Sigma Aldrich
    	
 
    	
3144-09-0
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Methanesulfonic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
75-75-2
    	
 
    	
Corrosive
    	
 
    	
372
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
M
    	
 
    	
 
    	
 
    	
Methanol
    	
 
    	
Sigma Aldrich
    	
 
    	
67-56-1
    	
 
    	
Flammable, toxic, irritant
    	
 
    	
50
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
M
    	
 
    	
2-
    	
 
    	
Methoxy-4-Nitrobenzoic Acid, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
2597-56-0
    	
 
    	
Target Organ liver
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
M
    	
 
    	
2-
    	
 
    	
Methoxy-5-Nitroaniline, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
99-59-2
    	
 
    	
female reproductive system
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
M
    	
 
    	
2-
    	
 
    	
Methoxyestradiol
    	
 
    	
Sigma Aldrich
    	
 
    	
362-07-2
    	
 
    	
Toxic, reproductive hazard
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
mg
    
	
M
    	
 
    	
(2-
    	
 
    	
Methoxyethyl)methylamine
    	
 
    	
Sigma Aldrich
    	
 
    	
38256-93-8
    	
 
    	
flammable, skin sensitizer
    	
 
    	
35
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
M
    	
 
    	
2-
    	
 
    	
Methoxyethylamine
    	
 
    	
Sigma Aldrich
    	
 
    	
109-85-3
    	
 
    	
Flammable, corrosive
    	
 
    	
54
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
ml
    
	
M
    	
 
    	
5-
    	
 
    	
Methoxyindole-3-carboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
10601-19-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
M
    	
 
    	
4-
    	
 
    	
Methoxyphenylacetic Acid, Reagent Plus
    	
 
    	
Sigma Aldrich
    	
 
    	
104-01-8
    	
 
    	
Harmful, irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
M
    	
 
    	
(S)-(+)-a-
    	
 
    	
Methoxy-a-trifluoromethylphenylacetyl chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
20445-33-4
    	
 
    	
Combustible, corrosive
    	
 
    	
192
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
M
    	
 
    	
1-
    	
 
    	
Methyl -2 Pyrrolidinone Anhydrous, 99&
    	
 
    	
Sigma Aldrich
    	
 
    	
872-50-4
    	
 
    	
Combustible, irritant, teratogen
    	
 
    	
196
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
M
    	
 
    	
 
    	
 
    	
Methyl 2-aminopyridine-4-carboxylate
    	
 
    	
sigma Aldrich
    	
 
    	
6937-03-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
M
    	
 
    	
1-
    	
 
    	
Methyl 2-iodoterephthalate
    	
 
    	
Sigma Aldrich
    	
 
    	
299173-24-3
    	
 
    	
Toxic, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Methyl 3-bromopropionate
    	
 
    	
Sigma Aldrich
    	
 
    	
3395-91-3
    	
 
    	
Combustible, irritant
    	
 
    	
167
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Methyl 3-formylbenzoate
    	
 
    	
Sigma Aldrich
    	
 
    	
52178-50-4
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Methyl 3-Isocyanatobenzoate, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
41221-47-0
    	
 
    	
respiratory sensitiser
    	
 
    	
235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
M
    	
 
    	
3-
    	
 
    	
Methyl -4 Nitrobenzoic Acid, 99%
    	
 
    	
Sigma Aldrich
    	
 
    	
3113-71-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Methyl bromoacetate
    	
 
    	
Sigma Aldrich
    	
 
    	
96-32-2
    	
 
    	
Combustible, corrosive
    	
 
    	
147
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Methyl cyanoacetate, 99%
    	
 
    	
Sigma Aldrich
    	
 
    	
105-34-0
    	
 
    	
Irritant
    	
 
    	
235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
M
    	
 
    	
2-(2-
    	
 
    	
Methyl-1 H-imidazol-1-yl)benzoic acid
    	
 
    	
Maybridge
    	
 
    	
159589-71-6
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
M
    	
 
    	
N-
    	
 
    	
Methyl-1,3-Propanediamne, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
6291-84-5
    	
 
    	
Combustible, highly toxic, corrosive
    	
 
    	
104
    	
 
    	
II
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
M
    	
 
    	
4-
    	
 
    	
Methyl-3-Nitrobenzoic acid, 99%
    	
 
    	
Sigma Aldrich
    	
 
    	
96-98-0
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
M
    	
 
    	
N-
    	
 
    	
Methyl-4-piperdinol
    	
 
    	
Sigma Aldrich
    	
 
    	
106-52-5
    	
 
    	
Irritant
    	
 
    	
234
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    

 

15

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
M
    	
 
    	
 
    	
 
    	
Methylamine solution
    	
 
    	
Sigma Aldrich
    	
 
    	
74-89-5
    	
 
    	
Flammable, harmful, corrosive, carcinogen
    	
 
    	
-29
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
M
    	
 
    	
3-
    	
 
    	
Methylamino)benzoic acid, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
51524-84-6
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
M
    	
 
    	
4-
    	
 
    	
Methylamino)benzoic acid, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
10541-83-0
    	
 
    	
Harmful, skin sensitiser
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
M
    	
 
    	
2-
    	
 
    	
Methylamino)ethanol
    	
 
    	
Sigma Aldrich
    	
 
    	
109-83-1
    	
 
    	
Combustible, corrosive
    	
 
    	
169
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
M
    	
 
    	
2-
    	
 
    	
methylcarboxy)pyridine-5-boronic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
M
    	
 
    	
2-
    	
 
    	
Methylindole, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
95-20-5
    	
 
    	
Irritant
    	
 
    	
286
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Methylmagnesium bromide solution
    	
 
    	
Sigma Aldrich
    	
 
    	
75-16-1
    	
 
    	
Flammable, water reactive, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
M
    	
 
    	
1-
    	
 
    	
Methylpiperazine
    	
 
    	
Sigma Aldrich
    	
 
    	
109-01-3
    	
 
    	
Combustible, toxic, corrosive
    	
 
    	
102
    	
 
    	
II
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
M
    	
 
    	
2-
    	
 
    	
Methyltetrahydrofuran
    	
 
    	
Sigma Aldrich
    	
 
    	
96-47-9
    	
 
    	
Flammable
    	
 
    	
10.4
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
M
    	
 
    	
4-
    	
 
    	
Methylthiophene-2-boronic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
mg
    
	
M
    	
 
    	
 
    	
 
    	
Methysergide maleate salt
    	
 
    	
Sigma Aldrich
    	
 
    	
129-49-7
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2
    	
 
    	
mg
    
	
M
    	
 
    	
 
    	
 
    	
Mexiletine hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
5370-01-4
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
MG-132 Inhibitor
    	
 
    	
Promega
    	
 
    	
—
    	
 
    	
Combutible, harmful
    	
 
    	
131
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
M
    	
 
    	
 
    	
 
    	
Mineral oil
    	
 
    	
Alfa Aesar
    	
 
    	
8020-83-5
    	
 
    	
 
    	
 
    	
450
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
 
    	
 
    	
 
    	
 
    	
Mission Control Vector Purified DNA Turbo
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
M
    	
 
    	
 
    	
 
    	
GFP
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
M
    	
 
    	
 
    	
 
    	
Molecular Sieves, 4 A
    	
 
    	
Sigma Aldrich
    	
 
    	
70955-01-0
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
M
    	
 
    	
 
    	
 
    	
Molybdenum hexacarbonyl
    	
 
    	
Acros Organics
    	
 
    	
13939-06-5
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Molybdenum(V) chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
10241-05-1
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Molybdenum(VI) oxide
    	
 
    	
Sigma Aldrich
    	
 
    	
131-27-5
    	
 
    	
Irritant, carcinogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Molybdenum(VI) tetrachloride oxide
    	
 
    	
Sigma Aldrich
    	
 
    	
13814-75-0
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Molybdenumhexacarbonyl
    	
 
    	
Sigma Aldrich
    	
 
    	
13939-06-5
    	
 
    	
Highly toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Monoclonal Anti-A-Tubulin, Clone DM 1A
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
M
    	
 
    	
 
    	
 
    	
MOPS
    	
 
    	
Sigma Aldrich
    	
 
    	
1132-61-2
    	
 
    	
Irritant
    	
 
    	
230
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Morpholine 99%
    	
 
    	
Sigma Aldrich
    	
 
    	
110-91-8
    	
 
    	
Flammable, harmful, toxic, corrosive
    	
 
    	
88
    	
 
    	
1C
    	
 
    	
 
    	
 
    	
5
    	
 
    	
ml
    
	
M
    	
 
    	
 
    	
 
    	
Mucochloric acid
    	
 
    	
Sigma Aldrich
    	
 
    	
87-56-9
    	
 
    	
Toxic, skin sensitizer, corrosive
    	
 
    	
212
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
M
    	
 
    	
 
    	
 
    	
Myra A hydrochloride
    	
 
    	
Sigma
    	
 
    	
—
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
mg
    

 

16

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
N
    	
 
    	
 
    	
 
    	
Nano-Glo Luciferase Assay Buffer
    	
 
    	
Promega
    	
 
    	
—
    	
 
    	
Suspected carcinogen and teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
N
    	
 
    	
 
    	
 
    	
Nano-Glo Substrate
    	
 
    	
Promega
    	
 
    	
—
    	
 
    	
Flammable
    	
 
    	
70
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
N
    	
 
    	
[1,8]
    	
 
    	
Naphthyrdine-2-carbaldehyde
    	
 
    	
Maybridge
    	
 
    	
64379-45-9
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
N
    	
 
    	
 
    	
 
    	
Neomycin Sulfate
    	
 
    	
Fisher
    	
 
    	
1405-10-3
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
 
    	
 
    	
 
    	
 
    	
NE-PER Nuclear & Cytoplasmic Extraction
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
N
    	
 
    	
 
    	
 
    	
reagents
    	
 
    	
Thermo Fisher
    	
 
    	
Kit
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Carcinogen, toxic, harmful, skin sensitiser,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
N
    	
 
    	
 
    	
 
    	
Nickel II) Sulfate, anhydrous 99.9%
    	
 
    	
Sigma Aldrich
    	
 
    	
7786-81-4
    	
 
    	
irritant, teratogen, mutagen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
N
    	
 
    	
 
    	
 
    	
Nitric Acid
    	
 
    	
Sigma Aldrich
    	
 
    	
7697-37-2
    	
 
    	
Oxidizer, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2.5
    	
 
    	
l
    
	
N
    	
 
    	
3-
    	
 
    	
Nitro-1,8-Naphthalic Anhydride
    	
 
    	
Sigma Aldrich
    	
 
    	
3027-38-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
N
    	
 
    	
3-
    	
 
    	
Nitrobenzoyl Chloride, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
121-90-4
    	
 
    	
Toxic, corrosive
    	
 
    	
230
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
N
    	
 
    	
4-
    	
 
    	
Nitrobenzoyl Chloride, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
122-04-3
    	
 
    	
Corrosive
    	
 
    	
216
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
N
    	
 
    	
4-
    	
 
    	
Nitrobenzyl bromide
    	
 
    	
Sigma Aldrich
    	
 
    	
100-11-8
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
N
    	
 
    	
 
    	
 
    	
Nitromethane
    	
 
    	
Sigma Aldrich
    	
 
    	
72-52-5
    	
 
    	
Flammable, carcinogen, harmful
    	
 
    	
97
    	
 
    	
1C
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
N
    	
 
    	
4-
    	
 
    	
Nitrophenyl Chlorformate 97%
    	
 
    	
Acros Organics
    	
 
    	
7693-46-1
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
N
    	
 
    	
 
    	
 
    	
Nocodazole
    	
 
    	
Sigma Aldrich
    	
 
    	
31430-18-9
    	
 
    	
Teratogen, mutagen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
N
    	
 
    	
 
    	
 
    	
Nonidet P 40 Substitute
    	
 
    	
Sigma Aldrich
    	
 
    	
9016-45-9
    	
 
    	
Irritant
    	
 
    	
235
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
L
    
	
N
    	
 
    	
 
    	
 
    	
NSC308848
    	
 
    	
Sigma Aldrich
    	
 
    	
69408-82-8
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
mg
    
	
O
    	
 
    	
 
    	
 
    	
Octylphenyl-polyethylene glycol
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
O
    	
 
    	
 
    	
 
    	
ONE-Glo luciferase assay buffer
    	
 
    	
Promega
    	
 
    	
76836-02-7
    	
 
    	
carcinogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
O
    	
 
    	
 
    	
 
    	
Oxalyl Chloride, Reagent Grade, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
79-37-8
    	
 
    	
Toxic, Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Palladium on acitvated Charcoal
    	
 
    	
Sigma Aldrich
    	
 
    	
7440-05-3
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
GHS- flammable liquid, skin irritation, eye
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
irritation, germ cell mutagenicity,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
carcinogenicity, reproductive toxicity,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
PAP pen for immunostaining - 5mm tip
    	
 
    	
 
    	
 
    	
106-94-5
    	
 
    	
specific target organ toxicity, acute aquatic
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
P
    	
 
    	
 
    	
 
    	
width
    	
 
    	
 
    	
 
    	
8032-32-4
    	
 
    	
toxicity, chronic aquatic toxicity
    	
 
    	
160 F
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
P
    	
 
    	
 
    	
 
    	
Paraformaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
30525-89-4
    	
 
    	
Flam solid, Toxic, skin sensitizer, carcinogen
    	
 
    	
158
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
1
    	
 
    	
Kg
    
	
P
    	
 
    	
 
    	
 
    	
Pentafluorophenol
    	
 
    	
Sigma
    	
 
    	
771-61-9
    	
 
    	
Irritant
    	
 
    	
162
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    

 

17

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
P
    	
 
    	
1,10-
    	
 
    	
Phenanthroline 99+%
    	
 
    	
Sigma Aldrich
    	
 
    	
66-71-7
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Phenol
    	
 
    	
Sigma Aldrich
    	
 
    	
108-95-2
    	
 
    	
Toxic, corrosive, mutagen
    	
 
    	
174
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
 
    	
 
    	
 
    	
 
    	
Phenol-chloroform-isoamyl alcohol
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Combustible, carcinogen, toxic, corrosive,
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
P
    	
 
    	
 
    	
 
    	
mixture
    	
 
    	
Sigma Aldrich
    	
 
    	
mixture
    	
 
    	
mutagen
    	
 
    	
174
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
GHS - flammable liquids, acute toxicity, skin
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
corrosion, serious eye damage, respiratory
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
sensitisation, skin sensitisation, acute
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
P
    	
 
    	
 
    	
 
    	
Phenyl isocyanate
    	
 
    	
 
    	
 
    	
103-71-9
    	
 
    	
aquatic toxicity, chronic aquatic toxicity
    	
 
    	
124 F
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
P
    	
 
    	
p-
    	
 
    	
Phenylenediamine
    	
 
    	
Sigma Aldrich
    	
 
    	
106-50-3
    	
 
    	
Toxic,skin sensitiser, irritant
    	
 
    	
230
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Phenylsilane
    	
 
    	
Sigma Aldrich
    	
 
    	
694-53-1
    	
 
    	
flammable, water reactive
    	
 
    	
46
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Phosphatase inhibitor cocktail 3 (DMSO)
    	
 
    	
Sigma Aldrich
    	
 
    	
67-68-5
    	
 
    	
Combustible
    	
 
    	
189
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
P
    	
 
    	
 
    	
 
    	
Phosphomolybdic acid hydrate
    	
 
    	
 
    	
 
    	
51429-74-4
    	
 
    	
GHS - Oxidizing solids, skin corrosion, serious eye   damage
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
P
    	
 
    	
 
    	
 
    	
Phosphorous (V) oxychloride, reagent plus
    	
 
    	
Sigma Aldrich
    	
 
    	
10025-87-3
    	
 
    	
Highly toxic, corrosive
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Phosphorus trichloride
    	
 
    	
Sigma Aldrich
    	
 
    	
7719-12-2
    	
 
    	
Corrosive, contact with water — toxic gas
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Phosphotungstic acid hydrate
    	
 
    	
 
    	
 
    	
12501-23-4
    	
 
    	
GHS- skin corrosion, serious eye damage
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
P
    	
 
    	
 
    	
 
    	
Pierce 660nm Protein Assay
    	
 
    	
Thermo Fisher
    	
 
    	
67-56-1
    	
 
    	
 
    	
 
    	
>212
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
P
    	
 
    	
 
    	
 
    	
Piperidine
    	
 
    	
Sigma Aldrich
    	
 
    	
110-89-4
    	
 
    	
Flammable, toxic, corrosive
    	
 
    	
61
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
P
    	
 
    	
 
    	
 
    	
Piperonal
    	
 
    	
Sigma Aldrich
    	
 
    	
120-57-0
    	
 
    	
Irritant
    	
 
    	
>235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Platinum(IV) oxide
    	
 
    	
Sigma Aldrich
    	
 
    	
1314-15-4
    	
 
    	
Oxidizer, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Plumbagin, from Plumbago indica
    	
 
    	
Sigma Aldrich
    	
 
    	
481-42-5
    	
 
    	
Toxic, Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
P
    	
 
    	
 
    	
 
    	
Pluronic F-127, Protein grade detergent
    	
 
    	
EMD
    	
 
    	
9003-11-6
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
P
    	
 
    	
 
    	
 
    	
PMA (phorbol 12-myristate 13-acetate)
    	
 
    	
Sigma Aldrich
    	
 
    	
16561-29-8
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
mg
    
	
P
    	
 
    	
 
    	
 
    	
Potassium bis(trimethylsilyl)amide solution
    	
 
    	
Sigma Aldrich
    	
 
    	
40949-94-8
    	
 
    	
Flammable, Corrosive, Carcinogen
    	
 
    	
-2
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
mL
    
	
P
    	
 
    	
 
    	
 
    	
Potassium carbonate
    	
 
    	
Sigma Aldrich
    	
 
    	
584-08-7
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Potassium chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
7447-40-7
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
mL
    
	
P
    	
 
    	
 
    	
 
    	
Potassium cyanide
    	
 
    	
Sigma
    	
 
    	
151-50-8
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    

 

18

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
P
    	
 
    	
 
    	
 
    	
Potassium hydroxide
    	
 
    	
Sigma Aldrich
    	
 
    	
1310-58-3
    	
 
    	
Toxic, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Potassium hydroxide solution
    	
 
    	
Sigma Aldrich
    	
 
    	
1310-58-3
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
P
    	
 
    	
 
    	
 
    	
Potassium iodate
    	
 
    	
Sigma Aldrich
    	
 
    	
7758-05-6
    	
 
    	
Oxidizer, teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Potassium permanganate
    	
 
    	
Sigma Aldrich
    	
 
    	
7722-64-7
    	
 
    	
Oxidizer, harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Potassium Phosphate Tribasic, reagent gr
    	
 
    	
Sigma Aldrich
    	
 
    	
7778-53-2
    	
 
    	
Irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Potassium phosphate, monobasic
    	
 
    	
Fisher
    	
 
    	
7778-77-0
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1-
    	
 
    	
—
    
	
P
    	
 
    	
5a
    	
 
    	
Pregnane-3,20-dione (allo)
    	
 
    	
Sigma Aldrich
    	
 
    	
566-65-4
    	
 
    	
Teratogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
mg
    
	
P
    	
 
    	
2
    	
 
    	
Propanol
    	
 
    	
Sigma Aldrich
    	
 
    	
67-63-0
    	
 
    	
Flammable, irritant
    	
 
    	
57
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
4
    	
 
    	
L
    
	
P
    	
 
    	
2
    	
 
    	
Propanol
    	
 
    	
Fisher
    	
 
    	
67-63-0
    	
 
    	
Flammable
    	
 
    	
54
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
P
    	
 
    	
 
    	
 
    	
Propylphosphonic anhydride solution
    	
 
    	
Sigma Aldrich
    	
 
    	
68957-94-8, 141-78-6
    	
 
    	
Flammable, corrosive
    	
 
    	
25
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
mL
    
	
P
    	
 
    	
 
    	
 
    	
Protocol 10% Neutral Buffered Formalin
    	
 
    	
Thermo Fisher
    	
 
    	
 
    	
 
    	
carcinogen, irritant
    	
 
    	
200
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
P
    	
 
    	
 
    	
 
    	
Pyrazole
    	
 
    	
Sigma Aldrich
    	
 
    	
288-13-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Pyridine
    	
 
    	
Sigma Aldrich
    	
 
    	
110-86-1
    	
 
    	
Flammable, harmful, carcinogen
    	
 
    	
63
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
P
    	
 
    	
2
    	
 
    	
Pyridinecarboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
1121-60-4
    	
 
    	
Combustible, toxic, mutagen
    	
 
    	
171
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
P
    	
 
    	
3
    	
 
    	
Pyridinecarboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
500-22-1
    	
 
    	
flammable, irritant
    	
 
    	
95
    	
 
    	
1C
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
P
    	
 
    	
4
    	
 
    	
Pyridinecarboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
872-85-5
    	
 
    	
Combustible, irritant
    	
 
    	
180
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
P
    	
 
    	
4
    	
 
    	
Pyridoxic Acid
    	
 
    	
Sigma Aldrich
    	
 
    	
82-82-6
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
mg
    
	
P
    	
 
    	
 
    	
 
    	
Pyrodoxamine Dihydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
524-36-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
P
    	
 
    	
3
    	
 
    	
Pyrrolidinamine
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
P
    	
 
    	
 
    	
 
    	
Pyruvic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
127-17-3
    	
 
    	
Combustive, corrosive
    	
 
    	
180
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
Q
    	
 
    	
 
    	
 
    	
Quick Start Bradford Protein Assay Kit 1
    	
 
    	
Bio-Rad
    	
 
    	
mixture
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
R
    	
 
    	
 
    	
 
    	
Rhodanine
    	
 
    	
Sigma Aldrich
    	
 
    	
141-84-4
    	
 
    	
Toxic, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
R
    	
 
    	
 
    	
 
    	
Ribonuclease A solution
    	
 
    	
Sigma Aldrich
    	
 
    	
56-81-5
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
R
    	
 
    	
 
    	
 
    	
RIPA Buffer
    	
 
    	
Sigma Aldrich
    	
 
    	
9036-19-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
mL
    
	
R
    	
 
    	
 
    	
 
    	
Ritanserin
    	
 
    	
Sigma Aldrich
    	
 
    	
87051-43-2
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
mg
    
	
S
    	
 
    	
 
    	
 
    	
SAHA
    	
 
    	
Sigma Aldrich
    	
 
    	
149647-78-9
    	
 
    	
reproductive hazard, mutagen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
mg
    

 

19

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
S
    	
 
    	
 
    	
 
    	
Salicylaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
90-02-8
    	
 
    	
Combustible, toxic, corrosive, mutagen
    	
 
    	
171
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sand, 50-70 mesh
    	
 
    	
Sigma Aldrich
    	
 
    	
14808-60-7
    	
 
    	
carcinogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sebacoyl chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
111-19-3
    	
 
    	
Toxic, Corrosive
    	
 
    	
235
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
50
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Secureline Lab Marker
    	
 
    	
Fisher
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
S
    	
 
    	
 
    	
 
    	
Selenium dioxide
    	
 
    	
Sigma Aldrich
    	
 
    	
7446-08-4
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
SeqPlex DNA Amplification Kit
    	
 
    	
Sigma Aldrich
    	
 
    	
—
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
S
    	
 
    	
 
    	
 
    	
SeqPlex Enhanced DNA amplificaiton kit
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
S
    	
 
    	
 
    	
 
    	
Silica gel
    	
 
    	
Sigma Aldrich
    	
 
    	
112926-00-8
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Silica gel
    	
 
    	
Acros Organics
    	
 
    	
7631-86-9
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Silver Nitrate
    	
 
    	
Sigma Aldrich
    	
 
    	
7761-88-8
    	
 
    	
Oxidizer, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Slide-A-Lyzer Dialysis Products
    	
 
    	
Thermo Fisher
    	
 
    	
—
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
S
    	
 
    	
 
    	
 
    	
Sodim tert- butoxide
    	
 
    	
Sigma Aldrich
    	
 
    	
865-48-5
    	
 
    	
Unstable reactive, corrosive
    	
 
    	
57
    	
 
    	
1B
    	
 
    	
Unstable reactive
    	
 
    	
5
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium Azide
    	
 
    	
Sigma Aldrich
    	
 
    	
26628-22-8
    	
 
    	
Toxic, rapidly absorbs through skin
    	
 
    	
 
    	
 
    	
 
    	
 
    	
may react with lead and copper to form highly   explosive metal azides
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium borohydride
    	
 
    	
Sigma Aldrich
    	
 
    	
16940-66-2
    	
 
    	
Water reactive, toxic, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium butyrate
    	
 
    	
Sigma Aldrich
    	
 
    	
156-54-7
    	
 
    	
Irritant, mutagen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
mg
    
	
S
    	
 
    	
 
    	
 
    	
Sodium carbonate
    	
 
    	
Fisher
    	
 
    	
497-19-8
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
S
    	
 
    	
 
    	
 
    	
Sodium chloride
    	
 
    	
Fisher
    	
 
    	
7647-14-5
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
S
    	
 
    	
 
    	
 
    	
Sodium Cyanide, ACS Reagent, > 95%
    	
 
    	
Sigma Aldrich
    	
 
    	
143-33-9
    	
 
    	
Highly toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
sodium cyanoborohydride
    	
 
    	
Sigma Aldrich
    	
 
    	
25895-60-7
    	
 
    	
Flammable solid, highly toxic, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium deoxycholate
    	
 
    	
Sigma Aldrich
    	
 
    	
302-95-4
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium dodecyl sulfate
    	
 
    	
Sigma Aldrich
    	
 
    	
151-21-3
    	
 
    	
Flammable solid, harmful, irritant
    	
 
    	
356
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
1
    	
 
    	
kg
    
	
S
    	
 
    	
 
    	
 
    	
Sodium ethoxide
    	
 
    	
Sigma Aldrich
    	
 
    	
141-52-6
    	
 
    	
Unstable reactive, corrosive
    	
 
    	
86
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium ethoxide solution
    	
 
    	
Sigma Aldrich
    	
 
    	
141-52-6
    	
 
    	
flammable, toxic, corrosive, carcinogen
    	
 
    	
48
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mL
    
	
S
    	
 
    	
 
    	
 
    	
Sodium hydride 60%
    	
 
    	
Sigma Aldrich
    	
 
    	
8012-95-1
    	
 
    	
Water reactive, irritant, carcinogen
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium hydroxide
    	
 
    	
Sigma Aldrich
    	
 
    	
1310-73-2
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    

 

20

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
S
    	
 
    	
 
    	
 
    	
Sodium hydroxide solution
    	
 
    	
Sigma Aldrich
    	
 
    	
1310-73-2
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mL
    
	
S
    	
 
    	
 
    	
 
    	
Sodium Iodide
    	
 
    	
Sigma Aldrich
    	
 
    	
7681-49-4
    	
 
    	
Toxic, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
S
    	
 
    	
 
    	
 
    	
Sodium Methoxide
    	
 
    	
Sigma Aldrich
    	
 
    	
124-41-4
    	
 
    	
Corrosive
    	
 
    	
91
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium methoxide solution
    	
 
    	
Sigma Aldrich
    	
 
    	
124-41-4
    	
 
    	
Flammable, Corrosive, Reacts violently with water
    	
 
    	
52
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
mL
    
	
S
    	
 
    	
 
    	
 
    	
Sodium n-Dodecyl sulfate, 20% solution (w/v)
    	
 
    	
EMD
    	
 
    	
151-21-3
    	
 
    	
Irritant
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
S
    	
 
    	
 
    	
 
    	
Sodium phosphate dibasic anyhyrous
    	
 
    	
Fisher
    	
 
    	
7558-79-4
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
500
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium phosphotungstate hydrate
    	
 
    	
 
    	
 
    	
312696-30-3
    	
 
    	
GHS - Acute toxicity, skin irritation, eye   irritation, specific target organ toxicity
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
S
    	
 
    	
 
    	
 
    	
Sodium tetraborate
    	
 
    	
 
    	
 
    	
1330-43-4
    	
 
    	
Eye irritation, reproductive toxicity, acute aquatic   toxicity, chronic aquatic toxicity
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sodium Triacetoxyborohydride
    	
 
    	
Sigma Aldrich
    	
 
    	
56553-60-7
    	
 
    	
Water reactive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
S
    	
 
    	
 
    	
 
    	
Sparkleen 1
    	
 
    	
Fisher
    	
 
    	
mixture
    	
 
    	
Corrosive, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
S
    	
 
    	
 
    	
 
    	
Succinic anhydride
    	
 
    	
Sigma Aldrich
    	
 
    	
108-30-5
    	
 
    	
Harmful, irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
S
    	
 
    	
 
    	
 
    	
Sulfo-NHS-Biotin
    	
 
    	
Thermo Fisher
    	
 
    	
119616-38-5
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
S
    	
 
    	
 
    	
 
    	
Sulfuric acid, 95-98%
    	
 
    	
Sigma Aldrich
    	
 
    	
7664-93-9
    	
 
    	
Highly toxic, irritant, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2.5
    	
 
    	
L
    
	
T
    	
 
    	
 
    	
 
    	
TCEP Solution
    	
 
    	
Thermo Fisher
    	
 
    	
51805-45-9
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
 
    	
 
    	
Terephthalic acid, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
100-21-0
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
T
    	
 
    	
 
    	
 
    	
Tetrabutylammonium bromide
    	
 
    	
 
    	
 
    	
1643-19-2
    	
 
    	
GHS- skin irritant, eye irritant, specific target   organ toxicity
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
T
    	
 
    	
2,4,5,6-
    	
 
    	
Tetrachloropyrimidine
    	
 
    	
Sigma Aldrich
    	
 
    	
1780-40-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
lachrymator
    	
 
    	
25
    	
 
    	
g
    
	
T
    	
 
    	
 
    	
 
    	
Tetrahydrofuran
    	
 
    	
Sigma Aldrich
    	
 
    	
109-99-9
    	
 
    	
Flammable, irritant, carcinogen
    	
 
    	
1.4
    	
 
    	
1B
    	
 
    	
may for explosive peroxides
    	
 
    	
100
    	
 
    	
ml
    
	
T
    	
 
    	
1,1,3,3-
    	
 
    	
Tetramethoxypropane
    	
 
    	
Sigma Aldrich
    	
 
    	
102-52-3
    	
 
    	
Combustible
    	
 
    	
129
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
T
    	
 
    	
N,N,N’,N’-
    	
 
    	
Tetramethylethylenediamine
    	
 
    	
Sigma Aldrich
    	
 
    	
110-18-9
    	
 
    	
Flammable, toxic, corrosive
    	
 
    	
68
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
(±)-
    	
 
    	
Thalidomide
    	
 
    	
Sigma Aldrich
    	
 
    	
50-35-1
    	
 
    	
Teratogen, reproductive hazard
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
mg
    
	
T
    	
 
    	
2-
    	
 
    	
Thiazolecarboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
10200-59-6
    	
 
    	
Combustible
    	
 
    	
154
    	
 
    	
IIIA
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
T
    	
 
    	
5-
    	
 
    	
Thiazolecarboxaldehyde
    	
 
    	
Sigma Aldrich
    	
 
    	
1003-32-3
    	
 
    	
Skin sensitizer, irritant
    	
 
    	
208
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
T
    	
 
    	
 
    	
 
    	
Thionyl Chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
7719-09-7
    	
 
    	
Toxic, corrosie, water reactive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
T
    	
 
    	
 
    	
 
    	
Tin(II) chloride 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
7772-99-8
    	
 
    	
Harmful, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    

 

21

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
T
    	
 
    	
 
    	
 
    	
Titanium(IV) ispropoxide
    	
 
    	
Sigma Aldrich
    	
 
    	
546-68-9
    	
 
    	
Combutible, irritant
    	
 
    	
113
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
T
    	
 
    	
 
    	
 
    	
Toluene
    	
 
    	
Sigma Aldrich
    	
 
    	
108-88-3
    	
 
    	
Flammable, irritant, teratogen
    	
 
    	
40
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
1
    	
 
    	
L
    
	
T
    	
 
    	
p-
    	
 
    	
Toluenesulfonic acid monohydrate
    	
 
    	
Sigma Aldrich
    	
 
    	
6192-52-5
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
T
    	
 
    	
p-
    	
 
    	
Toluenesulfonyl chloride
    	
 
    	
Sigma Aldrich
    	
 
    	
98-59-9
    	
 
    	
Irritant
    	
 
    	
262
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
T
    	
 
    	
p-
    	
 
    	
Tolunitrile
    	
 
    	
Sigma Aldrich
    	
 
    	
104-85-5
    	
 
    	
Irritant, respiratory sensitizer
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
250
    	
 
    	
ml
    
	
T
    	
 
    	
 
    	
 
    	
Trans-Blot Transfer Medium 0.2, 0.45 micron
    	
 
    	
Bio-Rad
    	
 
    	
9004-70-0
    	
 
    	
Flammable solid
    	
 
    	
212
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
T
    	
 
    	
 
    	
 
    	
Trans-crotonyl chloride, tech 90%
    	
 
    	
Sigma Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
T
    	
 
    	
 
    	
 
    	
Tri(o-tolyl)phosphine
    	
 
    	
Sigma Aldrich
    	
 
    	
6163-58-2
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
2,4,6-
    	
 
    	
Trichloro-5-methylpyrimidine
    	
 
    	
Sigma Aldrich
    	
 
    	
1780-36-5
    	
 
    	
Corrosive, lachrymator
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
T
    	
 
    	
2,4,6-
    	
 
    	
Trichloropyrimidine
    	
 
    	
Sigma Aldrich
    	
 
    	
3764-01-0
    	
 
    	
Harmful, irritant, lachymator
    	
 
    	
235
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
T
    	
 
    	
 
    	
 
    	
Triethylamine
    	
 
    	
Sigma Aldrich
    	
 
    	
121-44-8
    	
 
    	
Flammable, harmful, toxic, corrosive
    	
 
    	
5
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
T
    	
 
    	
 
    	
 
    	
Trifluoroacetic acid
    	
 
    	
Sigma Aldrich
    	
 
    	
76-05-1
    	
 
    	
Delayed organ effects, corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
T
    	
 
    	
3,4,5-
    	
 
    	
Trifluorobenzaldehyde
    	
 
    	
sigma Aldrich
    	
 
    	
132123-54-7
    	
 
    	
Toxic, irritant, teratogen
    	
 
    	
230
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
5
    	
 
    	
ml
    
	
T
    	
 
    	
 
    	
 
    	
Trifluoromethanesulfonmide, 95%
    	
 
    	
Sigma Aldrich
    	
 
    	
82113-65-3
    	
 
    	
Corrosive
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
T
    	
 
    	
2’-(
    	
 
    	
Trifluoromethyl)acetophenone
    	
 
    	
Sigma Aldrich
    	
 
    	
17408-14-9
    	
 
    	
Combustible
    	
 
    	
183
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
3’-(
    	
 
    	
Trifluoromethyl)acetophenone
    	
 
    	
Sigma Aldrich
    	
 
    	
349-76-8
    	
 
    	
Combustible, irritant
    	
 
    	
174
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
3,4,5-
    	
 
    	
Trihydroxybenzaldehyde monohydrate
    	
 
    	
Sigma Aldrich
    	
 
    	
2077-42-88-9
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
ml
    
	
T
    	
 
    	
2,4,6-
    	
 
    	
Trihydroxybenzaldehyde, >97%
    	
 
    	
Sigma Aldrich
    	
 
    	
487-70-7
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
T
    	
 
    	
2,3,4-
    	
 
    	
Trihydroxybenzaldehyde, 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
2144-08-3
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
T
    	
 
    	
2,3,4-
    	
 
    	
Trihydroxybenzoic acid 97%
    	
 
    	
Sigma Aldrich
    	
 
    	
610-02-6
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
T
    	
 
    	
 
    	
 
    	
Triisopropylsilane, 99%
    	
 
    	
Sigma Aldrich
    	
 
    	
6485-79-6
    	
 
    	
Combustible, irritant
    	
 
    	
100
    	
 
    	
II
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
T
    	
 
    	
 
    	
 
    	
Trimethylaluminum solution
    	
 
    	
Sigma Aldrich
    	
 
    	
75-24-1
    	
 
    	
Flammable, water reactive, corrosive, teratogen
    	
 
    	
39
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
T
    	
 
    	
(
    	
 
    	
Trimethylsilyl)Diazomethane, 2.0 M In
    	
 
    	
Sigma Aldrich
    	
 
    	
18107-18-1
    	
 
    	
Flammable, highly toxic, irritant, carcinogen
    	
 
    	
-31
    	
 
    	
1B
    	
 
    	
 
    	
 
    	
25
    	
 
    	
ml
    
	
T
    	
 
    	
 
    	
 
    	
Trimethylsulfonium iodide
    	
 
    	
Sigma Aldrich
    	
 
    	
2181-42-2
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
g
    
	
T
    	
 
    	
 
    	
 
    	
Triphenylphosphine
    	
 
    	
Sigma Aldrich
    	
 
    	
603-35-0
    	
 
    	
Harmful, skin sensitizer
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
g
    
	
T
    	
 
    	
 
    	
 
    	
Triruthenium dodecacarbonyl
    	
 
    	
Sigma
    	
 
    	
15243-33-1
    	
 
    	
Harmful
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    

 

22

 

	
Index
    	
 
    	
Prefix
    	
 
    	
Chemical Name
    	
 
    	
Vendor
    	
 
    	
CAS
    	
 
    	
Notes
    	
 
    	
Flashpoint
   (F)
    	
 
    	
Flammable
   Class
    	
 
    	
other hazards
    	
 
    	
Bottle
   Size
    	
 
    	
Amount unit (L, ml,
   g)
    
	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
Aldrich
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    
	
T
    	
 
    	
 
    	
 
    	
Tris Hydrochloride Buffer, pH 7.5 1M
    	
 
    	
Mediatech
    	
 
    	
1185-53-1
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
 
    	
 
    	
Tris Hydrochloride Buffer, pH 8.0 1M
    	
 
    	
Mediatech
    	
 
    	
1185-53-1
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
 
    	
 
    	
Tris(2-carboxyethyl)phospine hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
51805-45-9
    	
 
    	
Corrosive
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
T
    	
 
    	
10X
    	
 
    	
Tris/Glycine Buffer
    	
 
    	
Bio-Rad
    	
 
    	
77-86-1
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
 
    	
 
    	
Tri-tert-Butylphosphine, 98%
    	
 
    	
Sigma Aldrich
    	
 
    	
13716-12-6
    	
 
    	
pyrophoric, corrosive
    	
 
    	
1
    	
 
    	
1B
    	
 
    	
pyrophoric solid
    	
 
    	
1
    	
 
    	
g
    
	
T
    	
 
    	
 
    	
 
    	
Triton X 100
    	
 
    	
Sigma Aldrich
    	
 
    	
9002-93-1
    	
 
    	
Harmful, irritant
    	
 
    	
484
    	
 
    	
IIIB
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
T
    	
 
    	
 
    	
 
    	
Trizma base
    	
 
    	
Sigma Aldrich
    	
 
    	
77-86-1
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
 
    	
 
    	
Trt-diamino-PEG-NH2
    	
 
    	
EMD
    	
 
    	
—
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    
	
T
    	
 
    	
 
    	
 
    	
Tungsten hexacarbonyl
    	
 
    	
Sigma Aldrich
    	
 
    	
14040-11-0
    	
 
    	
Toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
10
    	
 
    	
g
    
	
V
    	
 
    	
(±)-
    	
 
    	
Verapamil hydrochloride
    	
 
    	
Sigma Aldrich
    	
 
    	
152-11-4
    	
 
    	
toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
g
    
	
V
    	
 
    	
 
    	
 
    	
Vinylmagnesium bromide solution
    	
 
    	
Sigma Aldrich
    	
 
    	
1826-67-1
    	
 
    	
Flammable, water reactive, irritant, corrosive,   carcinogen
    	
 
    	
1.4
    	
 
    	
 
    	
 
    	
 
    	
 
    	
100
    	
 
    	
ml
    
	
W
    	
 
    	
 
    	
 
    	
Water
    	
 
    	
Fisher
    	
 
    	
7732-18-5
    	
 
    	
 
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
25
    	
 
    	
L
    
	
X
    	
 
    	
 
    	
 
    	
Xylenes
    	
 
    	
 
    	
 
    	
1330-20-7
    	
 
    	
GHS- Flammable liquids, acute toxicity, acute   aquatic toxicity, chronic aquatic toxicity
    	
 
    	
77 F
    	
 
    	
 
    	
 
    	
 
    	
 
    	
2.5
    	
 
    	
ml
    
	
X
    	
 
    	
 
    	
 
    	
Xylenes, mixed isomers with ethylbenzene
    	
 
    	
Fisher
    	
 
    	
1330-20-7
    	
 
    	
Flammable
    	
 
    	
78
    	
 
    	
 
    	
 
    	
 
    	
 
    	
1
    	
 
    	
gal
    
	
Z
    	
 
    	
 
    	
 
    	
Zinc cyanide
    	
 
    	
Sigma Aldrich
    	
 
    	
557-21-1
    	
 
    	
Highly toxic
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
5
    	
 
    	
g
    
	
Z
    	
 
    	
 
    	
 
    	
Zinc trifluoromethanesulfinate
    	
 
    	
Sigma Aldrich
    	
 
    	
39971-65-8
    	
 
    	
Irritant
    	
 
    	
—
    	
 
    	
 
    	
 
    	
 
    	
 
    	
—
    	
 
    	
—
    

 

23

 

EXHIBIT 7

 

RULES AND REGULATIONS

 

To the extent of any conflict between these Rules and Regulations and the body of the Lease, the body of the Lease shall govern.

 

1.                                      Tenant and its employees shall not in any way obstruct the sidewalks, halls, stairways, or elevators of the Building, and shall use the same only as a means of passage to and from their respective offices.

 

2.                                      Corridor doors, when not in use, shall be kept closed.

 

3.                                      No animals, except seeing eye dogs, shall be brought into or kept in, on or about the Premises.

 

4.                                      The restroom fixtures shall be used only for the purpose for which they were constructed and no rubbish, ashes, or other substances of any kind shall be thrown into them.  Tenant will bear the expense of any damage resulting from misuse.

 

5.                                      Tenant shall not place any additional lock or locks on any exterior door in the Building or on any door in the Building core within the Premises, including doors providing access to the telephone and electric closets and the slop sink, without Landlord’s prior written consent; provided, however, that Tenant shall have control of all keys to doors within the Premises, but will provide Landlord with a master copy of same.  At Landlord’s option, all keys shall be surrendered to Landlord at the expiration or earlier termination of the Lease.

 

6.                                      Landlord reserves the right to exclude or expel from the Building any persons who, in the judgment of Landlord, is intoxicated under the influence of liquor or drugs, or shall do any act in violation of the rules and regulations of the Building.

 

7.                                      Landlord reserves the right to close and keep locked all entrance and exit doors of the Building during the hours Landlord may deem advisable for the adequate protection of the property.  Use of the Building and the leased Premises before 8 AM or after 6 PM, or any time during Sundays or legal holidays shall be allowed only to persons with a key/card key to the Premises or guests accompanied by such persons.  At these times, all occupants and their guests must sign in at the concierge when entering and exiting the Building.  Any persons found in the Building after hours without such keys/card keys are subject to the surveillance of building staff.

 

8.                                      Tenant shall not, without the prior written consent of Landlord (which consent will not be unreasonably withheld, conditioned or delayed), perform improvements or alterations within the Building or the Premises if the work has the potential of disturbing the fireproofing which has been applied on the surfaces of the structural deck.

 

9.                                      Landlord and Tenant shall mutually agree on the termite and pest extermination service to control termites and pests in the Premises.  Except as included in Landlord’s services, tenants shall bear the cost and expense of such extermination services.

 

1

 

10.                               Tenant shall not install, operate or maintain in the Premises or in any other area of the Building, any electrical equipment which does not bear the U/L (Underwriters Laboratories) or IEC (International Electrotechnical Conference) seal of approval, or which would overload the electrical system or any part thereof beyond its capacity for proper, efficient and safe operation as reasonably determined by Landlord, taking into consideration the overall electrical system, the capacities reserved to Tenant in 11. the Lease, and the present and future requirements therefor in the Building.  Tenant shall not use more than Tenant’s Building Share of telephone lines available to service the Building, unless Tenant provides its own conduits and service at its sole expense.  Landlord shall notify Tenant, at the time of Landlord’s review and approval of the plans for Tenant’s Work or for any future Alterations, if any work set forth therein will result in the use of more than Tenant’s Building Share of telephone lines.

 

11.                               Tenant shall not operate or permit to be operated on the Premises any coin or token operated vending machine or similar device (including, without limitation, telephones, lockers, toilets, scales, amusement devices and machines for sale of beverages food, candy, cigarettes or other goods), except for those vending machines or similar devices which are for the sole and exclusive use of Tenant’s employees.

 

12.                               Bicycles and other vehicles are not permitted inside or on the walkways outside the Building, except in those areas specifically designated by Landlord for such purposes.

 

13.                               Landlord may from time to time adopt appropriate systems and procedures for the security or safety of the Building, its occupants, entry and use, or its contents, provided that Tenant shall have access to the Building 24 hours per day, 7 days a week, 365 days a year.  Tenant, Tenant’s agents, employees, contractors, guests and invitees shall comply with Landlord’s reasonable requirements relative thereto.

 

14.                               Canvassing, soliciting, and peddling in or about the Building is prohibited.  Tenant shall cooperate and use reasonable efforts to prevent the same.

 

15.                               At no time shall Tenant permit or shall Tenant’s agents, employees, contractors, guests, or invitees smoke in any Common Area of the Building.

 

16.                               Tenant shall, at its sole cost and expense, keep any garbage, trash, rubbish and refuse in vermin-proof containers within the interior of the Premises until removed.

 

17.                               Landlord and Tenant shall mutually agree on those areas outside the Premises, if any, where lab coats are not allowed.

 

18.                               Lab operators carrying any lab related materials may only travel in Tenant’s freight elevator or stairwells within the Premises.  If such freight elevator is down, announcements will be sent from Landlord’s property manager designating use of another elevator.  At no time should any lab materials travel in passenger elevators.

 

19.                               Any dry ice brought into the Building must be delivered through Tenant’s freight elevator only.

 

2

 

20.                               All nitrogen tanks must travel in Tenant’s freight elevator and should never be left unmanned outside of the Premises

 

3

 

EXHIBIT 8

 

LANDLORD’S SERVICES

 

·                  On-site bicycle parking

 

·                  Shower facilities in the Building

 

·                  To the extent capacity is available beyond base Building requirements (such available capacity, “Lessee Capacity”), Landlord’s sole obligation for either providing emergency generators or providing emergency back-up power to Tenant shall be to:  (i) provide an emergency generator for use of one or more tenants in the Building, including Tenant (the “Back-up Generator”) with Tenant’s Share of the Lessee Capacity (Tenant hereby acknowledging that Tenant’s equipment to be connected to the Back-Up Generator collectively shall use no more than Tenant’s Share of the Lessee Capacity), and (ii) maintain the Back-up Generator as per the manufacturer’s standard maintenance guidelines.  In the event that Tenant’s equipment connected to the Back-Up Generator uses more than Tenant’s Share of the Lessee Capacity, Tenant shall, upon Landlord’s demand, disconnect from the Back-Up Generator such equipment as may be necessary to reduce Tenant’s use to equal or be less than Tenant’s Share of the Lessee Capacity.  Landlord shall provide reasonable prior notice of any planned period of replacement, repair or maintenance of the Back-up Generator and within one (1) business day after Landlord learns that the Back-up Generator is not operational, however Landlord shall have no obligation to provide Tenant with an alternative back-up generator or alternative sources of back-up power.  Tenant expressly acknowledges and agrees that Landlord does not guaranty that the Back-up Generator will be operational at all times or that emergency power will be available to the Premises when needed.  So long as Landlord is not in default of its obligations under this paragraph, in no event shall Landlord be liable to Tenant or any other party for any damages of any type suffered by Tenant or any other person in the event that any emergency generator or back-up power or any replacement thereof fails or does not provide sufficient power.

 

1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00259-of-00352.parquet"}]]